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GEnErAL intrOduCtiOn
Adverse life events are strong risk factors for adverse health outcomes, such as psychi-
atric problems, obesity and related cardiovascular disease and diabetes 1. The pathways 
through which stressful events can promote the development of such divergent dis-
orders in humans remain largely unknown. Often there is no convincing support for a 
specific genetic contribution to the development of these disorders. In recent years, a 
promising explanation has risen from the field of epigenetics (derived from the Greek 
“epi”, which means “on top of”). Epigenetics refers to the modification of DNA or histone 
proteins physically associated with the DNA, resulting in functional or operational 
changes without changing the primary sequence composition. These changes in gene 
expression may result in phenotypical variations that could be expressed as adverse 
health outcomes. Epigenetic modifications can be actively remodeled by environmental 
signals, and may therefore be considered as a “candidate mechanism for the environ-
mental ‘programming’ of gene expression” 2.
To date, the most well-known epigenetic modification is DNA methylation, an 
important regulator of gene expression through chemical modifications to the DNA. 
This modification involves the addition of a methyl group (CH3) to a cytosine base to 
form 5-methylcytosine in a cytosine-phosphate-guanine (CpG) dinucleotide combina-
tion (methylation at non-CpG sites has also been known to occur, but predominantly 
in plants and embryonic stem cells). CpG dinucleotides are underrepresented in the 
genome, i.e., this combination of nucleotides occurs less frequently (about 20%) than 
would be expected based on chance. This CpG depletion occurs because methylated 
CpG sites throughout the genome (70-80% of CpG sites are methylated) are at risk to 
be spontaneously deaminated (removal of an NH2 group), resulting in the conversion 
of 5-methylcytosine into the base thymine (resulting in a TpG dinucleotide) 3. However, 
there are regions that contain a much higher frequency of CpG dinucleotides. These 
regions are known as CpG islands and can be found in the promoter regions (i.e. the start 
site) of genes. Whereas single CpG sites throughout the genome are mostly methylated, 
CpG sites in CpG islands are often unmethylated 4. When these CpG sites in the CpG 
island become methylated, the gene is generally silenced as gene expression is reduced. 
This can be achieved by directly preventing transcriptional proteins to access the gene, 
or by recruiting methyl-CpG-binding domain proteins (MBDs). These proteins recruit 
other proteins that modify histones, which results in a structural change that makes the 
DNA inaccessible for other transcriptional proteins.
Chapter 1
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EPiGEnEtiCs in bEHAviOrAL rEsEArCH – PrELiminAry findinGs
Animal research has made a large contribution in understanding the processes of 
epigenetic regulation, particularly in a gene involved in the stress response, the gluco-
corticoid receptor gene (Nr3c1) 2, 5. Studies in rats showed that variations in maternal 
care towards offspring could result in altered hypothalamic-pituitary-adrenal (HPA) axis 
responses and behavioral responses to stress, through differences in Nr3c1 methylation 
levels. Glucocorticoid receptors regulate the release of glucocorticoids by providing 
negative feedback to the hypothalamus-pituitary-adrenals axis (HPA-axis). This inhibits 
the release of other hormones (corticotropin-releasing hormone (CRH) and adrenocor-
ticotropic hormone (ACTH)) that stimulate the release of glucocorticoids from the adre-
nals. Low levels of maternal licking and grooming (LG) and arched back nursing (ABN) 
behavior towards the offspring in the first week of life were associated with higher Nr3c1 
promoter methylation levels in the hippocampus of rat pups. As a result, expression 
of the glucocorticoid receptors was decreased and feedback inhibition was reduced, 
resulting in elevated stress responses and more fearful behavior 2, 5-7. Cross fostering 
of the pups resulted in a methylation and behavior pattern that matched the behavior 
of the foster mother. This indicates that epigenetic processes that regulate expression 
of the glucocorticoid receptor in the brain mediate the relationship between early life 
stress (reduced LG and ABN) and adult HPA-axis responses 5.
These findings in animal studies have been replicated in humans 8-13. McGowan and 
colleagues (2009) reported more hippocampal DNA methylation in the NR3C1 gene 
promoter in victims of suicide with a history of childhood abuse than in those without a 
history of childhood abuse and non-abused controls 8. In studies using peripheral DNA, 
from blood or saliva, NR3C1 methylation was found to be higher in individuals exposed 
to childhood abuse or neglect 10, 11 or other stressful life events (such as loss of a family 
member or parental depression) during childhood 11, 13. These studies suggest that the 
same epigenetic mechanisms tested in animals are also present in humans and that the 
relationship between adverse life events and adverse health outcomes may be medi-
ated by DNA methylation.
OtHEr POtEntiAL PrEdiCtOrs Of EPiGEnEtiC mOdifiCAtiOn
Although the association between early life adversity and DNA methylation has best 
been described for NR3C1, this association has also been investigated for the serotonin 
transporter gene (SLC6A4). The serotonin transporter protein is an important regulator 
of serotonergic neurotransmission through the reuptake of serotonin (5-hydrox-
tryptamine, 5HT) in brain synapses. Alterations in serotonergic neurotransmission and 
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genetic variation in this gene (e.g. 5HT-linked polymorphic region, 5HTTLPR) have been 
associated with an increased risk for various psychiatric disorders 14-17. Several studies 
have reported an association between childhood adversity and higher levels of SLC6A4 
methylation 18-24.
Notwithstanding the importance of these studies in humans, they were relatively 
small in size and vulnerable to confounding factors. The focus of these studies was pre-
dominantly on traumatic experiences (such as sexual abuse or neglect), and less on more 
common stressful life events (such as parental divorce or the loss of a family member) 
that may also affect DNA methylation. Additionally, most studies investigated adversity 
experienced in childhood, as the previously mentioned animal studies reported higher 
methylation levels only when exposed to reduced maternal care in the first week of life. 
In humans, however, adolescence is also an important period of development, often 
accompanied by an increased susceptibility to stress-related mental disorders 25, 26. Yet, 
the impact of adversity in adolescence on NR3C1 and SLC6A4 methylation had not been 
investigated.
OutCOmEs Of EPiGEnEtiC mOdifiCAtiOn
In humans, many studies have shown robust associations of early adverse life events 
with a wide range of disorders in later life, such as psychiatric, cardiovascular and meta-
bolic disorders, as well as for risk factors of these disorders, such as obesity 1, 27, 28. Not 
only have robust associations been found for disorders, but also with increased respon-
siveness of the autonomic nervous system and the HPA-axis to stress 29-31. However, not 
many studies have investigated the relationship between DNA methylation and these 
different outcomes.
For psychiatric problems such as anxiety and depression, only a few studies have 
investigated the association with SLC6A4 or NR3C1 methylation. These studies were 
cross-sectional or retrospective; prospective studies on this association are lacking. 
Similarly, research on the association between NR3C1 methylation and HPA-axis regula-
tion is scarce. The few studies that did investigate this association varied greatly in their 
measures of HPA-axis regulation and had a small sample size 9, 11, 32, and therefore require 
replication in a larger cohort.
The association between SLC6A4 or NR3C1 methylation and obesity has received even 
less attention. Although genetic variants of these genes have been associated with car-
diovascular problems, metabolic disorders and obesity, the association between DNA 
methylation and obesity has only been reported once for SLC6A4 33 and has not been 
investigated for NR3C1.
Chapter 1
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Besides psychiatric, cardiovascular and metabolic disorders, exposure to adverse 
life events has also been linked with substance use 34, 35. As DNA methylation by en-
vironmental factors is likely to affect multiple genes across the genome, it would be 
interesting to investigate whether substance use may be related to DNA methylation in 
a gene involved in dopamine regulation. Frequent substance use has been associated 
with altered dopamine levels in the brain, which is degraded by the enzyme catechol-
O-methyltransferase (COMT). Variations in enzyme activity can influence vulnerability 
to substance use, and perhaps differences in COMT gene (COMT) expression through 
methylation may also affect the tendency for substance use. Again, little is known about 
the association between COMT methylation and substance use: only the associations 
between COMT methylation and tobacco smoking 36 and alcohol use 37 have been in-
vestigated in two studies with a small sample size. For cannabis use, this association has 
not been reported.
To investigate the relationship between DNA methylation in NR3C1, SLC6A4 and COMT 
and the before-mentioned outcomes, large longitudinal studies are required that exam-
ine a wide range of exposures and outcomes, including long-term outcomes.
rEsEArCH Aims And tHEsis OutLinE
In this thesis I have investigated whether DNA methylation may serve as an underlying 
biological mechanism that predisposes individuals with a history of adversity to adverse 
health outcomes. DNA methylation could be an eligible mediator of the association 
between adversity and adverse health outcomes (illustrated in figure 1) when there 
is an association between adverse life events and DNA methylation, and between DNA 
methylation and adverse health outcomes. We therefore studied the associations of 
DNA methylation with both possible predictors and possible health outcomes.
tHEsis OutLinE
I first investigated whether stressful life events, during childhood and adolescence, 
are associated with higher CpG methylation in the genes encoding the glucocorticoid 
receptor (NR3C1, Chapter 2) and the serotonin transporter (SLC6A4, Chapter 3). I then 
investigated whether higher methylation levels of NR3C1 and SLC6A4 were associated 
with internalizing problems, i.e. anxiety and depression problems in Chapter 4. Next, 
I investigated whether NR3C1 methylation was associated with HPA-axis dysregulation 
in Chapter 5. In Chapter 6, I investigated whether methylation of SLC6A4 and NR3C1 
was associated with obesity, as obesity in adolescence is an important risk factor for 
13
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cardiovascular and metabolic disorders later in life. Next, to explore possible epigenetic 
associations with substance use, I investigated whether COMT methylation was associ-
ated with substance use in adolescents in Chapter 7. In Chapter 8 I discuss the main 
findings of this thesis, and combine the information from Chapters 2-4, by investigat-
ing whether DNA methylation acted as a mediator in the association between SLEs and 
internalizing symptom scores. A summary of all findings is given in Chapter 9.
sEttinG: tHE trAiLs study
This study was part of the TRacking Adolescents’ Individual Lives Survey (TRAILS), a 
prospective population study in which Dutch adolescents are followed from childhood 
(10-12 years) into adulthood (25 years and older). Assessment waves have been con-
ducted biennially or triennially, and five assessment waves have been completed thus 
far. A detailed description of sampling and methods can be found in de Huisman et al 38, 
Ormel et al 39, and Oldehinkel et al 40. With its prospective design, its large representative 
population and the availability of a large number of measures on outcomes, life histories 
and biological samples, TRAILS offers good data for this project.
figure 1. Proposed mediation model.
Chapter 1
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Chapter 2 
Glucocorticoid receptor gene (NR3C1) 
methylation following stressful events between 
birth and adolescence.  
The TRAILS study
L.J. van der Knaap
H. Riese
J.J. Hudziak
M.M.P.J. Verbiest
F.C. Verhulst
A.J. Oldehinkel
F.V.A. van Oort
Translational Psychiatry, 2014, 4, e381, doi:10.1038/tp.2014.22.
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Chapter 2
AbstrACt
Stress early in life is a known risk factor for the development of affective disorders later 
in life. Epigenetic mechanisms, such as DNA methylation, may have an important role in 
mediating that risk. Recent epigenetic research reported on the long-term relationship 
between traumatic stress in childhood and DNA methylation in adulthood. In this study, 
we examined the impact of various types of stress (perinatal stress, stressful life events 
(SLEs) and traumatic youth experiences) on methylation of the glucocorticoid receptor 
gene (NR3C1) in the blood of a population sample of 468 adolescents (50.4% female, 
mean age 16.1 years). Second, we determined whether stress at different ages was 
associated with higher NR3C1 methylation. NR3C1 methylation rates were higher after 
exposure to SLEs and after exposure to traumatic youth experiences. NR3C1 methylation 
in adolescence was not higher after exposure to perinatal stress. Experience of SLEs in 
adolescence was associated with a higher NR3C1 methylation, independently of child-
hood SLEs. We demonstrate that not only traumatic youth experiences but also (more 
common) SLEs are associated with higher NR3C1 methylation. In addition, our findings 
underline the relevance of adolescent stress for epigenetic changes in the NR3C1 gene.
21
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NR3C1 methylation following stressful experiences
intrOduCtiOn
Severe maltreatment or neglect in childhood are known risk factors for development 
of affective disorders and have been associated with altered programming of the hy-
pothalamic-pituitary-adrenal (HPA) axis 1-4. Epigenetic modifications are thought to link 
early-life stress to later susceptibility to affective disorders, such as anxiety or depression, 
through interference with the development and functioning of the HPA axis early in life 5. 
More recently, the notion that stress can have a direct effect on epigenetic modifications 
across the life span has been proposed, which in turn affects brain plasticity and may 
lead to anxiety 6. The epigenetic process of DNA methylation involves the addition of 
methyl groups on cytosine-guanine dinucleotides (CpGs) in gene promoters and regula-
tory regions, which regulate gene transcription7. The presence of these methyl groups is 
associated with reduced gene expression by reducing access to the DNA. Methyl groups 
on CpGs in regulatory regions for transcription factors can directly interfere with the 
binding of transcription factors to their recognition elements. Methylated regions can 
also repress transcription indirectly by attracting methylated DNA-binding proteins, 
which can alter the chromatin formation, disabling access to DNA for transcription 8-12. 
While much research focuses on the function of epigenetic modifications, less is known 
about how they are environmentally induced.
Whereas the genome is fixed, the epigenome is considered to be dynamic –that 
is, under influence of environmental factors 13, 14. In rats, exposure to early-life stress, 
measured as reduced levels of maternal licking and grooming (LG) behavior towards 
their offspring, led to increased methylation in the glucocorticoid receptor (GR) gene 
(Nr3c1) of their offspring. The GRs regulate the release of glucocorticoids through a 
negative feedback mechanism in the HPA-axis. Increased methylation in offspring and 
reduced expression of GRs in the hippocampus by low maternal LG behavior resulted in 
a diminished feedback sensitivity of the HPA-axis 15. Differences in methylation between 
offspring from high-LG and low-LG mothers persisted into adulthood, illustrating long 
lasting effects of early programming on the epigenome.
These animal findings were translated to humans by McGowan et al 16. They reported 
increased levels of methylation and decreased levels of GR-expression in post-mortem 
hippocampal tissue of suicide completers who were abused during childhood, com-
pared to non-abused suicide completers and non-abused controls 16. Other studies us-
ing peripheral DNA, from blood of infants, adolescents or adults, have shown increased 
levels of NR3C1 methylation in response to perinatal stress 17-19 and abuse or neglect 
during childhood 20, 21. Most studies thus far reported on DNA methylation in adults 
after enduring stress or traumatic events such as abuse or neglect 16, 20-22. Fewer stud-
ies have investigated whether NR3C1 methylation in humans can be induced by other, 
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more common, stressful life events (SLEs – for example, parental divorce, loss of a family 
member) as well 21, 23, 24.
Besides types of stress, the role of timing of stress on methylation is understudied. 
Humans are subjected to a high variety of stressors throughout life. The perinatal period 
and childhood years are regarded as sensitive periods for the developing brain in which 
the organism could be particularly susceptible to epigenetic modifications that influ-
ence HPA-axis development 25. However, some brain regions keep developing at least 
until early adulthood 26, hence there is a possibility that epigenetic modifications are not 
restricted to childhood 27-29. While there is preliminary evidence for epigenetic modifica-
tion of NR3C1 due to stressors in childhood 16, 20, 21, the adolescent period, in spite of 
its obvious importance as a period of increased susceptibility to stress-related mental 
disorders 30, 31, has had no examination of the impact of stress on NR3C1 methylation 
independent of stress experienced in childhood 6.
We studied the effects of stress on NR3C1 methylation in a large prospective popula-
tion study of adolescents in two ways. First, we examined the impact of various types 
of stress (for example, perinatal stress, SLEs and traumatic youth experiences) on NR3C1 
methylation. Second, we determined whether stress at different ages was associated 
with higher NR3C1 methylation. Based on previous findings 15-22, 32 we hypothesized 
that perinatal stress, many SLEs, and traumatic youth experiences would relate to 
higher NR3C1 methylation in adolescence. We further expected that SLEs experienced 
in childhood would, independently of later adolescent stress, relate to increased NR3C1 
methylation in adolescence.
mAtEriALs & mEtHOds
sample selection
Data from the TRAILS (TRacking Adolescents’ Individual Lives Survey) study were used. 
TRAILS is a prospective population study of Dutch adolescents (N = 2230) who are be-
ing followed from pre-adolescence into adulthood. Assessment waves are conducted 
biennially or triennially, and four assessment waves have been completed so far. Writ-
ten consent was obtained from each subject and their parents at every assessment 
wave. The present study involves data collected during the first assessment wave (T1, 
2001–2002, mean age 11.1 years, s.d. = 0.55), second (T2, 2003–2004, mean age 13.6 
years, s.d. = 0.53), third (T3, 2005–2007, mean age 16.3 years, s.d. = 0.71) and fourth 
(T4, 2008–2010, mean age 19.1 years, s.d. = 0.60) assessment waves. At T3, 715 TRAILS 
subjects (focus sample) participated in more extensive experimental data collection. 
Adolescents with an increased risk of mental health problems had a greater chance of 
being selected for the experimental session. Increased risk was defined as having at least 
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one of the following risk factors: child temperament (high frustration and fearfulness, 
low effortful control), parental psychopathology (depression, anxiety, addiction, psy-
choses or antisocial behavior) and environmental risk (living in a single-parent family), 
all measured at T1. Although high-risk adolescents were slightly oversampled (66% of 
the focus sample, the remaining 34% of the focus sample were selected at random from 
the low-risk TRAILS participants), the sample included the total range of mental health 
problems present in a community population of adolescents. The study was approved 
by the Dutch Central Medical Ethics Committee and all subjects received compensation 
for their participation. A detailed description of sampling and methods can be found in 
Huisman et al 33 and Ormel et al 34. DNA had been isolated from blood for 654 of these 
subjects. Initial selection for methylation analyses (N = 475) was obtained by excluding 
subjects with non-Dutch ethnicity (N = 58), unknown or insufficient DNA concentration 
(N = 116), and randomly excluding one of each sibling pair (N = 5). Following drop-out 
after DNA methylation analyses, 468 subjects were eligible for analysis. Our subsample 
subjects did not differ significantly (P>0.05) from the TRAILS focus sample with regard 
to sex, socioeconomic status (T1), age (T3), internalizing problems (T3) and externalizing 
problems (T3).
stress measures
Perinatal stress was operationalized as the sum of maternal psychological problems 
during pregnancy or the three months after delivery, preterm delivery (≤33 weeks), 
low birth weight (≤2500 g), hospitalization of mother or child within 1 month after 
delivery, and maternal alcohol use or smoking during pregnancy. For birth weight and 
gestational age we used records of the Preventive Child Healthcare services35. The other 
stressors were measured in a detailed interview with the parents at T1.
SLEs experienced between ages 0 and 15 years were assessed for the age categories 
of 0–5, 6–11, 12–13 and 14–15 years, as described by Bosch et al 4. Information on SLEs 
in early childhood (0-5 years) and middle childhood (6-11 years) was collected during a de-
tailed interview with the parents at T1, and included the number of times the child had 
experienced parental divorce, hospitalization, the death of a family member or friend, 
out-of-home placement, parental addiction or parental mental health problems 4. 
The total number of SLEs experienced in early adolescence (12-13 years) was assessed 
with a self-report questionnaire at T2 4. The 25 SLEs included illness or injury of the 
participant, a family member or a friend; parental divorce; death of family member or 
friend; changes in family composition; parental unemployment; conflicts with family or 
friends; and being bullied. SLEs in middle adolescence (14-15 years) were assessed at T3 
in an Event History Calendar Interview 36 with the adolescent. The list of possible events 
consisted of conflicts, physical or sexual intimidation, victim of bullying/gossiping, loss 
or lack of friends, psychological/addiction problems of family or friends, out-of-home 
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placement, running away from home, death/illness of family member, hospitalization of 
participant, and parental divorce. On the basis of the above-mentioned event measures, 
we calculated a measure of total SLEs experienced between ages 0 and 15 years by stan-
dardizing the sum score of the number of events for each age category, and summing 
the standardized scores. This procedure was chosen to account for differences in the 
number of possible SLEs by age group. The resulting total sum score (SLEs 0-15 years) 
was standardized for analyses.
Traumatic youth experiences. At T4, information on sexual, physical and other traumatic 
experiences before the age of 16 years was obtained with a 16-item self-report question-
naire. To determine sexual abuse, the participants were asked if an adult family member, 
friend of the family or stranger had ever, before the participant was 16, showed his/her 
genitals or masturbated in front of them; had sexually assaulted them; had forced them 
to touch him/her in a sexual manner; had attempted to have intercourse or had actu-
ally had intercourse with them. To determine physical abuse, participants were asked 
if a parent or caretaker had ever, before the participant was 16, hit them with a belt, 
brush, stick or other hard object; had hit them with a fist or kicked them very hard; had 
shaken or pinched them; had beaten them up (that is, hit them in succession) or had 
threatened them with a knife or other weapon. To determine other trauma, participants 
were asked if, before the age of 16, they had been involved in a life-threatening accident; 
had witnessed severe injury or death; had been a victim of physical violence or assault; 
had been threatened with a weapon, had been held captive or abducted or had been 
involved in a fire, flood or other (natural) disaster. Answers were coded into a single 
exposure or multiple exposures to traumatic youth experiences. We had no data on the 
timing of traumatic life stress. We cross-tabbed the three SLE profiles with traumatic 
experiences (Supplementary Table 1) and found that traumatic experiences were not 
strongly overrepresented in the childhood SLE group or the adolescence SLE group.
Amplicon selection
Three amplicons (genomic regions) within the NR3C1 cytosine-guanine dinucleotide 
(CpG) island in the promoter-region were selected for analyses (Figure 1). CpG-island 
position was determined using criteria from UCSC genome browser – that is, a genomic 
region with a CpG content of 50% or greater, length greater than 200bp, and a ratio 
greater than 0.6 of observed number of CG dinucleotides to the expected number on 
the basis of the number of Gs and Cs in the segment (UCSC human Feb. 2009 assembly 
GRCh37/hg19, (http://genome.ucsc.edu). Two primer sets were designed using the 
software EpiDesigner by Sequenom (www.epidesigner.com), covering the edges of 
the NR3C1 CpG-island. Additionally, we analyzed a region of the CpG-island using the 
primer set previously used by McGowan et al 16. This genomic region encompasses exon 
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1F which corresponds to the rat exon 17. Sequence information and primer properties 
can be found in Supplementary Figure 1 and Supplementary Table 2.
dnA methylation
Analysis. DNA was extracted from whole-blood samples using a manual salting-out 
procedure as described by Miller et al 39. DNA-methylation rates were analyzed using 
bisulfite-treated DNA, PCR, reverse transcription, base-specific cleavage of in vitro tran-
scribed RNA product, and mass spectrometry (Sequenom EpiTYPER, San Diego, CA, USA). 
Bisulfite conversion of DNA was performed using EZ-96 DNA Methylation Kit (Shallow; 
Zymo Research, CA, USA). Bisulfite treatment was performed according to manufactur-
ers’ protocol. It must be noted that bisulfite conversion does not differentiate between 
the different types of cytosine methylation (e.g. hydroxymethylation). PCR, reverse 
transcription, cleavage and mass spectrometry were performed in triplicate according 
to EpiTYPER protocol. Amplification conditions can be found in Supplementary Table 
3. The mass signal patterns generated are translated to quantitative methylation rates 
for different CpG units by the MassARRAY EpiTYPER analyzer software from Sequenom. 
(v1.0, build1.0.6.88 Sequenom, Inc, San Diego, USA). Fragments with CpG dinucleotides 
are referred to as CpG units. One CpG unit can contain one or more CpG dinucleotide.
Data cleaning. All samples were analyzed in triplicate, and samples with a s.d. of ⩾10% 
between replicates were removed for analysis. CpG units with ⩾25% missing values were 
not included in the analyses. For each CpG unit, methylation scores of the triplicates 
were averaged. We accounted for mass change in CpG units by single nucleotide length 
polymorphisms (only when minor allele frequency >5%) by removing CpG units from 
analyses containing the single nucleotide length polymorphism and removing units 
with overlapping mass caused by single nucleotide length polymorphisms in non-CpG 
units. Amplicon 1 consisted of 11 eligible CpG units, amplicon 2 contained 10 and am-
plicon 3 contained nine eligible CpG units.
NR3C1_1 NR3C1_2 NR3C1_3 
1F 1B 1J 1E 1H 2 1C1, 1C2, 1C3 1D 1I 
CpG Island 
figure 1. schematic representation of the glucocorticoid receptor gene (NR3C1). Amplicons (NR3C1_1, 
NR3C1_2 and NR3C1_3, shown in grey) are shown in relation to the NR3C1 CpG-island (chr5:142782072-
142785071, dotted box) and untranslated first exons (line boxes) upstream of exon 2 (striped box). Image 
based on Labonte et al 37 and Turner et al 38.
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statistical analyses
Main analyses. Linear regression analyses were conducted to examine the effects of type 
and timing of stress on NR3C1 methylation in adolescence. Amplicons were analyzed 
separately 40. For each CpG unit, methylation was mean-centered (resulting in mean 
methylation of 0, with original s.d.), to account for high methylation in a small number 
of CpG units. As individuals could have drop-out in one or more CpG units, an average 
methylation score for each amplicon was calculated by taking the average of the mean-
centered methylation scores of the CpG units within an amplicon. Separate models 
were run for perinatal stress, SLEs (0-15 years), the three categories of traumatic youth 
experiences (sexual, physical and other trauma). Smoking, gender and age at T3 were 
considered as potential confounders, but including them in the models appeared not 
to change the regression coefficients of stress variables with more than 10%. Therefore, 
these confounders were not included in the final models. To test our hypothesis on the 
timing of stress and NR3C1 methylation, we ran a linear regression model with the two 
SLEs variables (0-11 and 12-15 years).
As a post-hoc robustness check, we repeated analyses on type and timing of stress on 
methylation of amplicon 2 on an additional random sample of 454 TRAILS subjects, who 
were not part of the T3 focus sample. Information on the other two amplicons was not 
available for this sample. Amplicon 2 was chosen a priori for its correspondence with 
the study by McGowan et al 16 and the known presence of the nerve-growth-factor-
inducible-protein-A (NGFI-A)-binding site.
Exploratory analyses. In addition to the analyses of the three above-mentioned ampli-
cons, we performed exploratory linear regression analyses of type and timing of stress 
on mean-centered methylation scores of three individual CpG units, selected based on 
their relatively high methylation rates and s.d.’s (Supplementary Table 4).
The tests were conducted using SPSS (IBM SPSS, v.20.0. Armonk, NY: IBM Corp), 
whereas the latent profile analysis (LPA) was performed in Mplus 5 (Los Angeles, CA: 
Muthén & Muthén).
rEsuLts
Approximately half of the sample was female (50.4%) and the mean age of the adoles-
cents was 16.1 years at the time of the DNA collection, with a range from 14 to 18 years. 
Methylation was not correlated with age. Table 1 presents the descriptive statistics of 
perinatal stress, SLEs and traumatic youth experiences (uncentered, unstandardized).
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Life stress and methylation
The results of the linear regression models with stress variables as predictors of NR3C1 
methylation are presented in Table 2. Exposure to SLEs 0–15 years and to traumatic 
youth experiences significantly predicted higher methylation rates in amplicon 1. In 
amplicon 2, only single exposure to sexual abuse predicted higher methylation rates 
(B=0.44, P<0.001). For amplicon 3, repeated exposure to other traumatic youth experi-
ences was associated with lower methylation rates (B=-0.26, P<0.01).
Secondly, we analyzed timing of SLEs. We had no specific hypotheses for early versus 
late adolescence or for early versus late childhood stress 4. As these variables are cor-
related more strongly within childhood and adolescence age groups than between 
(see Supplementary Table 5), we considered creating a childhood SLE variable and an 
adolescence SLE variable. We used latent LPA to explore profiles of SLE in our sample. 
We found three distinct profiles (see Supplementary Table 6 and Supplementary Figure 
2): a ‘low stress group’ at all ages, a ‘high childhood stress group (0-5 years and 6-11 
table 1. Descriptives of perinatal stress, SLEs and traumatic youth experiences. 
median (min-max) n (%)
Perinatal stress 1 (0-6)
SLEs (0-15yrs)
0-15yrs 6 (0-23)
0-5yrs 1 (0-10)
6-11yrs 1 (0-8)
12-13yrs 2 (0-12)
14-15yrs 1 (0-11)
Traumatic Youth Experiences (0-16yrs)
Sexual abuse 
 None 403 (84.8%)
 Single exposure 22 (4.6%)
 Repeated exposure 12 (2.5%)
Physical abuse 
 None 253 (53.2%)
 Single exposure 170 (35.8%)
 Repeated exposure 14 (2.9%)
Other trauma
 None 319 (67.2%)
 Single exposure 90 (18.9%)
 Repeated exposure 28 (5.9%)
Abbreviation: SLE, stressful life event. 
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years)’ and a ‘high adolescent stress group (12-13 years and 14-15 years)’. Sample size 
was too small to use the three profiles as predictor of NR3C1 methylation; however, the 
LPA analysis provided the support to distinguish between SLEs in childhood (0-11 years) 
and SLEs in adolescence (12-15 years). The variables were constructed by summing 
standardized scores for each age period. The SLE scores (0-11 years and 12-15 years) 
were standardized before analyses.
Experience of SLEs in adolescence was associated with a higher methylation score 
independently of childhood SLEs in amplicon 1 (B=0.05, p<0.01), but not in amplicons 
2 and 3 (Table 2).
Exploratory analyses
Exploratory analyses on CpG unit-specific methylation (Table 3) showed higher methyla-
tion rates with more exposure to SLEs 0-15 years and to traumatic youth experiences 
in all three CpG units. Perinatal stress was not related to CpG unit-specific methylation. 
Additionally, the CpG unit-specific analyses show that SLEs in adolescence predicted 
table 2. Life stress and NR3C1 methylation scores by amplicons. 
NR3C1_1 NR3C1_2 NR3C1_3
b s.e. P b s.e. P b s.e. P
Perinatal stress 0.03 0.02 .14 -0.01 0.02 .78 0.01 0.02 .53
traumatic youth experiencesa
Sexual abuse
 single exposure 0.37 0.09 <.0001 0.44 0.12 <.001 -0.08 0.10 .40
 repeated exposure 0.50 0.12 <.0001 0.13 0.17 .45 -0.26 0.13 .05
Physical abuse
 single exposure 0.01 0.04 .73 0.02 0.06 .68 -0.02 0.05 .66
 repeated exposure 0.49 0.12 <.0001 -0.09 0.15 .56 -0.18 0.12 .15
Other trauma
 single exposure 0.09 0.05 .06 -0.04 0.07 .52 -0.10 0.06 .08
 repeated exposure 0.53 0.08 <.0001 0.07 0.11 .56 -0.26 0.09 <.01
sLEsb
 Total (0-15 years) 0.05 0.02 .02 0.03 0.03 .25 -0.03 0.02 .20
 Childhood (0-11 years) 0.01 0.02 .57 0.00 0.03 .97 -0.03 0.02 .22
 Adolescence (12-15 years) 0.05 0.02 <.01 0.04 0.03 .13 -0.01 0.02 .62
Abbreviations: B, regression coefficient; SLEs, stressful life events. Linear regression of early-life stress and 
multivariate regression analyses of SLEs in two age categories on NR3C1 methylation scores. Bold numbers 
indicate significant results (P<0.05). a No exposure is the reference category. b Z-scores.
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higher NR3C1 methylation in NR3C1_1CpGU12 and NR3C1_2CpGU13, whereas child-
hood SLEs predicted higher NR3C1 methylation in NR3C1_2CpGU14.
In the post hoc robustness check (Supplementary Table 7), we repeated the analyses 
for amplicon 2 exclusively. The significant association with single exposure to sexual 
abuse in the original sample failed to replicate in the additional sample.
disCussiOn
In this study, experience of multiple SLEs and exposure to traumatic experiences be-
tween birth and adolescence were associated with higher NR3C1 methylation rates in 
adolescents. In contrast with our initial expectation, we found that not perinatal or child-
hood stress, but rather SLEs in adolescence were associated with higher NR3C1 methyla-
tion. To the best of our knowledge no other comparable studies have focused on the 
timing of stressful events when investigating DNA methylation. Our results on traumatic 
table 3. Life stress and NR3C1 methylation scores of the three highest methylated CpG units. 
NR3C1_1CpGu12  NR3C1_2CpGu13 NR3C1_2CpGu14
b s.e. P  b s.e. P b s.e. P
Perinatal stress 0.05 0.11 .64  0.05 0.20 .81 - 0.05 0.09 .58
Traumatic youth experiencesa
Sexual abuse
 single exposure 1.95 0.52 <.001  5.06 0.95 <.0001  0.91 0.43 .04
 repeated exposure 3.07 0.70 <.0001  4.21 1.29 <.01  0.50 0.59 .40
Physical abuse
 single exposure 0.07 0.24 .78  0.34 0.45 0.46  0.15 0.20 .46
 repeated exposure 2.79 0.67 <.0001  2.68 1.20 .03 - 0.34 0.54 .52
Other trauma
 single exposure 0.36 0.28 0.20 - 0.02 0.53 .98  0.07 0.24 .78
 repeated exposure 3.32 0.46 <.0001  3.86 0.83 <.0001  0.22 0.39 .57
SLEsb
 Total (0-15yrs) 0.38 0.12 <.01  0.45 0.21 .03  0.24 0.09 .01
 Childhood (0-11yrs) 0.10 0.12 .41 - 0.05 0.21 .82  0.21 0.09 .02
 Adolescence (12-15yrs) 0.41 0.12 <.001  0.68 0.21 <.01  0.10 0.09 .26
Abbreviations: B, regression coefficient; CpG, cytosine–guanine dinucleotide; SLE, stressful life events. Lin-
ear regression of early life stress and multivariate regression analyses of SLEs in two age categories on 
NR3C1 methylation scores. Bold numbers indicate significant results (P<0.05). a No exposure is the reference 
category. b Z-scores.
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youth experiences are consistent with prior studies 16, 20-22, with higher methylation rates 
in individuals who have experienced traumatic youth experiences.
The absence of a significant relationship between NR3C1 methylation and perinatal 
stress in our sample appears to contrast with previous human studies that showed 
higher NR3C1 methylation after exposure to perinatal stress 17-19. NR3C1 methylation 
in newborns was positively associated with depressed maternal mood in the third 
trimester of pregnancy 17. In addition, war stress during pregnancy affected newborn 
NR3C1-methylation rates 19. As these studies involve newborns, no statement could be 
made on the effect of stressful experiences on NR3C1 methylation later in life. Radtke et 
al 18 and colleagues reported higher NR3C1 methylation in 25 adolescents with maternal 
exposure to intimate partner violence during pregnancy. However, they did not con-
sider the possible influences of more recent stressful experiences on NR3C1 methylation 
of the adolescents.
Our timing analysis on SLEs indicates that NR3C1 methylation was independently 
associated with SLEs in adolescence. Although this may not be very surprising given 
that adolescence is a significant neurodevelopmental stage, this is the first study to 
show that adolescent stress actually co-occurs with higher NR3C1 methylation. Our 
study did not support the notion of a sensitive period to SLEs in childhood for NR3C1 
methylation in adolescents, despite suggestive findings in animal studies 15, 32, 41 and 
a study on long-term effects of adversities on cortisol stress response in our TRAILS 
participants 4. However, in line with our results, a study in rodents did not report altera-
tions in NR3C1 methylation following early life stress 42, and others reported changes 
in NR3C1 methylation following chronic and acute stress in adult rats 43. Possibly, some 
epigenetic modifications by stress exposure may be short-term effects, which may allow 
for a more adaptive stress regulation. This may also explain the discrepancy between 
our study and those investigating methylation in newborns following maternal stress. 
Recent evidence on active removal of methyl groups 44, 45 gives rise to the possibility of 
dynamic regulation and reversibility of DNA methylation. Reversal of NR3C1 methylation 
in adult rats was proven possible through pharmacological manipulation 46, but it is cur-
rently unknown if active demethylation can be triggered by environmental factors, - for 
example, positive events following a stressful early life.
We expected to find associations with stress in amplicon 2 in particular. This amplicon 
is identical to the one studied by McGowan et al 16, and covers the exon 1F (analog to first 
exon 17 in rats 47) promoter containing the transcription factor NGFI-A binding site. In rats 
and humans, DNA methylation inhibited binding of NGFI-A to its binding site, causing a 
reduction in transcriptional activity 16, 48. However, most of the associations with stress 
measures were in amplicon 1, at the edge of the CpG-island (Figure 1). It is likely that 
the environment exerts its influence on other alternative first exon promoters spanning 
the CpG-island as well, since methylation is highly variable between individuals in these 
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promoters 49. Further, the presence of other CpG-rich transcription factor binding sites 
may also play a role 49. Recently, childhood abuse was related to methylation of other 
first exon promoters than the exon 1F promoter in human post-mortem brain tissue 37.
 The exploratory analyses on individual CpG units with relatively high methylation 
scores showed more pronounced relations between stress and methylation than the 
main analyses. Additionally, these analyses also showed higher methylation in a single 
CpG unit after childhood stress exposure. Differences between CpG units emphasize 
the need to understand which regions have a regulatory function and may be more 
responsive to environmental stimuli. In our post hoc robustness check on amplicon 2 the 
significant association with sexual abuse in the original sample failed to replicate. This 
may be due to the fewer individuals that have experienced a single exposure to sexual 
abuse in the replication sample or the initial association may have been due to chance.
It has to be noted that our assessment of SLEs differed between time periods because 
we aimed to measure age-appropriate SLEs for the different developmental stages of 
childhood and adolescence, and used different informants to optimize the reliability 
of event recall. As a consequence, some SLEs that were assessed in adolescence were 
not measured in childhood, including conflicts with family and friends, being bullied, 
sexual intimidation and loss or lack of friends. These added events in adolescence may 
have contributed to the difference in methylation rates we found for childhood and 
adolescence SLEs. As children lack the capacity to remember early childhood experi-
ences, childhood SLEs were based on parent-reports. SLEs in adolescence were based on 
self-report, because the parents may no longer be aware of all aspects of their children’s 
lives as they grow towards independence. Considering the nature of our study design 
and our desire to include as many relevant SLEs as possible, we could not fully overcome 
these dissimilarities but we do acknowledge that they warrant caution when interpret-
ing the results. It is possible, for instance, that self-reported SLEs more closely reflect the 
actual stress levels experienced than parent-reported events. Furthermore, some SLEs 
that were assessed only in adolescence may be more chronic than the SLEs measured in 
childhood (e.g. sexual intimidation or lack/loss of friends) and thus have a more lasting 
influence on stress levels. Hence, although our findings suggest that SLEs in adolescence 
are independently associated with NR3C1 methylation, we cannot completely exclude 
the possibility that this can be ascribed to specific SLEs measured in adolescence but not 
in childhood, or to informant differences.
Our study has several strengths: The TRAILS study provides data on NR3C1 methyla-
tion in a large population based sample. Furthermore, we had a detailed account of SLEs 
between birth and adolescence. This study is the first to explore the effect of SLEs during 
childhood and adolescence separately. A limitation of the study was that blood was col-
lected at T3 only, preventing analyses of changes in methylation. For this reason we 
could not establish any causal links between SLEs or trauma and methylation. Also, our 
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sample overrepresents adolescents with an increased risk of mental health problems. 
However, the use of sampling weights to reproduce the distribution in the total TRAILS 
sample 50 did not affect our results. In addition, unlike for the SLEs measure, no tim-
ing data were available for traumatic youth experiences. Another limitation is that our 
robustness check was only possible for amplicon 2.
Together, our findings add to the existing literature by showing that both SLEs and 
traumatic stress affect NR3C1 methylation in adolescents. In addition, it is the first study 
to show epigenetic effects of stress experienced in adolescence.
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supplementary table 1. The number of traumatic events experienced for subjects in each of the LPA cat-
egories. 
LPA category SLEs
Childhood Adolescence Overall low
sexual abuse no 74 (18.0%) 36 (8.8%) 300 (73.2%)
single 3 (13.6%) 6 (27.3%) 13 (59.1%)
repeated 3 (25.0%) 2 (16.7%) 7 (58.3%)
Physical abuse no 46 (18.0%) 21 (8.2%) 189 (73.8%)
single 30 (17.3%) 19 (11.0%) 124 (71.7%)
repeated 4 (26.7%) 4 (26.7%) 7 (46.7%)
Other trauma no 54 (16.7%) 29 (9.0%) 241 (74.4%)
single 19 (20.9%) 8 (8.8%) 64 (70.3%)
repeated 7 (24.1%) 7 (24.1%) 15 (51.7%)
note: Displayed percentages reflect the proportion of subjects who experienced no, single or repeated 
trauma over the three LPA categories. See method section for details on the ‘other trauma’ category.
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NR3C1_1 
a|a|aggggcc|actt|ag|a|a|acctc|AGGCGCG1|a|att|a|ac|a|ac|a|a|ACGCT2|a|a|ag|agc|a|AGCCCTTGCGGGGCGGGGGTGG3|ag|a|ag
|ag|a|a|a|a|a|AGTGCG4|aggtt|a|a|a|ag|ag|a|agt|ACGTCC5|ag|acctgttg|AGTTCTCTCTCCG6|ac|ACGCCC7|acttct|a|ac|ag|at|a|AC
GCCGGCCCCGGCCGC8|agtctcc|a|AGTTGCGGGCTGTC9|AGCCCCCCGCGTGTGC10|accctc|ACGCGCCCCGC11|ACGCCCTCCTC1
2|a|agcc|AGGCGCCGCCGGGGCCTCCCCGG13|AGCCCGGGCTCGCGCTCGGGCGCGCCGGGGTGGCGTGC14|a|a|at|ATTCGGGC
G15|agt|a|a|a|attc|ag|ACGCGGCTT16|AGCGTTC17|acc|ACG18|a|a|a|ACGGGTGTCGGGCG19|acccccttgg|aggg|a|a|agggg|ac|act|
aggggg|ag|a|a|a|ag|aggcc|agg|attcc 
NR3C1_2: 
tccctg|a|agcctcccc|ag|AGGGCGTGTC1|AGGCCGCCCGGCCCCG2|AGCGCGGCCG3|ag|ACGCTGCGGC4|ACCGTTTCCGTGC5|a|
ACCCCGT6|AGCCCCTTTCG7|a|agtg|ac|ac|acttc|ACGC8|a|ACTCGGCCCGGCGGCGGCGGCGCGGGCC9|actc|ACGC10|agctc|AG
CCGCGGG11|AGGCGCCCCGGCTCTTGTGGCCCGCCCGCTGTC12|ACCCGC13|aggggc|ACTGGCGGCGCTTGCCGCC14|a|aggggc|
ag|AGCG15|AGCTCCCG16|agtgggtctgg|AGCCGCGG17|AGCTGGGCGGGGGCGGG18|a|agg|aggt|AGCG19|ag|a|a|a|ag|a|a|actgg|
ag|a|a|act 
NR3C1_3 
cccctc|agtcc|a|agggg|a|aggg|a|ACTCGTGGTCCGTCCTG1|ag|a|a|agg|ag|AGGGCCGTGGGGCG2|AGGGGTGCCCGTGCGGG3|a|
AGCCCCCGCCCC4|agctcccttcccc|AGCTCGCCGCGTCGGG5|a|aggcttgg|ACG6|ATGCCGGG7|ACCG8|agcctcct|ACCTTGTGCGG
C9|ac|ag|att|atg|atttttgtg|actctggg|a|a|aggttgtgctgtgtgggttt|agggtttgggg|aggt|a|ACTTTTGCGCCCCC10|ac|aggtg|ac|ATCG
CTTGCC11|agctcctg|ac|ACGGGCGGGGGCTGCCGC12|agctcc|acct|a|ATCCTGCTCGGGCGCTCGGCC13|ac|agcc|actctctc|ACCTC
CCGCCGCGCTC14|ag|actg|ACGGCGGCTCCCCCTGCTCTG15|ac|atcttg|a|ag 
	  
	  
supplementary figure 1. CpG unit information for NR3C1 amplicons 1, 2 and 3. Vertical lines represent 
position of splice sites on complementary RNA strand (not shown). CpG units are numbered and shown 
in uppercase. Methylation rates for gray CpG units could not be obtained or used for analyses. This could 
be due to equality in mass with another fragment or a mass outside the detection range of the mass spec-
trometer. Also, CpG units with >25% missing methylation values are left out of the analyses. Bold letters 
indicate CpG dinucleotides and the underlined sequence represents the human NGFI-A core recognition 
motif. Note: sequence shown is non-bisulfite treated. PCR product of NR3C1_2 is on the bisulfite treated 
antisense chain. PCR products of NR3C1_1 and NR3C1_3 are on the bisulfite treated sense chain. CpG units 
are numbered from 5’-3’.
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supplementary table 2. Primer properties.
name Primer sequence1
size 
(bp)
Position2
ta (°C)
units 
covered
CpGs 
covered
NR3C1_1
f: AAAGGGGTTATTTAGAAATTTTAGG
427
Chr5: 142782046-
142782472
59 19 (11) 41 (22)
r: AAAATCCTAACCTCTTTTCTCCCC
NR3C1_2
f: TTTTTGAAGTTTTTTTAGAGGG 
322
Chr5: 142783585-
142783906
63-543 19 (10) 39 (19)
r: AATTTCTCCAATTTCTTTTCTC
NR3C1_3
f: TTTTTAGTTTAAGGGGAAGGGAAT
392
Chr5: 142784559-
142784950
56 15 (9) 28 (20)
r: CTTCAAAATATCAAAACAAAAAAAACC
note: 1Primers are extended with tags according to Sequenom protocol (forward primers contained a 10 
mer sequence tag (aggaagagag) to balance primer length, and reverse primers are equipped with a T7-
promoter tag (cagtaatacgactcactataggg) and an 8 base pair insert to prevent abortive cycling (agaaggct) 
for initiation of in vitro transcription. 2Position according to the UCSC human Feb. 2009 assembly (GRCh37/
hg19). 3Touchdown PCR. Ta: annealing temperature.
supplementary table 3. Amplification conditions
PCr conditions NR3C1_1 and NR3C1_3: 
1. 94°C 15 min
2. 94°C 20 sec
Annealing temp. 30 sec 45 cycles
72°C 1 min
3. 72°C 3 min
4. 4°C 5 min
5. 15°C Forever
PCr conditions NR3C1_2:
Touchdown: every cycle 1°C from 63°C to 54°C. 
1. 94°C 15 min
2. 94°C 30 sec
63-54°C. 30 sec 10 cycles
72°C 1 min
3. 94°C 30 sec
53°C. 30 sec 35 cycles
72°C 1 min
4. 72°C 5 min
5. 4°C Forever
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supplementary table 4. Mean methylation, SD and range of individual CpG units within the three NR3C1 
amplicons. 
methylation (%)
n mean sd range
NR3C1_1 CpGU3 441 4.62 1.65 0.00 - 8.50
CpGU6 451 0.03 0.26 0.00 - 3.33
CpGU8 453 1.58 0.75 0.00 - 4.50
CpGU9 454 3.07 0.73 1.67 - 7.50
CpGU10 454 2.51 1.16 0.50 - 6.67
CpGU11 454 2.90 0.87 0.50 - 7.67
CpGU12 453 9.89 2.45 2.00 - 16.00
CpGU15 454 2.81 0.79 0.33 - 6.33
CpGU16 454 0.96 0.63 0.00 - 6.33
CpGU17 454 0.84 0.90 0.00 - 6.00
CpGU19 454 0.21 0.33 0.00 - 2.00
NR3C1_2 CpGU2 450 1.35 0.57 0.00 - 4.00
CpGU4 450 1.10 0.97 0.00 - 6.00
CpGU5 450 2.04 0.84 0.00 - 5.67
CpGU6 450 1.87 0.95 0.00 - 6.00
CpGU7 449 2.32 1.27 0.00 - 8.33
CpGU11 450 0.86 0.77 0.00 - 6.50
CpGU13 395 12.23 4.20 4.00 - 27.00
CpGU14 449 8.48 1.95 2.00 - 14.67
CpGU17 449 0.83 1.19 0.00 - 9.33
CpGU18 448 4.10 1.59 1.67 - 12.33
NR3C1_3 CpGU1 407 2.51 1.03 0.00 - 8.67
CpGU2 406 3.64 1.58 1.00 - 11.00
CpGU4 410 2.22 1.50 0.00 - 8.50
CpGU5 404 4.62 1.91 1.00 - 11.00
CpGU9 408 0.59 0.98 0.00 - 11.50
CpGU10 412 0.37 0.67 0.00 - 5.00
CpGU11 410 1.93 1.30 0.00 - 7.33
CpGU12 404 2.10 1.36 0.00 - 10.00
CpGU15 397 3.18 1.24 0.00 - 7.67
note: NR3C1_1-3: amplicons within the NR3C1 CpG island. CpGU: CpG unit, fragment of DNA containing 
one or more CpG dinucleotides. For CpG unit sequence information, see Supplementary Figure 1. 
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supplementary figure 2. Latent Profile Analyses.
supplementary table 5. Correlations between stress measures.
sLEs 1 trauma type
0-5 6-11 12-13 14-15 sexual Physical Other
Perinatal stress 0.21** 0.13** 0.11* 0.08 - 0.02 0.07 0.03
sL
Es
1
0-5 0.49** 0.14** 0.09* - 0.01 0.05 0.07
6-11 0.11* 0.03  0.13** 0.06 0.05
12-13 0.34**  0.17** 0.13* 0.17**
14-15  0.05 0.20** 0.13**
0-15  0.12* 0.15** 0.14**
note: Pearson or Spearman correlations used where appropriate. 1Z-score, **p<.01, *p<.05.
supplementary table 6. Latent profile modeling of stress at different ages model fit statistics.
Classes biC Lmr-Lrt
2LL
Lmr-Lrt
p-value
1 5386.00 n.a. n.a.
2 5211.91 198.47 0.02
3 5122.10 116.84 0.006
4 5078.80 71.78 0.33
note: BIC = Bayesian Information Criterion; LMR-LRT = Lo-Mendell-Rubin likelihood ratio test; 2LL = 2 times 
the Loglikelihood Difference; n.a. = not applicable.
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supplementary table 7. Life stress and NR3C1 methylation rates in amplicon 2 for the original and replica-
tion sample.
Original sample replication sample 
n b sE p n b sE p
Perinatal stress - 0.01 0.02 .78 - 0.04 0.02 .10
Traumatic youth experiences2
Sexual abuse 389 380
 single exposure 21  0.44 0.12 <.001 15 - 0.05 0.13 .67
 repeated exposure 11  0.13 0.17 .45 14 - 0.16 0.13 .22
Physical abuse 247 265
 single exposure 160  0.02 0.06 .68 137  0.01 0.05 .79
 repeated exposure 14 - 0.09 0.15 .56 8  0.08 0.17 .66
Other trauma 308 319
 single exposure 85 - 0.04 0.07 .52 75  0.10 0.06 .10
 repeated exposure 28  0.07 0.11 .56 16  0.11 0.12 .35
Stressful life events1
 Total (0-15 yrs)  0.03 0.03 .25 - 0.01 0.02 .72
 Childhood (0-11 yrs)  0.00 0.03 .97  0.01 0.02 .68
 Adolescence (12-15 yrs)  0.04 0.03 .13 - 0.03 0.02 .28
note: Linear regression of early life stress and multivariate regression analyses of SLEs in two age cate-
gories on NR3C1 methylation scores. Bold numbers indicate significant results. B=regression coefficient; 
SE=standard error. 1 Z-scores, 2 No exposure is the reference category
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AbstrACt
Objectives: Adverse life events increase vulnerability to affective disorders later in life, 
possibly mediated by methylation of the serotonin transporter gene (SLC6A4). We inves-
tigated the relationship of SLC6A4 methylation with various types of adversity (perinatal 
adversity, traumatic youth experiences and stressful life events [SLEs]), as well as with the 
timing of SLEs (during childhood [0–11 years] or during adolescence [12–15 years]). In 
addition, we investigated whether different serotonin-transporter-linked polymorphic 
region genotypes were equally sensitive to SLE-related methylation.
methods: In a population sample of 939 adolescents (mean age=16.2 years), we assessed 
SLC6A4 methylation, SLC6A4 functionality (serotonin-transporter-linked polymorphic 
region “long” and “short” alleles, and rs25531), and adverse life events.
results: Only a higher number of SLEs was positively associated with higher SLC6A4 
methylation (B=0.11, p=.011). Adolescent SLEs were associated with higher SLC6A4 
methylation (B= 0.13, p= .004) independently of childhood SLEs (B=0.02, p=.57). L-allele 
homozygotes showed a greater impact of SLEs on methylation (B=0.37, p<.001) than 
did s-allele carriers (B=0.04, p=.66), resulting in higher levels of SLC6A4 methylation for 
l-allele homozygotes among those experiencing high levels of SLEs.
Conclusions: Our findings demonstrate a higher level of SLC6A4 methylation after SLEs 
in adolescents, with a more pronounced association for SLEs during adolescence than 
during childhood. Considering the allele-specific sensitivity of SLC6A4 methylation 
to SLEs, this study may help clarify the role of SLC6A4 in the development of affective 
disorders.
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intrOduCtiOn
Adverse life events increase vulnerability to developing affective disorders later in life. 
This process is presumably moderated by epigenetic modifications such as deoxyribo-
nucleic acid (DNA) methylation, which are known to be influenced by environmental 
factors 1. The addition of methyl groups occurs predominantly on cytosine-guanine 
dinucleotide combinations (CpGs); it affects transcriptional activity, generally reducing 
gene expression 2. Previous studies have shown that stressful experiences can alter HPA-
axis function by changing the epigenetic signature of stress-reactivity genes (e.g. the 
glucocorticoid receptor gene, NR3C1) 3-5, possibly increasing the risk of developing affec-
tive disorders 6. Recently, Zhao and colleagues reported differences in methylation levels 
of the serotonin transporter (5HTT) gene (SLC6A4) in monozygotic twins discordant for 
depressive symptoms. These differences were attributed to unique environmental fac-
tors7. Alterations in serotonergic neurotransmission have been associated with altered 
neurodevelopment and the incidence of various psychiatric disorders 8, 9. A genetic 
polymorphism in SLC6A4 was also shown to interact with stressful life events (SLEs) in 
moderating the risk for depression 10. Despite this, it is only recently that research on 
epigenetic modifications of genes involved in serotonergic neurotransmission following 
stress have attracted interest.
The serotonin transporter is an important regulator of serotonergic neurotransmis-
sion through the reuptake of serotonin (5-hydroxtryptamine, or 5HT) in brain synapses. 
Genetic variation of this gene, such as the 5HT-transporter-linked polymorphic region 
(5HTTLPR), has been associated, albeit not consistently11, with an increased risk for psy-
chopathology 12, 13. 5HTTLPR alleles are composed predominantly of short (“s”) or long 
(“l”) repeated elements and vary in their transcriptional activity, resulting in levels of 
SLC6A4 mRNA that are lower in s-allele carriers than in l-allele carriers 14, 15. The 5HTTLPR 
polymorphism accounts for only part of the variation in mRNA expression 16-18; higher 
levels of SLC6A4 methylation have also been associated with reduced expression 18-20 
and liability to depression 7, 20-22.
Few studies have investigated the effect of adverse life events on SLC6A4 methyla-
tion in humans. Decreased SLC6A4 methylation was observed in 82 infants exposed to 
second-trimester depressed maternal mood 23. In other studies, childhood abuse 24-26, 
childhood adversities 21 and bullying victimization in childhood 27 were associated with 
higher methylation levels in children or adults. A recent study on stressful work environ-
ments in adulthood found lower SLC6A4 methylation in a highly stressful environment 
28. In infant macaques, no effect of early life stress was found on SLC6A4 methylation 19, 29. 
However, sample sizes in these human and animal studies were relatively small.
Methylation levels have been shown to differ between 5HTTLPR genotypes: a lower 
level of methylation has been reported for carriers of the l-allele 18-20. These studies did 
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not investigate exposure to adverse life events, although it is important to know whether 
different genotypes are equally sensitive to be methylated after adverse life events 30. 
Thus far, no interaction has been found between rearing type (nursery reared or mother 
reared) and genotype on SLC6A4 methylation in macaques 19. Similarly, in humans no in-
teraction was found between work stress and 5HTTLPR genotype on SLC6A4 methylation 
in female healthcare professionals 28 and between sexual abuse and 5HTTLPR genotype 
in four functional SLC6A4 CpG residues in women 26. Again, since the sample sizes in 
these three studies were small, investigation in a larger sample is necessary.
The objective of the current study was to investigate the effects of adverse life events 
between birth and adolescence on SLC6A4 methylation in a large, representative, sample 
of adolescents. To investigate their relationship with SLC6A4 methylation, we incorpo-
rated different types of adverse life events; perinatal adversity, stressful life events (SLEs) 
during childhood and adolescence, and traumatic youth experiences (TYEs). The effect 
of perinatal adversity on SLC6A4 methylation in adolescence has never previously been 
examined. We are also the first to include SLEs experienced in both childhood and ado-
lescence. This allowed us to analyze the independent associations of SLEs experienced 
during these two periods of life. Finally, we also examined allele-specific sensitivity for 
SLC6A4 methylation in relation to SLEs.
mEtHOds And mAtEriALs
sample selection
This study was part of the TRacking Adolescents’ Individual Lives Survey (TRAILS), a pro-
spective population study of Dutch adolescents, who have been followed from preado-
lescence into adulthood. Assessment waves are conducted biennially or triennially, and 
five assessment waves have been completed so far. Written consent was obtained from 
each subject and their parents at every assessment wave. The present study involves data 
collected during the first four assessment waves: T1, 2001-2002, N=2230, mean (standard 
deviation [SD]) age 11.1 (0.55) years; T2, 2003-2004, N=2149, mean (SD) age 13.6 (0.53) 
years; T3, 2005-2007, N=1816, mean (SD) age 16.3 (0.71) years; and T4, 2008-2010, N=1881, 
mean (SD) age 19.1 (0.60) years. The study was approved by the Dutch Central Medical 
Ethics Committee and subjects received compensation for their participation. A detailed 
description of sampling and methods can be found in Huisman et al 31 and Ormel et al 32. 
The assessment at T3 included a blood draw (response N=1230). DNA was successfully 
isolated from blood for 1156 respondents. We excluded subjects with non-Dutch ethnicity 
(N=117). Next, samples with an insufficient DNA concentration were removed (N=79), and 
one of each sibling pair was randomly excluded (N=6). Few other samples could not be 
analyzed (N=15). In total, 939 subjects remained eligible for analysis. Adolescents who 
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had undergone venipuncture differed from adolescents who had not on sex (53.5% vs. 
47.4% females), Χ2(1, 2230)=8.18, p=.004), socioeconomic status (19.4% lowest, 49.3% 
middle and 31.4% highest class vs. 32.8% lowest, 49.9% middle and 17.3% highest, Χ2(2, 
2188)=80.72, p<.001) and age (16.2 years vs. 16.4 years, t(1817)=6.99, p<.001). The groups 
did not differ on measures of childhood and adolescence SLEs or perinatal adversity. At 
T4, responders differed from non-responders in regards to sex (54.7% vs. 37.8% females, 
p<.001) and age (mean age 19.0 vs. 19.4, p<.001).
Adverse life event measures
Perinatal adversity was operationalized as the sum of maternal psychological problems 
during pregnancy or the three months after delivery, preterm delivery (≤33 weeks), 
low birth weight (≤2500g), hospitalization of mother or child within one month after 
delivery, and maternal alcohol use or smoking during pregnancy. For birth weight and 
gestational age, we used the records of the Preventive Child Healthcare services 33. The 
other stressors were measured in a detailed interview with the parents at T1.
SLEs experienced between ages 0 and 15 years were assessed for the age categories 
of 0-5, 6-11, 12-13 and 14-15 years, as described by Bosch et al 34. Information on SLEs in 
early childhood (0-5) and middle childhood (6-11) was collected during a detailed inter-
view with the parents at T1, and included the number of times the child had experienced 
parental divorce, hospitalization, the death of a family member or friend, out-of-home 
placement, parental addiction or parental mental health problems 34. SLEs experienced 
in early adolescence (12-13) were assessed with a self-report questionnaire at T2 34. The 
25 SLEs included illness or injury of the participant, a family member or a friend; psy-
chopathology of family members; parental divorce; death of family member or friend; 
changes in family composition; parental unemployment; conflicts with family or friends; 
and bullying. SLEs in middle adolescence (14-15) were assessed at T3 in an Event History 
Calendar Interview35 with the adolescent. The total number of events referred to the 
frequency of conflicts with family or friends, physical or sexual intimidation, bullying/
gossiping, loss or lack of friends, mental health problems /addiction problems of family 
or friends, out-of-home placement, running away from home, death/sickness of a family 
member, hospitalization of participant, and parental divorce.
Based on the above-mentioned event measures, we calculated a measure of total SLEs 
experienced between ages 0 and 15 years by standardizing the sum score of the number 
of events for each age category, and summing the standardized scores. This procedure 
was chosen to account for differences in the number of possible SLEs by age group. The 
resulting total sum score (SLEs 0-15) was standardized before analyses. The correlation 
coefficient between the 0-5 and 6-11 age categories was .48 (p<.001), and the correlation 
coefficient between the 12-13 and 14-15 age categories was .23 (p<.001). Other correla-
tions between SLE categories were <.15 (.001<p<.050). We used one measure for child-
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hood SLEs and one for SLEs in adolescence. These variables were constructed by summing 
standardized scores for the two variables of childhood SLEs and the two variables of SLEs 
in adolescence. The SLE scores (0-11 and 12-15) were standardized before analyses.
At T4, information on TYEs, i.e. sexual abuse, physical abuse and other traumatic youth 
experiences, was obtained with a 16-item self-report questionnaire designed for TRAILS 
(available upon request) and inspired by the Childhood Trauma Questionnaire 36. To 
determine sexual abuse, the participants were asked if an adult family member, friend 
of the family or stranger had ever, before the age of 16, showed their genitals or mas-
turbated in front of them; had sexually assaulted them; had forced them to touch them 
in a sexual manner; had attempted to have sexual contact or had actually had sexual 
contact with them. To determine physical abuse, participants were asked if a parent or 
caretaker had ever, before the age of 16, hit them with a belt, brush, stick or other hard 
object; had hit them with a fist or kicked them very hard; had shaken or pinched them; 
had beaten them up (i.e., hit them in succession) or had threatened them with a knife or 
other weapon. To determine ‘other trauma’, participants were asked if, before the age of 
16, they had been involved in a life-threatening accident; had witnessed severe injury 
or death; had been a victim of physical violence or assault; had been threatened with a 
weapon, had been held captive or abducted; or had been involved in a fire, flood or other 
(natural) disaster. Answers were coded into a single exposure or multiple exposures to 
TYEs. We had no data on the timing of TYEs.
dnA methylation
Analysis. DNA was extracted from whole-blood samples using a manual salting-out pro-
cedure as described by Miller et al 37. Using a primer set previously used by Philibert et al 
20 (set B), we analyzed a genomic region that encompasses the CpG island surrounding 
exon 1 (Figure 1). We used forward primer GGTTATTTAGAGATTAGAT TATGTGAGGGT and 
reverse primer CCTACAACAATAAACAAAAAAACCCC (Chr17:28562358–28562783, UCSC 
build (GRCh37/hg19), Feb. 2009, see Figure S1 for sequence details). Forward primers 
contained a 10 mer sequence tag (aggaagagag), and reverse primers are equipped with 
a T7-promoter tag (cagtaatacgactcactataggg) and an 8 base pair insert (agaaggct). DNA 
methylation levels were analyzed using the EpiTYPER method from Sequenom. Bisulfite 
conversion was followed by PCR amplification, reverse transcription, base-specific cleav-
age of in vitro transcribed RNA product, and mass spectrometry (Sequenom EpiTYPER, San 
Diego, CA, USA). Bisulfite conversion of DNA was performed using EZ-96 DNA Methylation 
Kit (Shallow; Zymo Research, CA, USA), according to manufacturers’ protocol. PCR, reverse 
transcription, cleavage and mass spectrometry were performed in triplicate, according 
to EpiTYPER protocol. The mass signal patterns generated are translated to quantitative 
methylation levels for different CpG units by the MassARRAY EpiTYPER analyzer software 
from Sequenom (v1.0, build1.0.6.88 Sequenom, Inc, San Diego, USA).
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Data cleaning. All samples were analyzed in triplicate, and samples with a standard devia-
tion of ≥10% between replicates were removed for analysis. Fragments with CpG dinucleo-
tides are referred to as CpG units. One CpG unit can contain one or more CpG dinucleotide. 
CpG units with a mass outside the range of the mass spectrometer, or with overlap in mass 
of another CpG unit, could not be analyzed (9 CpG units). We accounted for mass-change 
in CpG units by SNPs (only when the minor allele frequency >5%) by removing CpG units 
from analyses containing the SNP and from units with overlapping mass caused by SNPs in 
non-CpG units (1 CpG unit). For each CpG unit, methylation scores of the triplicates were 
averaged. CpG units with >25% missing values were removed (1CpG unit).
Genotyping
To determine the 5-HTT-linked-polymorphic-region genotype in the promoter region of 
SLC6A4 we used sequence length analysis. The length assessment of the 5HTTLPR alleles 
was measured by direct analysis on an automated capillary sequencer (ABI3730, Applied 
Biosystems, Nieuwerkerk aan den IJssel, the Netherlands). The call rate was 91.6%. The 
single nucleotide substitution (A>G) present in the 5HTTLPR l-allele (rs25531) was geno-
typed using a custom made TaqMan assay (Applied Biosystems). Additional informa-
tion is described in Nederhof et al 38. The call rate for rs25531 was 96.5%. Concordance 
between DNA replicates showed an accuracy of 100%. Because the lg-allele is considered 
functionally equivalent to the s-allele 39, it was recoded as an s-allele, and the la-allele 
was recoded as an l-allele. Genotype frequencies for 5HTTLPR (L/L = 324, L/S = 455, S/S = 
148) and rs25531 (A/A = 245, A/G = 473, G/G = 209) were in Hardy-Weinberg equilibrium 
3’ 
1 2 3 4 5 6 7 8 9 14 10 11 12 13 
CpG island 
PCR fragment 
5’ 
5HTTLPR 
TSS 
Exon 1 
figure 1. Schematic representation of the SLC6A4 gene. Exons are represented by numbered black boxes. 
Approximate position of 5HTTLPR is shown. The CpG island (Chr17:28562388-28563186) is represented by 
the gray box and is enlarged to show the positioning of the PCR fragment (Chr17:28562358-28562783) and 
their position relative to the TSS in exon 1 (based on Ensembl Transcript ID ENST00000394821). 5HTTLPR is 
located outside the PCR fragment. SLC6A4 = solute carrier family 6 (neurotransmitter transporter), member 
4; 5HTTLPR = serotonin-transporter–linked polymorphic region; CpG = cytosine-phosphateguanine; PCR = 
polymerase chain reaction; TSS = transcription start site.
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(χ2=0.31 [df = 1, p= 0.58] and χ2= 0.45 [df = 1, p= 0.50], respectively). Allele frequencies 
were L = .59 and S = .41 for 5HTTLPR, and A = .52 and G = .48 for rs25531. After recoding, 
new genotype frequencies, S/S (including S/Lg and Lg/ Lg) = 209, S/L (including Lg/
La)=473 and L/L (La/La only)=245 were still in Hardy-Weinberg equilibrium (χ2=0.45, df 
= 1, p= 0.50), with allele frequencies for L=.52 and S=.48.
Covariates
We have explored the potential confounding of the analyses by age, daily smoking, oral 
contraceptive use, medication use, pubertal status and acute infection. Smoking habits, 
oral contraceptive use, pubertal status and medication use were measured in a self-report 
questionnaire. Pubertal development was measured using the pubertal development 
scale (PDS 40) and was recoded into Tanner stages using the Shirtcliff method 41. Only one of 
the respondents used fluoxetine (a selective serotonin re-uptake inhibitor), and removing 
this individual from the sample did not affect our results. As marker for acute infection we 
used high sensitive C-reactive protein (hsCRP). HsCRP was assessed in blood collected at 
the same blood draw as the blood for methylation analyses. The serum was transported to 
the laboratory for processing within four hours. On the same day, hsCRP was determined 
using a immunonephelometric method using a BN2, Siemens CardioPhaseR hsCRP, with a 
lower detection limit of 0.175 mg/L. Intra-assay coefficients of variance ranged from 2.1 to 
4.4, and inter-assay coefficients of variation ranged from 1.1 to 4.0.
statistical analyses
Linear regression analyses were performed to examine the associations of type and 
timing of adverse life events with SLC6A4 methylation in adolescence. Since randomly 
missing methylation values in higher methylated units (methylation values for indi-
vidual units are presented in Table S1) may falsely lower the average methylation score, 
we opted to mean-center our methylation data to reduce bias in individual CpG unit 
methylation levels, while maintaining the individual variation in CpG units. We mean-
centered the methylation score for each CpG unit, resulting in a mean methylation of 
0, with original SD. An average SLC6A4 methylation score was calculated by taking the 
average of the mean-centered methylation scores of the CpG units. Separate analyses 
were performed for perinatal adversity, SLEs (0-15) and the three categories of TYEs 
(sexual abuse, physical abuse, and other trauma). To study the relationship between 
childhood and adolescence SLEs and SLC6A4 methylation, we performed a linear 
regression analysis with the two SLEs variables (0-11 and 12-15). Analyses were rerun 
with the putative confounders. Differences in methylation levels between genotypes 
were tested with ANOVA, and sex differences in methylation levels were tested with a 
T-test. We explored allele-specific methylation by adding 5HTTLPR genotype (using s/s 
genotype as reference group) and an interaction term of genotype with SLE (0-15) to the 
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regression model with SLC6A4 methylation as dependent variable. In case of a signifi-
cant interaction term, analyses were stratified by genotype. All analyses were adjusted 
for sex. Statistical tests were performed in SPSS (IBM SPSS, v.21.0. Armonk, NY: IBM Corp). 
A p-value <.050 was considered statistically significant.
rEsuLts
The sample consisted of 51.8% women and the average (SD) age of the adolescents was 
16.2 (0.65) years at the time of DNA collection, with a range of 14-18 years. In Table 1 the de-
scriptive statistics are given of the adverse life events in the total sample, and in the sample 
stratified by 5HTTLPR genotype. In Figure 2 the centered SLC6A4 methylation levels by geno-
type and sex are shown. SLC6A4 methylation was higher in girls (N=486, mean [SD]=0.43% 
[1.27%]) than in boys (N=453, mean [SD]=-0.49% [1.27%]; t(937)=11.137, p<.001).
table 1. Descriptives of adverse life event variables, by 5HTTLPR genotype.
total 5HTTLPR genotype (n)
p
s/s s/l l/l
n n  % or m(sd) n  % or m(sd) n  % or m(sd)
Perinatal adversitya 931 208  0.01(1.01) 467 - 0.02 (0.97) 244  0.03 (1.08) .81
SLEs (0-15 years)a
Total (0-15 years) 859 195 - 0.03 (1.00) 432  0.04 (1.03) 222 - 0.08 (0.92) .29
 Childhood (0-11 years) 939 209 - 0.06(0.97) 473  0.01 (1.00) 245  0.03 (1.03) .57
 Adolescence (12-15 years) 859 195  0.03 (1.04) 432  0.05 (1.03) 222 - 0.15 (0.84) .045
TYEsb
Sexual abuse
 no exposure 795 184  93.4 388  91.3 213  93.4
.73 single exposure 38 7  3.6 20  4.7 10  4.4
 repeated exposure 28 6  3.0 17  4.0 5  2.2
Physical abuse
 no exposure 529 133  67.5 258  60.7 134  58.8
.18 single exposure 310 62  31.5 156  36.7 85  37.3
 repeated exposure 23 2  1.0 11  2.6 9  3.9
Other trauma
 no exposure 650 147  74.6 316  74.4 179  78.5
.69 single exposure 166 41  20.8 84  19.8 40  17.5
 repeated exposure 46 9  4.6 25  5.9 9  3.9
5HTTLPR = serotonin-transporter–linked polymorphic region; s = short; l = long; M = mean; SD = standard 
deviation; SLEs = stressful life events; TYEs = traumatic youth experiences. The s-allele includes the s and lg 
alleles; the l-allele includes the l and la alleles. a z Score. b No abuse is the reference category.
Chapter 3
52
Adverse life events and methylation
In Table 2 the results of the regression analyses with adverse life event variables as 
predictors for SLC6A4 methylation are presented. Exposure to perinatal adversity or TYEs 
was not related to methylation. Exposure to SLEs (0-15) significantly predicted higher 
methylation levels. In the model including both SLEs during childhood and adolescence, 
exposure to SLEs in adolescence was related to higher methylation levels. No statistical 
significant interaction was found for adverse life event variables and sex on methylation.
Analyses with putative confounders showed little (<10%) change in the regression 
coefficients of adverse life event variables (Table S2-S5). In the analyses in the next sec-
tions these putative confounders were therefore not included.
figure 2. Boxplot of SLC6A4 meth-
ylation scores (%) according to 
functional 5HTTLPR genotype (i.e., 
including rs25531) and sex. Error 
bars represent the highest and 
lowest values that are not outli-
ers. SLC6A4 = solute carrier family 
6 (neurotransmitter transporter), 
member 4; 5HTTLPR = serotonin-
transporter–linked polymorphic 
region. * p < .001.
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sLEs and 5HTTLPR genotype
Methylation levels did not differ between genotypes, F(2,924)=2.234, p=.11 (Figure 2). 
Adding 5HTTLPR genotype in the regression model predicting methylation by SLEs (0-15) 
showed a significant interaction between genotype and SLEs (Table 3). This interaction 
did not differ as a function of sex (p-values >.050, see Table S6, for a graphical represen-
tation of this interaction, see Figure S2). The direction of the interaction was consistent 
over the majority of individual CpG units (Table S7), which suggest that the mean value 
of methylation is a good representation of the impact of SLEs on methylation across a 
larger region of the CpG island. The interaction was not significant when genotype was 
coded non-functionally, i.e., regardless of rs25531 genotype, (Table S8) but revealed a 
trend in the same direction. The interaction between genotype and perinatal adversity 
was not significant (p>.050). Due to the small number of participants who had experi-
enced trauma, the interaction between TYEs and genotype could not be tested.
table 2. Regression analyses of adverse life events and SLC6A4 methylation.
 SLC6A4 methylation
 b sE p 95% Ci of b
Perinatal adversitya - 0.07 0.04 .089 - 0.15 - 0.01
SLEsa
Total (0-15 years)  0.11 0.04 .011  0.03 - 0.20
 Childhood (0-11)  0.02 0.04 .57 - 0.06 - 0.11
 Adolescence (12-15)  0.13 0.04 .004  0.04 - 0.22
TYEsb
Sexual abuse
 single exposure - 0.13 0.21 .53 - 0.54 - 0.28
 repeated exposure  0.03 0.24 .91 - 0.45 - 0.50
Physical abuse
 single exposure - 0.01 0.09 .94 - 0.18 - 0.17
 repeated exposure - 0.20 0.27 .46 - 0.72 - 0.33
Other trauma
 single exposure  0.04 0.10 .69 - 0.16 - 0.24
 repeated exposure  0.08 0.15 .60 - 0.21 – 0.36
SLC6A4 = solute carrier family 6 (neurotransmitter transporter), member 4; B = regression coefficient; SE = 
standard error; CI = confidence interval; SLEs = stressful life events; TYEs = traumatic youth experiences. 
Adjusted for sex. Bold numbers indicate significant (p < .05) results. All models were models with a single 
measure of adverse life events, except for one model in which childhood SLEs and adolescence SLEs were 
included together. a z Score. b No abuse is the reference category.
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Stratification by genotype (Table 4, Figure 3) showed that SLC6A4 methylation was 
higher amongst l-allele homozygotes after exposure to more SLEs. S-allele carriers did 
not show a significant association between SLEs and methylation.
disCussiOn
In the current study, having experienced SLEs was associated with higher SLC6A4 
methylation in adolescents. This association was more prominent for SLEs experienced 
in adolescence than SLEs experienced in childhood. We found that the relationship 
between SLEs and SLC6A4 methylation was influenced by 5HTTLPR genotype: methyla-
table 3. Regression analyses of SLEs, genotype and the interaction between SLEs and 5HTTLPR genotype, 
on SLC6A4 methylation. 
SLC6A4 methylation
b sE P  95% Ci of b
SLEs (0-15 years)a 0.03 0.09 .73 - 0.15 - 0.21
s/lb 0.26 0.11 .017  0.05 - 0.47
l/lb 0.30 0.12 .016  0.06 - 0.54
SLEs (0-15 years)a X s/lb 0.01 0.11 .90 - 0.20 - 0.23
SLEs (0-15 years)a X l/lb 0.33 0.13 .010  0.08 - 0.59
SLEs = stressful life events; 5HTTLPR = serotonin-transporter–linked polymorphic region; SLC6A4 = solute 
carrier family 6 (neurotransmitter transporter), member 4; B = regression coefficient; SE = standard error; 
CI = confidence interval; s = short; l = long; SNP = single nucleotide polymorphism. Adjusted for sex. Bold 
numbers indicate significant results. S-allele includes s and lg alleles; the l-allele includes the la allele. Table 
S8 shows the results when genotype was coded functionally while taking account of SNP rs25531. a z Score. 
b S/s is reference category.
table 4. Regression analyses of SLEs and SLC6A4 methylation stratified by 5HTTLPR genotype.
 SLC6A4 methylation
 s/s s/l l/l
 b sE p b sE p b sE  p
SLEsa
Total (0-15 years)  0.04 0.09 .66 0.04 0.06 .49 0.37 0.10 < .001
 Childhood (0-11) - 0.08 0.09 .34 0.00 0.06 .97 0.17 0.09  .066
 Adolescence (12-15)  0.13 0.08 .11 0.06 0.06 .33 0.36 0.11  .001
SLEs = stressful life events; SLC6A4 = solute carrier family 6 (neurotransmitter transporter), member 4; 5HT-
TLPR = serotonin-transporter–linked polymorphic region; s = short; l = long; B = regression coefficient; SE = 
standard error. Adjusted for sex. Bold numbers indicate significant (p < .05) results. Total SLEs was entered 
in a model individually, whereas childhood SLEs and adolescence SLEs were included together in a model. 
a z Score.
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tion levels were higher in adolescents who were homozygous for the l-allele and experi-
enced more SLEs, but SLEs were not associated with methylation for s-allele carriers. Like 
Philibert and colleagues 20, we found that sex affected SLC6A4 methylation, with higher 
methylation levels in females than in males. The relationship between SLEs (0-15) and 
methylation did not differ between males and females.
Our finding that perinatal adversity was not associated with SLC6A4 methylation con-
trasts with the study by Devlin and colleagues 23, who reported higher levels of SLC6A4 
methylation in cord blood after exposure to depressed maternal mood during pregnan-
cy. Possibly, stress related methylation may have a relatively low temporal stability and 
may be a reflection of exposure to recent adverse life events. As our methylation data 
originated from blood collected in adolescence, methylation marks from the perinatal 
period may have been gradually lost over time, perhaps through active demethylation 
mechanisms 42. This may also explain the lack of an association with perinatal stress 
and the difference in regression coefficients for childhood SLEs and adolescence SLEs. 
Since the assessment of SLE measures differed between time periods, it needs to be 
acknowledged that differences in measurements of SLEs in childhood and adolescence 
may also be reflected in our analyses. However, the advantage of this operationalization 
was that the SLE measures more accurately reflected the SLEs that were appropriate for 
the different developmental stages of childhood and adolescence.
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figure 3. Interaction of 5HTTLPR genotype and score for stressful life events (SLEs, 0-15 years) on mean-
centered SLC6A4 methylation scores (%). Error bars represent standard errors. 5HTTLPR = serotonin-trans-
porter–linked polymorphic region; SLEs = stressful life events; SLC6A4 = solute carrier family 6 (neurotrans-
mitter transporter), member 4; SD = standard deviation.
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Also, no association was found between TYEs and SLC6A4 methylation. While this find-
ing was unexpected and in contrast with other reports on higher methylation following 
childhood abuse 21, 24, 25, these studies had relatively small sample sizes (N=108-192), 
sometimes with specific study populations, and were thus in need of replication. More 
specific, Kang and colleagues 21 studied patients diagnosed with Major Depressive Dis-
order (MDD), and reported an association for family history of depression with methyla-
tion of SLC6A4. They suggest that this finding may be ascribed to a stressful childhood 
environment. It is possible that this association was affected by SLEs, which may explain 
the disparity between our study and theirs. Also, it cannot be ruled out that MDD itself 
may have affected methylation. In an earlier study in our (TRAILS) population, TYEs were 
associated with higher methylation of NR3C1 43, suggesting that methylation by TYEs 
may be dependent on the gene investigated. In addition, because rates of reported TYEs, 
particularly repeated sexual abuse and physical abuse of the sort that might plausibly 
influence methylation, were quite low, it is possible that the current investigation was 
not well powered to examine these effects.
Although carriers of the 5HTTLPR l-allele have previously been associated with 
lower SLC6A4 methylation 18-20, 28, we found no differences in methylation levels between 
genotypes. However, when taking the number of SLEs experienced into account, we 
found that l-allele homozygotes with few SLEs had lower methylation levels than s-allele 
carriers. It should be noted that, to the extent that there was a differential susceptibility 
effect in the current study, it was in the direction of the l-allele rather than the s-allele, 
considered to be the susceptibility allele 44. In addition, the difference between the l-
allele homozygotes and s-allele carriers was most pronounced at high levels of SLEs, 
suggesting that the effect might be best characterized as a vulnerability effect.
The genotype-SLE interaction on SLC6A4 methylation seemed to contrast with the 
work of Caspi and colleagues 10, who showed that individuals with two l-alleles were 
not at risk for depression, regardless of how many SLEs they experienced. Replication 
of this finding, however, has not always been successful 45, 46. More recently, Mueller 
et al 47 showed that only the experience of SLEs in the first five years of life showed an 
interaction with 5HTTLPR in predicting depression in young adults. In TRAILS, there was 
no support for an interaction between 5HTTLPR genotype and childhood adversities on 
depression 38. To shed light on this paradox, it may be necessary to incorporate methyla-
tion patterns into these interactions: a highly methylated l-allele is considered to have 
a poor transcriptional activity, and methylation might nullify the protective function 
of the l-allele, resulting in a functionality equivalent to the s-allele. This suggestion is 
supported by a study that showed more unresolved loss or trauma in highly methylated 
l-allele carriers and low methylated s-allele homozygotes 48. More research is needed 
to gain understanding of the relation between genetic and epigenetic variation and its 
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possible implication in clinical practice. A manuscript investigating the relation between 
methylation and 5HTTLPR genotype on internalizing problems is in preparation.
Our study has several strengths. SLC6A4 genotype and methylation data was obtained 
from a large population-based sample. The TRAILS study also provides a detailed ac-
count of SLEs between birth and adolescence, and is the first study to explore the effect 
of SLEs during childhood and adolescence on SLC6A4 methylation separately. Several 
limitations should also be acknowledged. Because blood was collected only at the third 
assessment wave, changes in methylation by SLEs could not be analyzed, and no causal 
links could be established. Sample size was large, but not large enough to study geno-
type-specific methylation by TYEs. Another limitation is the lack of a replication sample, 
but obtaining a suitable replication sample of adolescents with comparable measures 
of adverse life events and population characteristics is very challenging. An important 
limitation concerns the use of peripheral tissue (blood) as a proxy of the target tissue 
(the brain), which is often inaccessible in living humans. However, correlations between 
methylation levels in the brain and blood have been found to be high 49. Recently, pre-
liminary evidence was provided that SLC6A4 methylation in peripheral blood leukocytes 
reflects DNA methylation of a specific part of the brain involved in emotion regulation, 
i.e., the amygdala 50, suggesting that blood may be a valid biomarker for brain meth-
ylation. However, since we were unable to account for the cellular heterogeneity of the 
blood cells, potentially influenced by stress exposure, we could not rule out that the 
associations may be in part a reflection of differences in cellular composition. Finally, we 
analyzed one region of SLC6A4, located in the promoter and thus probably relevant for 
regulation of transcription, yet we suggest further research to include more regions of 
SLC6A4.
In conclusion, we showed that adverse life events affect SLC6A4 methylation in 
adolescents, and that this association was 5HTTLPR genotype dependent. Allele-specific 
methylation may be a mechanism through which a stressful environment can lead to 
vulnerability to affective disorders. Our findings are new, the first to be reported in a 
young sample of this size. They are important to the field, but we acknowledge that 
replication is warranted, also in light of generalization: our final sample individuals with 
low SES scores were underrepresented, and investigation in ethnicities other than white 
is warranted. The study can be regarded as a starting point for new ways to explore 
the complex relations between SLC6A4, stressful experiences, and the risk of developing 
affective disorders.
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suPPLEmEntAry infOrmAtiOn
dnA fragment details
ggct|atct|ag|ag|atc|ag|acc|atgtg|AGGGCCCGCGGGT1|ac|a|a|at|ACGGCCGCGCCGGCGCCCCTCCGTSSC2|ac|agcc|AGCGCCGC
CGGGTGCCTCG3|AGGGCGCG4|aggcc|AGCCCGCCTGCCC5|AGCCCGGG6|acc|AGCCTCCCCGCGC7|agcctggc|AGGTGGGTCCG
CTTTTCCTCTCCGCCTCG8|a|accc|ACGTTTCTTTCC9|ag|ACCTTCTTCCCCGCCTCGGGG10|aggggg|at|ag|a|ACCGCTGCGCCCC11|
ACCGCCCTGCG12|agg|AGGCG13|agg|aggtgc|ATGCGCCCC14|AGCGGTGGGCGCCGG15|ATCCTGCCCCTGCGCCCTCC16|ACGC
TC17|agc|a|ag|agcc|ag|agctg|a|agctg|ACCGGCC18|ag|agtggg|ag|ACG19|agg|a|ACGTGG20|AGTGCTCG21|a|AGTGGGCGGGCG
T22|agggggctcctttgtct|attgttgc|agg 
 
figure s1. Sequence of DNA fragment used for methylation analysis, positioned on the reverse strand. 
Forward and backward primers are underlined. Numbers represent CpG units and vertical lines represent 
splice sites. CpG units in grey could not be analyzed for methylation rates. Bases in italics are outside of CpG 
island (according to UCSC build GRCh37/hg19). TSS marks transcription start site and grey marked area 
covers exon 1 (based on Ensembl Transcript ID ENST00000394821).
descriptives CpG unit methylation
table s1. CpG unit methylation; range, mean and SD.
n minimum maximum m sd
CpGU1 938 1.0%  8.0%  2.8% 0.9%
CpGU3 936 2.0% 12.0%  5.8% 1.6%
CpGU4 920 0.0% 19.0%  6.0% 2.5%
CpGU6 934 0.0% 10.0%  1.4% 1.6%
CpGU9 935 2.0% 14.0%  7.6% 1.9%
CpGU10 774 0.0% 10.0%  2.4% 1.5%
CpGU12 898 5.0% 27.0% 15.4% 3.3%
CpGU14 892 1.0% 23.0%  9.5% 3.2%
CpGU15 930 3.0% 20.0%  8.6% 2.3%
CpGU16 843 5.0% 31.0% 15.9% 3.8%
CpGU22 859 8.0% 47.0% 28.0% 5.3%
note: M=mean, SD=standard deviation.
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Analyses with confounders/covariates
table s2a. Regression analyses of adverse life events and SLC6A4 methylation.
SLC6A4 methylation
 b sE p  95% Ci of b
Perinatal adversity1 - 0.07 0.04 0.118 - 0.15 - 0.02
SLEs1
Total (0-15 years)  0.11 0.04 0.012  0.03 - 0.20
 Childhood (0-11)  0.04 0.04 0.414 - 0.05 - 0.12
 Adolescence (12-15)  0.12 0.05 0.009  0.03 - 0.21
TYEs2
Sexual abuse
 single exposure - 0.18 0.22 0.405 - 0.61 - 0.24
 repeated exposure - 0.01 0.26 0.963 - 0.52 - 0.49
Physical abuse
 single exposure - 0.02 0.09 0.823 - 0.20- 0.16
 repeated exposure - 0.21 0.27 0.429 - 0.74 - 0.31
Other trauma
 single exposure  0.03 0.11 0.759 - 0.19 - 0.26
 repeated exposure - 0.17 0.20 0.392 - 0.57 - 0.22
Covariates: Sex and use of oral contraceptives. note: SLEs= Stressful life events; TYEs= Traumatic Youth 
experiences. 1Z-score, 2No abuse is the reference group.
table s2b. Regression analyses of SLEs, genotype and the interaction between SLEs and 5HTTLPR geno-
type, on SLC6A4 methylation.
SLC6A4 methylation
b sE P  95% Ci of b
SLEs (0-15 years)2 0.04 0.09 0.656 - 0.14 - 0.22
s/l1 0.24 0.11 0.029  0.02 - 0.46
l/l1 0.27 0.13 0.032  0.02 - 0.52
SLEs (0-15 years)2 X s/l1 0.00 0.11 0.985 - 0.22 - 0.22
SLEs (0-15 years)2 X l/l1 0.32 0.13 0.016  0.06 - 0.58
Covariates: Sex and use of oral contraceptives. note: SLEs= Stressful life events; 1 s/s is the reference group, 
2Z-score. The s-allele includes only the s-allele, the l-allele includes the lg and la alleles.
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table s2c. Regression analyses of SLEs and SLC6A4 methylation stratified by 5HTTLPR genotype.
 SLC6A4 methylation
 s/s s/l l/l
 b sE p b sE p b sE p
SLEs1
Total (0-15 years)  0.05 0.09 0.591 0.04 0.06 0.515 0.34 0.10 0.001
 Childhood (0-11) - 0.07 0.09 0.457 0.00 0.06 0.946 0.17 0.09 0.064
 Adolescence (12-15)  0.13 0.09 0.134 0.05 0.06 0.414 0.33 0.12 0.005
Covariates: Sex and use of oral contraceptives. note: SLEs= Stressful life events. 1Z-score. The s-allele in-
cludes only the s-allele, the l-allele includes the lg and la alleles.
table s3a. Regression analyses of adverse life events and SLC6A4 methylation.
 SLC6A4 methylation
 b sE p  95% Ci of b
Perinatal adversity1 - 0.07 0.04 0.085 - 0.15 - 0.01
SLEs1
Total (0-15 years)  0.11 0.04 0.009  0.03 - 0.20
 Childhood (0-11)  0.03 0.04 0.550 - 0.06 - 0.11
 Adolescence (12-15)  0.13 0.04 0.003  0.04 - 0.22
TYEs2
Sexual abuse
 single exposure - 0.13 0.21 0.525 - 0.55 - 0.28
 repeated exposure  0.02 0.24 0.938 - 0.46 - 0.50
Physical abuse
 single exposure  0.00 0.09 0.983 - 0.18 - 0.17
 repeated exposure - 0.19 0.27 0.474 - 0.72 - 0.33
Other trauma
 single exposure  0.05 0.11 0.683 - 0.17 - 0.26
 repeated exposure - 0.11 0.19 0.580 - 0.48 - 0.27
Covariates: Sex and CRP (C-reactive protein, mg/l). note: SLEs= Stressful life events; TYEs= Traumatic Youth 
experiences. 1Z-score, 2No abuse is the reference group.
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table s3b. Regression analyses of SLEs, genotype and the interaction between SLEs and 5HTTLPR geno-
type, on SLC6A4 methylation.
SLC6A4 methylation
b sE P  95% Ci of b
SLEs (0-15 years)2 0.03 0.09 0.748 - 0.15 - 0.21
s/l1 0.25 0.11 0.020  0.04 - 0.47
l/l1 0.30 0.12 0.017  0.05 - 0.54
SLEs (0-15 years)2 X s/l1 0.02 0.11 0.866 - 0.19 - 0.23
SLEs (0-15 years)2 X l/l1 0.34 0.13 0.009  0.08 - 0.59
Covariates: Sex and CRP (C-reactive protein, mg/l). note: SLEs= Stressful life events; 1 s/s is the reference 
group, 2Z-score. The s-allele includes only the s-allele, the l-allele includes the lg and la alleles.
table s3c. Regression analyses of SLEs and SLC6A4 methylation stratified by 5HTTLPR genotype.
 SLC6A4 methylation
 s/s s/l l/l
 b sE p b sE p b sE p
SLEs1
Total (0-15 years)  0.04 0.09 0.663 0.05 0.06 0.421 0.37 0.10 < .001
 Childhood (0-11) - 0.08 0.09 0.346 0.00 0.06 0.998 0.17 0.09 0 .065
 Adolescence (12-15)  0.13 0.08 0.115 0.06 0.06 0.277 0.37 0.11 0 .001
Covariates: Sex and CRP (C-reactive protein, mg/l). note: SLEs= Stressful life events. 1Z-score. The s-allele 
includes only the s-allele, the l-allele includes the lg and la alleles.
table s4a. Regression analyses of adverse life events and SLC6A4 methylation.
 SLC6A4 methylation
 b sE p  95% Ci of b
Perinatal adversity1 - 0.07 0.04 0.103 - 0.15 - 0.01
SLEs1
Total (0-15 years)  0.12 0.04 0.009  0.03 - 0.20
 Childhood (0-11)  0.03 0.04 0.493 - 0.06 - 0.12
 Adolescence (12-15)  0.13 0.05 0.005  0.04 - 0.22
TYEs2
Sexual abuse
 single exposure - 0.12 0.21 0.555 - 0.54 - 0.29
 repeated exposure  0.09 0.25 0.727 - 0.40 - 0.57
Physical abuse
 single exposure  0.02 0.09 0.865 - 0.16 - 0.20
 repeated exposure - 0.18 0.27 0.504 - 0.71 - 0.35
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table s4a. Regression analyses of adverse life events and SLC6A4 methylation. (continued)
SLC6A4 methylation
 b sE p  95% Ci of b
Other trauma
 single exposure  0.06 0.11 0.610 - 0.16 - 0.28
 repeated exposure - 0.11 0.20 0.564 - 0.50 - 0.27
Covariates: Sex and pubertal development. note: SLEs= Stressful life events; TYEs= Traumatic Youth expe-
riences. 1Z-score, 2No abuse is the reference group.
table s4b. Regression analyses of SLEs, genotype and the interaction between SLEs and 5HTTLPR geno-
type, on SLC6A4 methylation.
SLC6A4 methylation
b sE P  95% Ci of b
SLEs (0-15 years)2 0.05 0.09 0.598 - 0.13 - 0.23
s/l1 0.27 0.11 0.013  0.06 - 0.49
l/l1 0.30 0.13 0.018  0.05 - 0.54
SLEs (0-15 years)2 X s/l1 0.00 0.11 0.993 - 0.22 - 0.21
SLEs (0-15 years)2 X l/l1 0.30 0.13 0.021  0.05 - 0.56
Covariates: Sex and pubertal development. note: SLEs= Stressful life events; 1 s/s is the reference group, 
2Z-score. The s-allele includes only the s-allele, the l-allele includes the lg and la alleles.
table s4c. Regression analyses of SLEs and SLC6A4 methylation stratified by 5HTTLPR genotype.
 SLC6A4 methylation
 s/s s/l l/l
 b sE p b sE p b sE p
SLEs1
Total (0-15 years)  0.05 0.09 0.534 0.04 0.06 0.488 0.36 0.10 < .001
 Childhood (0-11) - 0.07 0.09 0.452 0.00 0.06 0.980 0.17 0.09 0 .069
 Adolescence (12-15)  0.14 0.09 0.106 0.06 0.06 0.337 0.35 0.11 0 .002
Covariates: Sex and pubertal development. note: SLEs= Stressful life events. 1Z-score. The s-allele includes 
only the s-allele, the l-allele includes the lg and la alleles. 
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table s5a. Regression analyses of adverse life events and SLC6A4 methylation.
 SLC6A4 methylation
 b sE p  95% Ci of b
Perinatal adversity1 - 0.07 0.04 0.119 - 0.15 - 0.02
SLEs1
Total (0-15 years)  0.12 0.05 0.010  0.03 - 0.21
 Childhood (0-11)  0.04 0.04 0.335 - 0.04 - 0.13
 Adolescence (12-15)  0.12 0.05 0.011  0.03 - 0.21
TYEs2
Sexual abuse
 single exposure - 0.17 0.22 0.423 - 0.60 - 0.25
 repeated exposure  0.03 0.26 0.917 - 0.49 - 0.54
Physical abuse
 single exposure  0.01 0.09 0.914 - 0.17 - 0.19
 repeated exposure - 0.19 0.27 0.475 - 0.72 - 0.34
Other trauma
 single exposure  0.04 0.11 0.719 - 0.18 - 0.27
 repeated exposure - 0.18 0.20 0.382 - 0.57 - 0.22
Covariates: Sex, age, use of oral contraceptives, CRP (C-reactive protein, mg/l) and pubertal development. 
note: SLEs= Stressful life events; TYEs= Traumatic Youth experiences. 1Z-score, 2No abuse is the reference 
group.
table s5b. Regression analyses of SLEs, genotype and the interaction between SLEs and 5HTTLPR geno-
type, on SLC6A4 methylation.
SLC6A4 methylation
b sE P  95% Ci of b
SLEs (0-15 years)2 0.05 0.09 0.590 - 0.13 - 0.24
s/l1 0.26 0.11 0.021  0.04 - 0.48
l/l1 0.26 0.13 0.039  0.01 - 0.52
SLEs (0-15 years)2 X s/l1 0.00 0.11 0.985 - 0.22 - 0.22
SLEs (0-15 years)2 X l/l1 0.30 0.13 0.026  0.04 - 0.56
Covariates: Sex, age, use of oral contraceptives, CRP (C-reactive protein, mg/l) and pubertal development. 
note: SLEs= Stressful life events; 1 s/s is the reference group, 2Z-score. The s-allele includes only the s-allele, 
the l-allele includes the lg and la alleles.
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table s5c. Regression analyses of SLEs and SLC6A4 methylation stratified by 5HTTLPR genotype.
 SLC6A4 methylation
 s/s s/l l/l
 b sE p b sE p b sE p
SLEs1
Total (0-15 years)  0.06 0.09 0.493 0.05 0.06 0.432 0.33 0.10 0.001
Childhood (0-11) - 0.05 0.09 0.607 0.01 0.06 0.877 0.18 0.09 0.052
Adolescence (12-15)  0.12 0.09 0.148 0.06 0.06 0.365 0.30 0.12 0.011
Covariates: Sex, age, use of oral contraceptives, CRP (C-reactive protein, mg/l) and pubertal development. 
note: SLEs= Stressful life events. 1Z-score. The s-allele includes only the s-allele, the l-allele includes the lg 
and la alleles.
three-way interaction of sex, 5HTTLPR genotype and sLEs on methylation.
table s6. Three-way interaction of sex, 5HTTLPR genotype and SLEs on methylation.
 b sE  p
sex1 - 0.68 0.18 < .001
s/l 2  0.39 0.15  .008
l/l 2  0.40 0.17  .023
SLEs (0-15 years)3  0.04 0.11  .715
sex 1 * s/l 2 - 0.30 0.22  .176
sex1 * l/l 2 - 0.22 0.25  .376
sex 1 * SLEs (0-15 years)3 - 0.01 0.19  .979
s/l 2 * SLEs (0-15 years)3  0.03 0.13  .804
l/l 2 * SLEs (0-15 years)3  0.23 0.18  .207
sex 1 * s/l 2 * SLEs (0-15 years)3 - 0.08 0.23  .741
sex 1 * l/l 2 * SLEs (0-15 years)3  0.16 0.27  .563
note: 1Female is the reference category; 2s/s is the reference category; 3Z-score. SLEs= Stressful life events. 
Bold numbers indicate significant results. S-allele includes s and lg alleles, the l-allele includes the la allele.
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figure s2. Graphical representation of the interaction between stressful live events (SLEs) and different 
genotypes on methylation levels in males and females.
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CpG-unit specific interaction
table s7. Regression analyses of SLEs, genotype and the interaction between SLEs and 5HTTLPR genotype, 
on SLC6A4 methylation per CpG unit. 
Methylation
SLEs
(0-15 years)2
s/l1 l/l1
SLEs
(0-15 years)2 X s/l1
SLEs
(0-15 years)2 X l/l1
CpGU1
b  0.07  0.12  0.10 - 0.04  0.06
sE  0.06  0.08  0.09  0.08  0.09
P  0.241  0.102  0.243  0.612  0.475
CpGU3
b - 0.02  0.24  0.19  0.15  0.31
sE  0.11  0.13  0.15  0.13  0.16
P  0.844  0.078  0.214  0.269  0.054
CpGU4
b  0.06  0.46  0.51 - 0.17  0.16
sE  0.18  0.22  0.25  0.22  0.26
P  0.732  0.034  0.042  0.422  0.545
CpGU6
b  0.02  0.11  0.24 - 0.07  0.05
sE  0.12  0.14  0.16  0.14  0.17
P  0.851  0.439  0.132  0.612  0.746
CpGU9
b  0.38  0.07 - 0.17 - 0.04 - 0.07
sE  0.13  0.16  0.18  0.16  0.19
P  0.005  0.665  0.353  0.822  0.723
CpGU10
b  0.13  0.18  0.16 - 0.02 - 0.10
sE  0.12  0.15  0.17  0.14  0.17
P  0.272  0.218  0.329  0.895  0.555
CpGU12
b  0.03 - 0.02 - 0.24  0.17  0.22
sE  0.24  0.29  0.33  0.28  0.34
P  0.907  0.948  0.469  0.549  0.513
CpGU14
b - 0.08  0.49  0.67  0.30  0.42
sE  0.23  0.27  0.31  0.27  0.33
P  0.727  0.072  0.033  0.270  0.196
CpGU15
b - 0.02  0.29  0.39  0.00  0.21
sE  0.16  0.19  0.22  0.19  0.23
P  0.886  0.132  0.081  0.980  0.358
CpGu16
b  0.00  0.11  0.70 - 0.01  1.10
sE  0.26  0.33  0.37  0.32  0.38
P  0.991  0.747  0.060  0.969  0.004
CpGu22
b - 0.22  0.67  0.71 - 0.05  1.28
sE  0.33  0.41  0.47  0.40  0.49
P  0.503  0.100  0.129  0.905  0.008
note: Adjusted for sex. 1s/s is reference category, 2Z-score. Bold numbers indicate significant results. The 
s-allele includes only the s-allele, the l-allele includes the lg and la alleles. SLEs= Stressful life events; CpGU= 
CpG unit.
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interaction without snP recoding
table s8. Regression analyses of SLEs, genotype and the interaction between SLEs and genotype, on SL-
C6A4 methylation, regardless of rs25531. 
 SLC6A4 methylation
 b sE p 95% Ci of b
SLEs (0-15 years)2 - 0.01 0.11 .947 -0.22 - 0.21
s/l1  0.14 0.13 .302 -0.12 - 0.39
l/l1  0.10 0.14 .458 -0.17 - 0.37
SLEs (0-15 years)2 X s/l1  0.14 0.13 .274 -0.11 - 0.39
SLEs (0-15 years)2 X l/l1  0.24 0.14 .078 -0.03 - 0.51
note: Adjusted for sex. 1s/s is reference category, 2Z-score. Bold numbers indicate significant results. The 
s-allele includes only the s-allele, the l-allele includes the lg and la alleles. SLEs= Stressful life events.
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AbstrACt
background: The relationship between early adverse life events and later internalizing 
problems could be mediated by DNA methylation. Adversity has been associated with 
higher methylation levels in the glucocorticoid receptor gene (NR3C1) and the serotonin 
transporter gene (SLC6A4) in adolescents. We investigated cross-sectional and prospec-
tive associations of NR3C1 and SLC6A4 methylation with adolescents’ clinical diagnoses 
of internalizing disorders and internalizing symptom scores.
methods: In a population sample (mean age=16.2) we measured DNA methylation in 
three regions of NR3C1 (NR3C1_1, N=454; NR3C1_2, N=904; NR3C1_3, N=412) and one 
region of SLC6A4 (N=939) at baseline. Internalizing problems were operationalized as 
clinical DSM-IV diagnoses, assessed at 3 year follow-up with a diagnostic interview, and 
internalizing symptom scores, assessed with Self-Report questionnaires at baseline and 
follow-up.
results: Only NR3C1_1 methylation was positively associated with risk of lifetime inter-
nalizing disorders, and with symptom scores at follow-up. However, after accounting for 
baseline symptom scores there was only a tendency for association with internalizing 
symptom scores at follow-up. There was no association between SLC6A4 methylation 
and risk of lifetime internalizing disorders. SLC6A4 methylation and internalizing 
symptom scores showed a tendency for association, also after accounting for baseline 
symptom scores.
Limitations: There was no repeated measure of DNA methylation to study causality 
between methylation and internalizing problems. Gene expression data were not avail-
able.
Conclusions: Although the role of gene methylation in the development of internal-
izing problems remains unclear, our findings suggest that gene methylation, particularly 
of NR3C1, may be involved in the development of internalizing problems in adolescence.
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intrOduCtiOn
Despite consistent reports of associations between adverse life events and anxiety and 
depression later in life 1, 2, not all individuals exposed to adversity develop internalizing 
problems. Heritability estimates ranging between 27% and 50% (e.g., 3, 4, 5) suggest a 
genetic predisposition for the development of these disorders. Yet, GWAS studies have 
not shown convincing support for specific loci that contribute to the development of 
internalizing problems. In recent years, the focus of research on adverse life events and 
psychopathology has shifted from the interplay between genetic variation and the en-
vironment towards epigenetic variation and the environment. Epigenetic modifications 
such as DNA methylation, have become popular targets for investigation and evidence 
of the influence of the environment on DNA methylation is steadily growing 6-8. DNA 
methylation involves the addition of a methyl group to a cytosine-phosphate-guanine 
(CpG) combination and generally inhibits gene expression 9-13 when located in the 
promoter region. Reduced expression of genes that regulate physiological processes 
that underlie normal behavior may contribute to the development of internalizing 
disorders 9.
Two genes of interest in the study of adverse life events and internalizing disorders are 
the serotonin transporter gene (SLC6A4) and the glucocorticoid receptor gene (NR3C1). 
Depression has consistently been linked to alterations in stress reactivity 14, and the 
glucocorticoid receptor (GR) is an important regulator of the stress response system by 
providing negative feedback in the HPA-axis. Higher NR3C1 methylation levels results 
in an altered stress response 12, 15, which may underlie the development of internalizing 
problems 16.
Similarly, alterations in serotonergic transmission have been associated with anxious 
or depressed mood 17, 18. Serotonin levels are regulated by serotonin transporter (5HTT) 
availability and can be altered by selective serotonin reuptake inhibitors (SSRIs), a fre-
quently prescribed medication for both mood and anxiety disorders.
Only a few studies have investigated the relationship between NR3C1 or SLC6A4 meth-
ylation and internalizing problems. For NR3C1, one study on NR3C1 methylation and 
depression showed uniformly low methylation in both patients with major depressive 
disorder (MDD) and controls 19, whereas a more recent study showed lower methylation 
levels in patients with MDD than controls 10, both in the 1F promoter region. Methylation 
of SLC6A4 has been positively associated with depressive symptoms in monozygotic 
twin pairs 13 and patients with MDD 20, and a positive trend was found for methylation 
with lifetime history of MDD 11 (for a graphical representation of the genomic regions 
studied, see Supplementary Figures S1 (SLC6A4) and S2 (NR3C1)). The link between 
NR3C1 and SLC6A4 methylation and anxiety has not been investigated thus far. Yet this 
link seems plausible: for some anxiety disorders an association with hyperactivity of the 
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HPA axis has been reported 21, which suggests that NR3C1 methylation may be related 
to anxiety. Also, the effectiveness of SSRIs on the treatment of anxiety disorders makes 
SLC6A4 a plausible candidate for the involvement in anxiety disorders.
Whereas the existing literature focused on concurrent associations, we aimed to study 
whether NR3C1 and SLC6A4 methylation levels are associated with internalizing prob-
lems, both concurrently and prospectively. The few studies on the relationship between 
methylation and internalizing problems up till now have shown mixed findings, pos-
sibly due to their small sample sizes (12< N <192). To overcome this limitation, we used 
prospective data of a large sample of 945 adolescents, in whom internalizing disorders 
often have a first onset 22. Given that adverse life events have often been associated with 
higher methylation levels and more internalizing problems, we hypothesized that higher 
levels of methylation are associated with higher internalizing symptom scores and a 
higher risk of developing any internalizing disorder. In two studies, a polymorphism in 
the SLC6A4 gene, the 5HTT-linked polymorphic region (5HTTLPR), has been shown to 
modify methylation levels when associated with stressful life events 23 or unresolved loss 
or trauma 24. We have therefore included this polymorphism as a possible moderator of 
the association between SLC6A4 methylation levels and internalizing symptom scores.
mEtHOds
sample selection
This study was part of the TRacking Adolescents’ Individual Lives Survey (TRAILS), a 
prospective population study in which Dutch adolescents are followed from preado-
lescence into adulthood. Assessment waves are conducted biennially or triennially, and 
five assessment waves have been completed so far. Written consent was obtained from 
each subject and their parents at every assessment wave. The present study involves 
data collected during the third (T3, 2005-2007, N=1816, mean age 16.3, SD 0.71) and 
fourth (T4, 2008-2010, N=1881, mean age 19.1, SD 0.60) assessment waves. The study 
was approved by the Dutch Central Medical Ethics Committee and subjects received 
compensation for their participation. A detailed description of sampling and methods 
can be found in Huisman et al 25 and Ormel et al 26.
The T3 assessment involved a blood draw, from which DNA was successfully extracted 
in 1156 T3 participants. Selection for methylation analyses was based on the availability 
of blood, Dutch ethnicity, and sufficient DNA concentration. We randomly excluded one 
of each sibling pairs and removed DNA samples which were not suitable for analyses. 
Together, this resulted in a total of 945 individuals (48.3% males) suitable for methyla-
tion analyses. Assessment waves T3 and T4 will henceforth be referred to as baseline and 
follow-up.
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dnA methylation analyses
DNA selection and methylation analyses. DNA was extracted from whole-blood samples 
using a manual salting-out procedure as described by Miller et al 27. We used primer sets 
previously used by McGowan et al 28 for NR3C1 and Philibert et al 11 (set B) for SLC6A4 , 
which encompass regions of the CpG island (i.e., a region with a higher frequency of 
CpG sites than expected) in the promoter regions of both genes. Two additional NR3C1 
primer sets were designed (with EpiDesigner by Sequenom) and analyzed in a subsam-
ple (N=475) of the individuals initially selected for methylation analyses, to increase the 
coverage of the CpG island (described in detail in van der Knaap et al 8). For NR3C1, DNA 
regions were numbered (NR3C1_1 to 3) according to their position in the CpG island. 
More details and graphical representations of these specific DNA regions can be found 
in van der Knaap et al 8 for NR3C1, and van der Knaap et al 23 for SLC6A4. Forward primers 
contained a 10 mer sequence tag (aggaagagag), and reverse primers are equipped with 
a T7-promoter tag (cagtaatacgactcactataggg) and an 8 base pair insert (agaaggct). DNA 
methylation levels were analyzed using the EpiTYPER method from Sequenom. Bisulfite 
conversion was followed by PCR amplification, reverse transcription and base-specific 
cleavage. Fragments were analyzed on a mass spectrometer (Sequenom EpiTYPER, San 
Diego, CA, USA). Bisulfite conversion of DNA was performed using EZ-96 DNA Methyla-
tion Kit (Shallow) (Zymo Research, CA, USA), according to manufacturers’ protocol. PCR, 
reverse transcription, cleavage and mass spectrometry were performed in triplicate, 
according to EpiTYPER protocol. The mass signal patterns generated were translated 
to quantitative methylation levels for different CpG-units by the MassARRAY EpiTYPER 
analyzer software from Sequenom (v1.0, build1.0.6.88 Sequenom, Inc, San Diego, USA). 
Fragments with CpG dinucleotides are referred to as CpG units. One CpG unit can con-
tain one or more CpG dinucleotides. CpG units with a mass outside the range of the 
mass spectrometer or overlap in mass of another CpG unit could not be analyzed.
Data cleaning procedures. All samples were analyzed in triplicate, and methylation levels 
of the triplicates were averaged for each CpG unit 8. Samples with a standard deviation 
of ≥10% between replicates and CpG units with >25% missing values were removed 
(NR3C1_1: CpGU4; NR3C1_3: CpGU13; SLC6A4: CpGU17). We accounted for mass-change 
in CpG units by SNPs (only when minor allele frequency >5%) by removing CpG units 
containing SNPs (SLC6A4: CpGU18) equal in mass to non- or other CpG units contain-
ing SNPs (none in our sample). In total, 11 CpG units remained eligible for NR3C1_1, 
10 for NR3C1_2, 9 for NR3C1_3, and 11 for SLC6A4. Overall, we obtained methylation 
levels of NR3C1_1 for 454 individuals, of NR3C1_2 for 904 individuals, of NR3C1_3 for 412 
individuals, and of SLC6A4 for 939 individuals.
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5HTTLPR and rs25531 genotyping
Sequence length analysis was used to determine the 5-HTT-linked-polymorphic-region 
genotype in the promoter region of SLC6A4. The length assessment of the 5HTTLPR al-
leles was measured by direct analysis on an automated capillary sequencer (ABI3730, 
Applied Biosystems, Nieuwerkerk aan den IJssel, the Netherlands). The call rate was 
91.6%. The single nucleotide substitution (A>G) present in the 5HTTLPR l-allele (rs25531) 
was genotyped using a custom made TaqMan assay (Applied Biosystems). Additional 
information is described in Nederhof et al 29. The call rate for rs25531 was 96.5%. Con-
cordance between DNA replicates showed an accuracy of 100%. Because the lg-allele is 
considered functionally equivalent to the s-allele 30, it was recoded as an s-allele, and the 
la-allele was recoded as an l-allele. The genotype frequencies for 5HTTLPR (s/s: N=209, s/l: 
N=473, l/l: N=245) were in Hardy-Weinberg equilibrium (χ2=0.45, df = 1, p=.50).
internalizing problems
Symptom scores: Internalizing symptom scores were assessed dimensionally at baseline 
with the Internalizing Problems scale from the Youth Self-Report (YSR 31, 31 items; α= 
.89), and at follow-up with the Adult Self-Report (ASR 32, 39 items; α= .93) 33. Specific 
problems scales from the YSR and ASR included DSM-IV Affective Problems scale (YSR: 
13 items, α=.78; ASR: 14 items, α= .84) and DSM-IV Anxiety Problems scale (YSR: 6 items; 
α= .65; ASR: 7 items, α= .75). Mean item scores were used. All items referred to the past 
six months.
Clinical DSM-IV diagnoses: Internalizing disorders were assessed at follow-up using 
the Composite International Diagnostic Interview (CIDI; Version 3.0 34). The CIDI is a 
structured diagnostic interview that yields lifetime and current diagnoses according to 
criteria of the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM–IV; American Psychiatric Association, 2000). Of all participants at follow-up, 84.2% 
(N=1584) agreed to have the diagnostic interview. In addition to lifetime prevalence, the 
CIDI generates the age of first onset, the age at which the last episode started, and the 
age at which the last episode ended.
We constructed a binary score indicating the presence or absence of lifetime diagno-
sis of any internalizing disorder, subdivided into Depression and Anxiety. Depression 
included Major Depressive Disorder and Dysthymia; Anxiety included Adult Separation 
Anxiety, Agoraphobia, Generalized Anxiety Disorder, Panic Disorder, Obsessive Com-
pulsive Disorder, Separation Anxiety Disorder, and Social Phobia. We did not exclude 
individuals with comorbid anxiety and depressive disorders, because comorbid anxiety 
and depressive disorder are highly common and this may result in non-representative 
groups.
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statistical analyses
Missing data on internalizing symptom scores and CIDI diagnoses were imputed. Using 
the Multiple Imputations procedure in SPSS (version 21) twenty datasets were generated 
and subsequently used to generate pooled estimates from analyses. DNA methylation 
data was mean-centered, a method previously used in van der Knaap et al 8, and aver-
aged over all CpG units within each DNA region.
Descriptive statistics were calculated and associations among internalizing problems 
and methylation values were examined with the use of Spearman correlations. The 
association between methylation levels and internalizing disorders was analyzed with 
a series of binary logistic regression models, each with the methylation level at a spe-
cific DNA region as predictor and the lifetime prevalence of an internalizing disorder as 
outcome variable. Associations between methylation levels and internalizing symptom 
scores, and the interaction between methylation and 5HTTLPR in predicting internalizing 
symptom scores, were explored with linear regression analyses. In case of a significant 
interaction we will stratify the analyses by genotype. Methylation level at a specific DNA 
region was specified as predictor and internalizing symptom scores at follow-up was 
specified as outcome variable. In addition, we fitted a model that included internalizing 
symptom scores at baseline as additional predictor, to test whether methylation levels 
would predict a change in symptom scores over time. Each model contained age at 
baseline and sex as covariates, since age and sex may affect both methylation patterns 
35 and the prevalence of internalizing problems 36. To explore whether the association 
between DNA methylation and internalizing problems differs between sexes, we also 
tested interactions between methylation and sex in the models, and stratified the analy-
ses by sex in case of a significant interaction effect.
rEsuLts
Descriptive statistics of internalizing problems and methylation values are presented 
in Table 1 and Table 2. Bivariate associations between internalizing problems and DNA 
methylation are presented in Table 3. On average, slightly fewer internalizing problems 
were reported at follow-up than at baseline, but this does not necessarily imply a lack of 
emergence of new symptoms. The correlation between internalizing symptom scores at 
baseline and at follow-up is not very high (0.58), which indicates that a large proportion 
of individuals experience either a loss of symptoms or an emergence of new symptoms. 
We did not find an interaction between methylation and 5HTTLPR genotype in predict-
ing internalizing symptom scores prior to imputation (all ps>.05, see Supplementary 
Table S1), suggesting that 5HTTLPR does not moderate the association between SLC6A4 
methylation levels and internalizing problems. None of the interactions with sex was 
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statistically significant, except for the interaction with NR3C1_3 methylation when 
adjusted for baseline symptom scores (see Supplementary Table S2). For boys, low 
NR3C1_3 methylation was associated with an increase in internalizing symptom scores, 
whereas no effect was found in girls (see Supplementary Table S2a).
NR3C1 methylation at DNA region 1 was associated with an increased risk for lifetime 
internalizing disorders (Table 4). An absolute increase of 1% methylation (percentage 
point) in this region indicated an almost 3-fold higher odd of suffering from an internal-
izing disorder at age 19. No associations were found between methylation in other DNA 
regions of NR3C1 and lifetime internalizing disorders, or between SLC6A4 methylation 
and lifetime internalizing disorders.
Higher methylation levels of NR3C1 in DNA region 1 were also associated with higher 
internalizing symptom scores at follow-up (Table 5; for a graphical representation see 
Supplementary Figure S3). This association was not found in the other DNA regions of 
NR3C1. When accounting for internalizing symptom scores at baseline, the association 
became non-significant, indicating no prediction of symptom score change over time. 
Methylation levels of SLC6A4 were not significantly associated with internalizing symp-
tom scores at follow-up, but showed a tendency for association in the same direction, 
also when accounting for internalizing symptom scores at baseline.
Post hoc analyses
To explore whether the associations were driven by either depression or anxiety prob-
lems, we performed post hoc analyses using either depression or anxiety disorders, or 
symptom scores as outcome variable. Firstly, for anxiety and depression disorders, NR3C1 
table 1. Descriptive statistics of internalizing problems
n yes (%)
Cidi
Lifetime internalizing disorder 945 277 (29.3%)
Lifetime anxiety disorder 945 193 (20.5%)
Lifetime depression disorder 945 149 (15.8%)
n mean (sd)
ysr (Assessment wave 3)
Age 945 16.2 (0.7)
Internalizing symptom scores 945  0.3 (0.2)
Asr (Assessment wave 4)
Age 945 19.0 (0.6)
Internalizing symptom scores 945  0.2 (0.2)
ASR=adult self-report; YSR=Youth self-report; CIDI=Composite international diagnostic interview. ASR and 
YSR scores are based on mean symptom scores for internalizing, anxiety and affective/depressive problems 
(N=945).
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table 2. Range, mean and SD of individual CpG units within the three NR3C1 regions. 
n min max mean sd
NR3C1_1
CpGU3 441 0.0%  8.5%  4.6% 1.6%
CpGU6 451 0.0%  3.3%  0.0% 0.3%
CpGU8 453 0.0%  4.5%  1.6% 0.7%
CpGU9 454 1.7%  7.5%  3.1% 0.7%
CpGU10 454 0.5%  6.7%  2.5% 1.2%
CpGU11 454 0.5%  7.7%  2.9% 0.9%
CpGU12 453 2.0% 16.0%  9.9% 2.4%
CpGU15 454 0.3%  6.3%  2.8% 0.8%
CpGU16 454 0.0%  6.3%  1.0% 0.6%
CpGU17 454 0.0%  6.0%  0.8% 0.9%
CpGU19 454 0.0%  2.0%  0.2% 0.3%
NR3C1_2
CpGU2 904 0.0%  4.0%  1.3% 0.5%
CpGU4 903 0.0%  7.0%  1.3% 1.0%
CpGU5 904 0.0%  5.7%  1.7% 1.0%
CpGU6 904 0.0%  7.0%  1.5% 1.1%
CpGU7 903 0.0%  8.3%  2.5% 1.3%
CpGU11 904 0.0%  6.5%  0.7% 0.7%
CpGU13 819 1.0% 27.5% 10.1% 4.8%
CpGU14 903 1.5% 14.7%  7.5% 2.1%
CpGU17 902 0.0%  9.3%  0.7% 1.0%
CpGU18 900 1.0% 12.3%  4.3% 1.6%
NR3C1_3
CpGU1 407 0.0%  8.7%  2.5% 1.0%
CpGU2 406 1.0% 11.0%  3.6% 1.6%
CpGU4 410 0.0%  8.5%  2.2% 1.5%
CpGU5 404 1.0% 11.0%  4.6% 1.9%
CpGU9 408 0.0% 11.5%  0.6% 1.0%
CpGU10 412 0.0%  5.0%  0.4% 0.7%
CpGU11 410 0.0%  7.3%  1.9% 1.3%
CpGU12 404 0.0% 10.0%  2.1% 1.4%
CpGU15 397 0.0%  7.7%  3.2% 1.2%
SLC6A4
CpGU1 938 0.5%  8.3%  2.8% 0.9%
CpGU3 936 2.3% 12.0%  5.8% 1.6%
CpGU4 920 0.0% 19.0%  6.0% 2.5%
CpGU6 934 0.0% 10.3%  1.4% 1.6%
CpGU9 935 2.0% 14.0%  7.6% 1.9%
CpGU10 774 0.0%  9.5%  2.4% 1.5%
CpGU12 898 5.0% 27.3% 15.4% 3.3%
CpGU14 892 0.7% 22.7%  9.5% 3.2%
CpGU15 930 2.7% 20.0%  8.6% 2.3%
CpGU16 843 5.0% 31.0% 15.9% 3.8%
CpGU22 859 7.7% 47.0% 28.0% 5.3%
A CpG unit (CpGU) is a fragment of DNA containing one or more CpG dinucleotides. NR3C1=Glucocorticoid 
receptor gene. SLC6A4=Serotonin transporter gene
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methylation levels at NR3C1_1 were positively associated with the risk of a depressive 
(OR=3.71, 95%CI=2.00–6.89, p<.001) and an anxiety (OR=2.41, 95%CI=1.35–4.31, 
p=.003) disorder. For SLC6A4, higher levels of methylation were associated with a higher 
odds for anxiety (OR=1.16, 95%CI=1.02–1.33, p=.026), but not depression (OR=1.04, 
95%CI=0.90–1.21, p=.613). Secondly, for symptom scores, NR3C1 methylation levels 
in NR3C1_1 were positively associated with depressive symptom scores at follow-up 
(B=0.13, SE=0.03, p<.001), but became non-significant when accounting for depressive 
symptom scores at baseline (B=0.05, SE=0.03, p=.119). SLC6A4 methylation levels were 
also positively associated with depressive symptom scores at follow-up (B=0.02, SE=0.01, 
p=.011), and this association remained significant when accounting for depressive 
symptom scores at baseline (B=0.02, SE=0.01, p=.015). For anxiety symptom scores, we 
only found an association between NR3C1 methylation in NR3C1_1 and higher anxiety 
symptom scores at follow up (B=0.13, SE=0.04, p<.001), which remained significant after 
accounting for anxiety symptom scores at baseline (B=0.07, SE=0.03, p=.044). No as-
sociations were found between SLC6A4 methylation levels and anxiety symptom scores 
(B=0.01, SE=0.01, p=.250).
disCussiOn
We found that NR3C1 methylation at age 16 positively predicted the probability of a 
lifetime diagnosis of internalizing disorder, as well as internalizing symptom scores three 
years later. Methylation of SLC6A4 was not associated with internalizing disorders, while 
the association with internalizing symptom scores only showed a tendency for associa-
tion.
table 4. Associations between methylation levels of NR3C1 and SLC6A4 and lifetime internalizing disorders. 
methylation
Lifetime internalizing disorder
Or 95% Ci of Or p n
NR3C1_1 2.91 1.70 - 4.98 < .001 454
NR3C1_2 0.97 0.76 - 1.24  .809 904
NR3C1_3 0.65 0.38 - 1.11  .113 412
methylation
Lifetime internalizing disorder
Or 95% Ci of Or p n
SLC6A4 1.08 0.96 - 1.22 .193 939
Results were derived from binary logistic regression analyses; bold numbers indicate significant results. 
All models were adjusted for sex and age. NR3C1=Glucocorticoid receptor gene; SLC6A4=Serotonin trans-
porter gene.
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DNA methylation has scarcely been investigated in relation to internalizing disorders, 
particularly anxiety disorders. The association between NR3C1 methylation and risk of 
internalizing disorders found in this study may provide a first step in unraveling the role 
of epigenetic modification in the pathophysiology of internalizing disorders. SLC6A4 
methylation was not associated with internalizing disorders as a whole in this study, 
but post hoc analyses suggested that it might be related to anxiety disorders only. In 
contrast, NR3C1 methylation seemed to increase the risk of both anxiety and depres-
sion disorders. Our exploratory analyses on sex differences did not reveal convincing 
evidence that the relation between methylation and internalizing symptom scores is 
modified by sex. We did find a significant interaction with NR3C1_3 methylation, but 
only when adjusted for baseline symptom levels, and the effect was only just significant 
(p=0.049). Therefore, this interaction effect could well be a chance finding and requires 
replication before justifying speculation about mechanisms.
The prospective relationship between NR3C1 methylation and internalizing symptom 
scores at follow-up appeared to be largely explained by the cross-sectional association 
with symptom scores at baseline. When we compared the first model with the second 
model, in which we additionally adjusted for baseline symptom scores, we noticed a 
difference in effect size for both genes. For NR3C1 the value of the regression coefficient 
was lower in the second model, yet it is still somewhat elevated. This may suggest that 
table 5. Associations between methylation levels of NR3C1 and SLC6A4 and internalizing symptom scores 
at follow-up. 
methylation
 internalizing symptom scores at follow-up
 b sE p n
NR3C1_1  0.11 0.03 < .001
454
NR3C1_1a  0.04 0.02  .059
NR3C1_2  0.00 0.01  .862
904
NR3C1_2a - 0.01 0.01  .615
NR3C1_3 - 0.04 0.03  .123
412
NR3C1_3a - 0.02 0.02  .397
methylation
internalizing symptom scores at follow-up
b sE p n
SLC6A4 0.01 0.01 .054
939
SLC6A4a 0.01 0.01 .085
Results were derived from linear regression analyses; bold numbers indicate significant results. All 
models were adjusted for sex and age. a Additionally adjusted for internalizing problems at baseline. 
NR3C1=Glucocorticoid receptor gene; SLC6A4=Serotonin transporter gene.
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although most of the effect is explained by baseline symptom scores, there is still some 
vulnerability for internalizing symptom scores 3 years later. For SLC6A4, this drop in the 
regression coefficient is not observed. The association between SLC6A4 and internal-
izing symptom scores at follow-up is not affected by internalizing symptom scores at 
baseline. Possibly, these differences in decrease of effect size may reflect gene-specific 
differences in the temporal stability of methylation, with less stable methylation for 
NR3C1 than for SLC6A4.
The post hoc analyses for NR3C1 showed that associations with internalizing symptom 
scores could be attributed to both anxiety and depression symptoms, and for SLC6A4 
only to depression symptoms. Together with the post hoc results on internalizing disor-
ders, NR3C1 methylation seems to have a more generic role in internalizing problems, 
whereas the role of SLC6A4 may be less consistent across phenotypes of internalizing 
problems. However, drawing a firm conclusion from this single study is opportunistic, as 
replication of the current findings and extension the current findings to more specific 
phenotypic internalizing problems is warranted. Still, our findings may be useful in the 
search to unravel the physiological processes that underlie the different internalizing 
problems.
Further investigation of the link between DNA methylation and internalizing dis-
orders may lead to a better understanding of the etiology, but may also have clinical 
implications, such as the potential for diagnostic biomarkers, which have already been 
suggested for the BDNF gene in relation to MDD 37. The association between NR3C1 
methylation and internalizing problems in the current study makes it a likely target for 
a potential biomarker. For SLC6A4, the association with internalizing problems is not so 
straight forward, thus reducing its potential as a biomarker. However, a recent study by 
Okada et al 38 suggests that potential biomarkers for SLC6A4 should be CpG unit specific, 
as they also did not find an association between overall SLC6A4 methylation and early 
adversity or the severity of depression.
Associations between NR3C1 methylation and internalizing problems were only found 
for DNA region 1 (positioned at the 3’ end of the CpG island). This particular DNA region 
covers an area that extends beyond the CpG island, into the so-called CpG island shores 
(regions up to 2kb outside of the CpG island borders) 39. More methylation in these 
shores has been strongly associated with a decrease in expression of the gene, which 
indicates an important functional role of CpGs in these shores 39, 40. It is tempting to 
speculate that the associations between methylation in our other DNA regions (2 and 3) 
and gene expression were not sufficiently strong to influence any physiological process 
that may lead to the development of internalizing problems. However, more research is 
needed on the potential influence of individual methylated CpG sites or locations on the 
development of these disorders.
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Several limitations should be acknowledged. Because blood was collected only at 
baseline, changes in methylation levels could not be analyzed. We could therefore not 
establish a causal link between methylation level and the onset of internalizing prob-
lems. Also, we were unable to analyze gene expression levels of NR3C1 and SLC6A4 in 
this study, although it should be noted that for both NR3C1 and SLC6A4, higher methyla-
tion levels have been associated with lower expression levels before 11, 12, 28, 41.
Nonetheless, our large sample size and the use of multiple outcome measures ( i.e. 
symptom scores and DSM-IV diagnoses) strengthen our findings. The association be-
tween stress-related environmental factors and methylation in previous TRAILS studies 
8, 23, and the associations with internalizing problems in the current TRAILS study, also 
support the theory of the mediating effect of methylation in the development of inter-
nalizing disorders 42. Although the functional role of gene methylation in the develop-
ment of internalizing problems is still unclear, our findings provides suggestive evidence 
that gene methylation, of NR3C1 in particular, may be involved in the development of 
internalizing problems in adolescence.
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suPPLEmEntAry infOrmAtiOn
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figure s1. Schematic representation of the position of the serotonin transporter gene (SLC6A4) CpG island 
(Chr17:28562388-28563186; represented by the grey box, based on the UCSC human Feb. 2009 assembly 
GRCh37/hg19) relative to the transcription start site (TSS) in exon 1 (dark grey box; based on Ensembl Tran-
script ID ENST00000394821). The relative position of the genomic fragments of the gene used in methyla-
tion analyses in previous studies are represented by the lined boxes with letters A 1, B 2 and C (3[primer set 
B] and this study).
1 2 3 
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figure s2. Schematic representation of the glucocorticoid receptor gene (NR3C1) and CpG island 
(chr5:142782072-142785071, represented by the grey box, based on the UCSC human Feb. 2009 assem-
bly GRCh37/hg19). Genomic fragments (1=NR3C1_1, 2=NR3C1_2 and 3=NR3C1_3, white lined boxes) are 
shown in relation to the NR3C1 CpG-island (grey box) and untranslated first exons (dark grey boxes) up-
stream of exon 2 (striped box). Image based on Labonte et al 4 and Turner et al 5 and adapted from van der 
Knaap et al 6.
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table s1. Regression analyses of internalizing symptom scores at follow-up, 5HTTLPR genotype and the in-
teraction between SLC6A4 methylation and 5HTTLPR genotype, on internalizing symptom scores at follow-
up. 
methylation  internalizing symptom scores at follow-up 
 b sE P n
SLC6A4  0.00 0.01 0.927
853SLC6A4 X SLa  0.01 0.02 0.476
SLC6A4 X LLa  0.02 0.02 0.332
SLC6A4 b - 0.01 0.01 0.522
830SLC6A4 X SLa b  0.02 0.01 0.094
SLC6A4 X LLa b  0.01 0.01 0.331
Analyses performed on non-imputed dataset. 5HTTLPR S-allele includes S and Lg alleles, the L-allele in-
cludes the La allele (see method section for further details). a = SS is the reference category, b = additionally 
adjusted for internalizing symptom scores at baseline.
table s2. Regression analyses of internalizing symptom scores at follow-up, and the interaction between 
DNA methylation and sex, on internalizing symptom scores at follow-up. 
methylation  internalizing symptom scores at follow-up
 b sE P n
NR3C1_1  0.13 0.04 0.000
426
NR3C1_1 X sex - 0.05 0.05 0.331
NR3C1_1a  0.03 0.03 0.330
419
NR3C1_1 X sexa  0.03 0.05 0.477
NR3C1_2  0.00 0.02 0.869
834
NR3C1_2 X sex  0.00 0.03 0.895
NR3C1_2a - 0.01 0.01 0.519
813
NR3C1_2 X sexa  0.00 0.02 0.936
NR3C1_3 - 0.04 0.04 0.345
389
NR3C1_3 X sex - 0.02 0.06 0.753
NR3C1_3a  0.03 0.03 0.408
385
NR3C1_3 X sexa - 0.09 0.05 0.049
methylation  internalizing symptom scores at follow-up
 b sE P n
SLC6A4  0.02 0.01 0.021
856
SLC6A4 X sex - 0.02 0.01 0.133
SLC6A4a  0.02 0.01 0.017
841
SLC6A4 X sexa - 0.02 0.01 0.102
note: Results were derived from linear regression analyses; bold numbers indicate significant results. 
All models were adjusted for age. aAdditionally adjusted for internalizing symptom scores at baseline. 
NR3C1=Glucocorticoid receptor gene; SLC6A4=Serotonin transporter gene.
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table s2a. Associations between methylation rates of NR3C1_3 and internalizing symptom scores at fol-
low-up for boys and girls separately.
methylation
boys Girls
internalizing symptom 
scores at follow-up
internalizing symptom 
scores at follow-up
b sE P n b sE P n
NR3C1_3a -0.07 0.03 0.022 203 0.02 0.04 0.674 209
note: Results were derived from linear regression analyses; bold numbers indicate significant re-
sults. The model was adjusted for age. aAdditionally adjusted for internalizing problems at baseline. 
NR3C1=Glucocorticoid receptor gene.
Internalizing symptom scores at follow-up
1,201,00,80,60,40,20,00
N
R3
C1
_1
 m
ea
n-
ce
nt
er
ed
 m
et
hy
la
tio
n 
(%
)
1,50
1,00
,50
,00
-,50
-1,00
-1,50
Male
Female
Page 1
figure s3. Graphical representation of NR3C1_1 centered methylation and internalizing symptom scores 
at follow-up.
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AbstrACt
Early life adversity and psychopathology are thought to be linked through HPA-axis 
deregulation. Changes in methylation levels of stress reactivity genes such as the glu-
cocorticoid receptor gene (NR3C1) can be induced by adversity. Higher NR3C1 methyla-
tion levels have been associated with a reduced NR3C1 expression, possibly leading to 
impaired negative feedback regulation of the HPA-axis. In this study we tested whether 
methylation levels of NR3C1 were associated with HPA-axis regulation, operationalized 
as cortisol responses. In 361 adolescents (mean age 16.1, SD = 0.6), salivary cortisol 
samples were collected before, during, and after a social stress task, from which response 
measures (cortisol activation and recovery) were calculated. Higher NR3C1 methylation 
levels were associated with a flattened cortisol recovery slope, indicating a delayed 
recovery time. Cortisol response activation was not associated with NR3C1 methylation. 
These results suggest that methylation of NR3C1 may impair negative feedback of the 
HPA-axis in adolescents.
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NR3C1 and HPA-axis regulation
intrOduCtiOn
Early life adversity and later psychopathology have been commonly linked with impair-
ments in HPA-axis feedback regulation 1, 2. Studies in rats showed that variations in ma-
ternal care (i.e. pup licking and grooming [LG] and arched-back nursing [ABN] behavior) 
can alter offspring HPA-axis responses to stress through epigenetic modifications such as 
DNA methylation. High methylation levels in the glucocorticoid receptor gene (NR3C1) 
of offspring from mothers exhibiting low levels of LG and ABN behavior were associ-
ated with a decreased NR3C1 expression 3. Decreased NR3C1 expression could impair 
the feedback sensitivity of the HPA-axis and so result in higher levels of glucocorticoids 
(corticosterone in rats, cortisol in humans) in response to stress, a finding previously re-
ported in offspring from low LG/ABN mothers. In humans, early life adversity is known to 
be an important risk factor for the development of psychopathology. Early life adversity 
has been associated with epigenetic modification of NR3C1 (e.g., 4, 5), which may medi-
ate the association with later psychopathology by influencing the HPA-axis responses to 
stress. Only a few human studies explored the association between NR3C1 methylation 
and the cortisol response 6-8. These studies focused on a region of the NR3C1 CpG island 
homologous to the region investigated in the rat studies, the exon 1F promoter (17 in 
rats), but the results reported are inconclusive. Oberlander et al 7 reported an association 
between high methylation and increased salivary stress response in infants, whereas 
Tyrka et al 8 reported attenuated cortisol response to a dexamethasone/ corticotrophin-
releasing hormone test in adults with high NR3C1 methylation. Edelman et al 6 reported 
an association between NR3C1 methylation and cortisol area under the curve (AUC) 
following the Trier Social Stress Task (TSST), but only in adult women. We investigated 
the association between NR3C1 methylation and HPA-axis regulation, operationalized 
as the activation and recovery of the cortisol response following social stress, in a large 
sample of adolescents. Assuming comparable HPA-axis regulation mechanisms in rats 
and humans, we hypothesized that higher levels of methylation would be associated 
with an impaired feedback sensitivity, represented by a delayed recovery following 
social stress. As the activation of the HPA-axis is independent of glucocorticoid receptor 
availability, we further hypothesized that the cortisol response activation would not be 
related to the methylation level.
mAtEriALs And mEtHOds
sample and procedure
This study was part of the TRacking Adolescents’ Individual Lives Survey (TRAILS), a pro-
spective population study of Dutch adolescents with biennial or triennial assessment 
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waves from age 11 to at least age 25. A detailed description of sampling and methods 
can be found in Oldehinkel et al 9. For this study, data from the third assessment wave 
(T3, N=1816, mean age=16.3, SD=0.71) were used, which involved a blood draw and 
a series of laboratory tasks (for which 715 adolescents were selected to participate, 
see Figure S1 for a flow diagram of selection procedures), hereafter referred to as the 
experimental session. The experimental sessions took place on weekdays, lasted about 
3 hours and 15 minutes, and started between 08:00 and 09:30 a.m. (morning sessions, 
49%) or between 01:00 and 02:30 p.m. (afternoon sessions, 51%). Although cortisol 
levels may be higher in the morning due to the circadian rhythm of cortisol produc-
tion, morning and afternoon cortisol responses to social stress were comparable in our 
sample 10, analog to prior reports 11. The participants were asked to refrain from smoking 
and consuming coffee, milk, chocolate, and other sugar containing foods in the 2 hours 
before the experimental session. At the start of the session, the test assistant explained 
the procedure and administered a short checklist on current medication use (including 
oral contraceptives), and adherence to the smoking and food restrictions. One of the 
tasks of the experimental session was the Groningen Social Stress Test (GSST), a stan-
dardized protocol for the induction of moderate performance-related social stress. A 
detailed description of the GSST can be found in Bouma et al 10. In short, participants 
were given 7 minutes to prepare a 6-min speech about themselves and their lives, which 
they had to present in front of a video camera. They were told that their videotaped per-
formance would be judged on content of speech as well as on use of voice and posture, 
and rank-ordered by a panel of peers after the experiment. Participants had to speak 
continuously and the test assistant watched the performance critically, without showing 
empathy or encouragement. After 6 min of speech, a 3 minute interlude was introduced 
in which the participants were not allowed to speak. After this interlude, participants 
were instructed to perform mental arithmetic and subtract 17 repeatedly, starting with 
13,278, whilst receiving negative feedback from the test assistant. The mental arithmetic 
challenge lasted for 6 min, again followed by a 3-min period of silence. In total, this 
test lasted about 30 minutes, after which the participants were debriefed about the 
experiment. Readministration of (an adapted version of ) the social stress test after three 
years in a subsample (n=177) of TRAILS revealed test-retest correlations of cortisol levels 
during stress of about .40 (O.M. Laceulle, E. Nederhof, M.A.G. van Aken and J. Ormel, 
unpublished observations). Information about how the cortisol stress responses were 
related to other physiological responses and subjectively experienced stress can be 
found in Oldehinkel et al 12.
Sample selection for the methylation analyses was based on the availability of blood, 
participation in the experimental session, availability of cortisol samples, Dutch ethnic-
ity, and sufficient DNA concentration. We randomly excluded one of each sibling pair 
and removed DNA samples that were not suitable for analyses due to poor quality. From 
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the remaining sample (N=468), we excluded girls using oral contraceptives as they 
displayed no cortisol response during the GSST 10; adolescents who used SSRIs, systemic 
corticosteroids, or analgesic (pain-relieving) drugs on the day of the experiment or the 
day before, because these medications can influence responses to stress; and adoles-
cents who smoked before the experiments and thus failed to adhere with the protocol; 
and adolescent with laboratory detection failures in more than 2 of the 4 saliva samples. 
In total, data of 361 adolescents were used in the statistical analyses.
Cortisol responses
Details on cortisol assessment (expressed in nmol/l) and analyses are described in 
Bouma et al 10 and Janssens et al 13. In short, free cortisol concentrations were measured 
directly in duplicate in 100 ml saliva using an in-house radioimmunoassay (RIA) applying 
a polyclonal rabbit cortisol antibody and 1,2,6,7 3H Cortisol (Amersham International 
Ltd., Amersham, UK) as tracer. After incubation for 30 min at 60°C, the bound and free 
fractions were separated using activated charcoal. Responses to the GSST were assessed 
by four cortisol samples, referred to as C1, C2, C3, and C4. C1 was taken just before the 
start of the GSST. Cortisol levels in saliva reflect HPA-axis activity circa 20 minutes earlier, 
as there is a time window between the production of cortisol by the adrenal cortices 
and the presence of cortisol in saliva 14. Hence C1 reflects HPA-axis activity before the 
GSST, and is considered a pretest measure. C2 was collected directly after the end of 
the GSST and thus reflects HPA-axis responses during speech. C3, collected 20 minutes 
after the end of the GSST is considered a reflection of HPA-axis activity around the end 
of the GSST. C4 was collected 40 minutes after the end of the GSST and is considered a 
post-stress activity measure of the HPA-axis.
Cortisol response variables were computed from the response to the social stress 
task 15. Response activation was computed by regressing cortisol levels during the task 
(C2) on cortisol levels before the task (C1) and saving the standardized residuals. Positive 
scores represent relatively high HPA-axis activation compared to other participants. Re-
sponse recovery was computed by regressing cortisol levels measured 40 minutes after 
the task (C4) on cortisol levels during the task (C2) and saving the standardized residuals. 
A positive score represents a flat recovery slope compared to other participants.
NR3C1 methylation
DNA was extracted from whole-blood samples using a manual salting-out procedure as 
described by Miller et al 16. Three regions in the NR3C1 CpG island were analyzed, using a 
primer set previously used by McGowan et al 4 and two additional primer sets designed 
for this study (with EpiDesigner by Sequenom) to optimize coverage of the CpG island. 
DNA regions were numbered (NR3C1_1 to 3) according to their position in the CpG 
island (NR3C1_1 Chr5: 142782046-142782472, encompassing exon 1H; NR3C1_2 Chr5: 
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142783585-142783906, encompassing exon 1F; NR3C1_3 Chr5: 142784559-142784950, 
encompassing exon 1D; further details, a graphical representation on DNA regions and 
methylation assessment were published before 5). DNA methylation was analyzed us-
ing bisulfite treated DNA, PCR, reverse transcription, base-specific cleavage of in vitro 
transcribed RNA product, and mass spectrometry (Sequenom EpiTYPER, San Diego, CA, 
USA). Bisulfite conversion of DNA (500ng) was performed using EZ-96 DNA Methylation 
Kit (Shallow) (Zymo Research, Irvine, CA, USA). It must be noted that bisulfite conversion 
required for methylation analyses does not differentiate between the different types of 
cytosine methylation (i.e., 5-hydroxycytosine) or other derivatives, such as 5-formylcy-
tosine, and 5-carboxylcytosine. As such, our use of the term DNA methylation reflects 
multiple cytosine modifications, but to remain consistent with primary publications, 
we will adhere to the term DNA methylation. PCR, reverse transcription, cleavage and 
mass spectrometry was performed in triplicate, according to the EpiTYPER protocol. 
The generated mass signal patterns were translated to quantitative methylation lev-
els (expressed in percentages) by the MassARRAY EpiTYPER analyzer software (v1.0, 
build1.0.6.88 Sequenom, Inc, San Diego, USA).
statistical analyses
DNA methylation levels were mean-centered 5, and averaged over all CpG units within 
a DNA region. We used linear regression to study the associations between NR3C1 
methylation and HPA-axis responses to social stress. Statistical tests were performed in 
SPSS (v.21.0). We adjusted for multiple testing using the Bonferroni method; effects were 
regarded as significant if the p-value was smaller than .008. We included the covariates 
sex, age, daily smoking, and the start time of the experimental session in our analyses. 
Analyses without covariates are given in Supplementary Table S1.
rEsuLts
Of the 361 participants, 222 were male (61.5%), and the mean age was 16.1 years 
(SD=0.6). Whereas no association was found between methylation of NR3C1 and activa-
tion of the cortisol response in any of the three regions, methylation of NR3C1 in region 
2 was positively associated with cortisol response recovery (Table 1). Controlling for 
cortisol response activation in the analyses on cortisol response recovery resulted in 
highly similar outcomes (data not shown).
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disCussiOn
In this study on the relationship between NR3C1 methylation and cortisol responses 
during social stress in adolescents, a high NR3C1 methylation level in region 2 was as-
sociated with a flattened cortisol response recovery slope, indicating a longer recovery 
time. There was no association between NR3C1 methylation and cortisol response 
activation, nor between response recovery and methylation in the other NR3C1 regions.
Increased levels of glucocorticoids act at the glucocorticoid receptor sites in the 
extrahypothalamic centers, hypothalamus, and pituitary gland to inhibit activation of 
the HPA-axis after the stressor has subsided 17, 18. Our findings suggest that high NR3C1 
methylation is associated with a less functional HPA-axis feedback regulation mecha-
nism. As glucocorticoids are downstream effectors of the HPA-axis which mediate the 
negative feedback control of CRH and ACTH secretion 18, it is not surprising that there 
was no association between NR3C1 methylation and HPA-axis activation.
Comparing our findings with those of other studies is difficult due to differences in 
age range of the subjects included, differences in the experimental design and the way 
cortisol was assessed and used in statistical analyses. HPA-axis regulation methods re-
ported by others include the use of the AUC of cortisol from blood of a dexamethasone/
corticotropin-releasing hormone test 8, the AUC of salivary cortisol responses to the Trier 
Social Stress Test 6. These methodological differences could account for inconsistencies 
between reported findings 19, e.g. the attenuated response to the DEX/CRH test reported 
by Tyrka et al 8 and the increased AUC reported by Edelman et al 6.
The association between high methylation and impaired recovery of the cortisol 
stress response was only found in a specific region of the NR3C1 CpG island, the same 
in which high methylation levels were previously associated with childhood maltreat-
ment in suicide victims 4. This region encompasses the exon 1F NR3C1 promoter, the 
human homolog of the exon NR3C1 17 promoter in rats, which contains a nerve growth 
factor-inducible protein (NGFI-A) response element that is involved in regulating DNA 
table 1. Results of the linear regression analyses of NR3C1 methylation and HPA-axis regulation in the Gron-
ingen Social Stress Task.
n
 cortisol response activation cortisol response recovery
 b sE p b sE  p
NR3C1_1 339 - 0.01 0.13 .96 0.01 0.13  .96
NR3C1_2 337  0.00 0.10 .99 0.38 0.10 < .001
NR3C1_3 307  0.05 0.13 .72 0.02 0.11  .88
Methylation variables are mean-centered. Cortisol variables are standardized. Significant results (p<0.008 
after Bonferroni correction) are indicated with bold numbers. See Section 2 for details on the calculation 
of cortisol reactivity and cortisol recovery variables. Analyses are adjusted for sex, age, daily smoking, and 
start time of the experimental session.
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transcription 3. Reduced transcription of NR3C1, and thus reduced expression of gluco-
corticoid receptors, can alter HPA-axis responses through diminished negative feedback 
sensitivity. In an earlier study in the present population, we showed that exposure to 
stressful life events or traumatic youth events was positively associated NR3C1 methyla-
tion 5, and that methylation of NR3C1 was associated with an increased risk of a lifetime 
internalizing disorder and more internalizing problems 20. However, these associations 
involved another region, located at the 3’end of the CpG island (region 1 of NR3C1). We 
could speculate that the CpG sites that are vulnerable to stress exposure or linked with 
psychopathology are independent of the CpG sites involved in regulation of the HPA-
axis, which would deny the postulated mediating role of the HPA-axis. This is unlikely, 
however, since a flattened cortisol recovery at age 16 has recently been associated with 
a higher risk of psychopathology at 3-year follow-up in TRAILS 15. Replication of our find-
ings is required to determine robustness and gain insight into the mediating role of DNA 
methylation in the development of psychopathology.
Several limitations of the study must be acknowledged. Because of the cross-sectional 
nature of the study and the single assessment of DNA methylation and cortisol responses, 
we are unable to determine whether NR3C1 methylation is a cause or a possible conse-
quence of altered HPA-axis functioning. Another limitation is the use of blood as a proxy 
of the target tissue, the brains. This seems justified, however, because methylation levels 
of CpG islands in the brain and blood have been found to be highly correlated 21, and 
the association between childhood adversity and NR3C1 1F methylation that was initially 
described in postmortem human hippocampal tissue has repeatedly been replicated in 
studies using peripheral samples for review, see 22. Also, for our DNA analysis we used 
whole blood, containing a heterogeneous mixture of cell type. Since we were unable to 
account for the cellular heterogeneity of the blood cells, we could not rule out that the 
associations may be in part a reflection of differences in cellular composition.
To conclude, our findings support the notion that methylation of NR3C1 may be 
associated with an impaired negative feedback of the HPA-axis in adolescents. This 
could reflect a pathway through which exposure to stressful experience change stress 
responses and so contribute to a higher risk of developing psychopathology later in life.
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suPPLEmEntAry infOrmAtiOn
table s1. Results of the linear regression analyses of NR3C1 methylation and HPA-axis regulation in the 
Groningen Social Stress Task.
n
 cortisol response activation cortisol response recovery
 b sE p b sE  p
NR3C1_1 341 - 0.02 0.13 .88 0.05 0.13  .69
NR3C1_2 339 - 0.08 0.10 .40 0.45 0.10 < .001
NR3C1_3 308  0.05 0.14 .69 0.00 0.11  .99
Methylation variables are mean-centered. Cortisol variables are standardized. Significant results (p<0.008 
after Bonferroni correction) are indicated in boldface. See method section for details on the calculation of 
cortisol reactivity and cortisol recovery variables. Analyses are unadjusted for covariates. 
Participation T3 
 
N=1816 
 
  
 
 
 
Selection for experimental session 
 
N=744 
 
  
 
 
 
Participated in experimental session 
 
N=715 
 
  
 
 
 
Selection for methylation analyses 
 
N=475 
 
  
 
 
 
Data available for methylation analyses 
 
N=468 
 
  
 
 
 
Final sample after exclusion criteria for 
cortisol data 
 
N=361 
 
  
 
Adolescents with an increased risk of mental health 
problems had a greater chance of being selected for the 
experimental session. Increased risk was defined based on 
temperament (high frustration and fearfulness, low 
effortful control), parental psychopathology (depression, 
anxiety, addiction, psychoses, or antisocial behavior), and 
environmental risk (living in a single-parent family).a 
Twenty-nine did not agree to participate.a 
Exclusion based on: participation in the experimental 
session, availability of blood, availability of cortisol 
samples, Dutch ethnicity, and sufficient DNA 
concentration.a 
We randomly excluded one of each sibling pair and 
removed DNA samples that were not suitable for analyses 
due to poor quality.b 
figure s1. Flow diagram of selection procedures. a Described before in e.g. Bouma et al 1. b Described before 
in van der Knaap et al 2. See method section for details on exclusion criteria for cortisol data.
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AbstrACt
background: In recent years epigenetics has gained interest as a possible mechanism 
underlying obesity. Particular targets for investigation are genes involved in appetite 
and energy regulation, such as the serotonin transporter gene (SLC6A4) and the 
glucocorticoid receptor gene (NR3C1). Thus far, only the association between SLC6A4 
methylation and obesity measures has been investigated, and only in males. We aimed 
to replicate this study by investigating the association between SLC6A4 methylation and 
obesity measures in adolescent boys, and to extend the study by including girls and 
NR3C1 methylation.
subjects: In a population sample of 941 adolescents (age 14-18y), we investigated as-
sociations between SLC6A4 and NR3C1 methylation and obesity measures, i.e. weight, 
BMI, the sum of four skinfold thicknesses (S4SF), body fat percentage (%BF), waist 
circumference (WC), waist-hip-ratio and height. We assessed methylation levels from 
blood samples.
results: SLC6A4 methylation was positively associated with weight, BMI, S4SF, %BF and 
WC in boys. A 1% higher mean methylation was associated with a 2.27mm higher S4SF 
(p=0.006), a 0.54 higher %BF (p=0.002) and a 0.68cm higher WC (p=0.025). For girls, we 
did not find any associations between SLC6A4 methylation and obesity measures. NR3C1 
methylation was only positively associated with height in boys. A 1% higher mean meth-
ylation was associated with a 1.60cm higher body height (p=0.009) in boys. There were 
no associations between NR3C1 methylation and obesity measures in girls.
Conclusions: We replicated previous findings by reporting a positive association be-
tween SLC6A4 methylation and obesity measures in boys. SLC6A4 methylation may thus 
contribute to obesity risk in adolescent boys, but not in girls. NR3C1 methylation does 
not contribute to an obese phenotype in adolescence, but may be involved in body 
height in adolescent boys.
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intrOduCtiOn
Human obesity is a worldwide public health concern that has been associated with 
increased health risks such as cardiovascular disease, type II diabetes and various can-
cers. Although the risk of obesity is partly genetically determined, effect sizes are small 
and a large portion of the heritability remains unexplained 1. In recent years, epigenetic 
mechanisms have gained interest as a possible underlying mechanism that may con-
tribute to obesity risk. Epigenetic modifications can be influenced by environmental 
triggers and regulate gene expression without changing the underlying DNA sequence. 
One type of epigenetic modification is DNA methylation, which regulates gene expres-
sion by chemically modifying cytosine-phosphate-guanine (CpG) dinucleotides in the 
DNA, and thereby altering the access to DNA for transcription factors. DNA methylation 
in CpG islands (i.e. regions with an increased frequency of CpG sites often located in the 
gene promoter) is generally associated with decreased gene expression 2.
Obesity generally results from an energy imbalance, which occurs when energy intake 
exceeds energy expenditure. Therefore, potential epigenetic targets for investigation are 
genes involved in appetite regulation and maintaining energy balance. The serotonergic 
system plays an important role in both the maintenance of energy balance 3 and regu-
lating eating behavior 4. Animal studies have shown that hyperphagia or obesity can 
be induced by manipulating the serotonergic synthesis, e.g. by creating lesions in the 
raphe nuclei, by creating genetic knock-outs of the serotonin transporter gene (Slc6a4; 
Slc6a4-/- mice have an obese phenotype 5), or through pharmacological interventions 
(for review, see Donovan and Tecott 3).
Another candidate gene involved in the pathogenesis of obesity is the glucocorticoid 
receptor gene (NR3C1), an important regulator of the stress response. Glucocorticoid 
synthesis is stimulated in response to stress, and glucocorticoids (cortisol in humans) 
also play an important role in maintaining HPA-axis homeostasis by providing nega-
tive feedback. Glucocorticoids exert metabolic effects and play an important role in 
appetite regulation and the regulation of lipid homeostasis through their effects on 
other hormones involved in feeding regulation, such as insulin, leptin and ghrelin 6, 7. 
An excess of glucocorticoids has been associated with visceral fat accumulation 6. This 
is also observed in individuals with Cushing’s syndrome, who are exposed to extremely 
high levels of glucocorticoids, and develop rapid weight gain, as well as central obesity. 
Deregulated feedback of glucocorticoids in the HPA-axis can occur when NR3C1 expres-
sion is impaired 8, a consequence of higher methylation levels 9. This may also contribute 
to the risk of developing obesity. Genetic variations in the glucocorticoid receptor gene, 
and thus receptor functionality, have also been shown to be associated with obesity 
measures in men 10 and adolescent boys 11, but this association could not be replicated 
in an older cohort within the same study 11.
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Although the number of studies investigating the relationship between epigenetics 
and obesity is increasing 12, candidate gene studies on SLC6A4 and NR3C1 are largely 
lacking. In a recent publication, Zhao et al 13 reported that SLC6A4 promoter methyla-
tion was positively associated with obesity measures in a sample of adult male veteran 
monozygotic twins, with an overrepresentation of individuals suffering from major 
depression or post-traumatic stress disorder. To the best of our knowledge, the associa-
tion between NR3C1 methylation and obesity measures has not been reported before.
In the present study, we aimed to replicate the findings reported by Zhao et al 13 in a 
younger age group, by investigating the relationship between SLC6A4 methylation and 
obesity in adolescent boys. In addition, we wanted to extend their findings by including 
female adolescents and methylation of NR3C1. For SLC6A4, we hypothesized a positive 
association between methylation and measures of obesity in adolescent boys, similarly 
to the findings reported by Zhao et al 13. For girls, we expected to find an association in 
the same direction. Given that the glucocorticoid receptor is an important regulator of 
glucocorticoid levels and high methylation is likely to impair glucocorticoid receptor 
functioning, we hypothesized that high NR3C1 methylation levels would also be posi-
tively associated with obesity measures.
subJECts And mEtHOds
sample selection
This study was part of the TRacking Adolescents’ Individual Lives Survey (TRAILS), a 
prospective population study in which Dutch adolescents are followed from preado-
lescence into adulthood. Assessment waves are conducted biennially or triennially, and 
five assessment waves have been completed so far. Written consent was obtained from 
each subject and their parents at every assessment wave. The present study involves 
data collected during the third assessment wave (T3, 2005-2007, N=1816, mean age 
16.3, SD 0.71). The study was approved by the Dutch Central Medical Ethics Committee 
and subjects received compensation for their participation. A detailed description of 
sampling and methods can be found in Ormel et al 14 and Oldehinkel et al 15.
The T3 assessment involved a blood draw, from which DNA was successfully extracted 
in 1156 T3 participants. Selection for methylation analyses was based on the availability 
of blood, Dutch ethnicity, and sufficient DNA concentration. We randomly excluded one 
of each sibling pair and removed DNA samples that were not suitable for analyses. To-
gether, this resulted in a total of 945 individuals (48.3% males) suitable for methylation 
analyses.
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dnA methylation analyses
DNA selection and methylation analyses. DNA was extracted from whole-blood samples 
using a manual salting-out procedure as described by Miller et al 16. We used primer sets 
previously used by McGowan et al 17 for NR3C1 (Chr5: 142783585-142783906) and Phi-
libert et al 18 (set B) for SLC6A4 (Chr17: 28562358-28562783), which encompass regions 
of the CpG island (i.e., a region with a higher frequency of CpG sites than expected) 
in the promoter regions of both genes. Forward primers contained a 10 mer sequence 
tag (aggaagagag), and reverse primers are equipped with a T7-promoter tag (cagta-
atacgactcactataggg) and an 8 base pair insert (agaaggct). DNA methylation levels were 
analyzed using the EpiTYPER method from Sequenom. Bisulfite conversion was followed 
by PCR amplification, reverse transcription and base-specific cleavage. Fragments were 
analyzed on a mass spectrometer (Sequenom EpiTYPER, San Diego, CA, USA). Bisulfite 
conversion of DNA was performed using EZ-96 DNA Methylation Kit (Shallow) (Zymo 
Research, CA, USA), according to manufacturers’ protocol. PCR, reverse transcription, 
cleavage and mass spectrometry were performed in triplicate, according to EpiTYPER 
protocol. The mass signal patterns generated were translated to quantitative methyla-
tion levels for different CpG units by the MassARRAY EpiTYPER analyzer software from 
Sequenom (v1.0, build1.0.6.88 Sequenom, Inc, San Diego, USA). Fragments with CpG 
dinucleotides are referred to as CpG units. One CpG unit can contain one or more CpG 
dinucleotides. CpG units with a mass outside the range of the mass spectrometer or 
overlap in mass of another CpG unit could not be analyzed.
Data cleaning procedures. All samples were analysed in triplicate, and methylation 
levels of the triplicates were averaged for each CpG unit 19. Samples with a standard 
deviation of ≥10% between replicates and CpG units with >25% missing values were 
removed (SLC6A4: CpGU17). We accounted for mass-change in CpG units by SNPs (only 
when minor allele frequency >5%) by removing CpG units containing SNPs (SLC6A4: 
CpGU18) equal in mass to non CpG units or other CpG units containing SNPs (none 
in our sample). In total, 10 CpG units remained eligible for NR3C1 and 11 for SLC6A4. 
Overall, we obtained methylation levels of NR3C1_2 for 904 individuals and of SLC6A4 
for 939 individuals, with a combined total of 941 individuals with methylation data of at 
least one gene.
Obesity measures
We measured weight, height, hip and waist circumference and skinfolds using regularly 
calibrated equipment after removing shoes and heavy clothing. Weight was measured 
in kilograms using a calibrated analogue Seca balance scale (Model 770; SECA Corp., 
Hamburg, Germany). Height was measured in centimeters using a Seca stadiometer 
(model 214; SECA Corp.). BMI (kg/m2) was calculated by dividing the weight by the 
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squared height in meters (cut-off points for BMI are based on 20). We obtained triceps, 
biceps, subscapular, and suprailiac skinfold thicknesses in millimeters with a Harpenden 
skinfold caliper (CMS Instruments, London, United Kingdom); and calculated the sum 
of the four thicknesses (S4SF). Waist circumference (WC) in centimeters was measured 
at the midpoint between the lower costal margin and the iliac crest. All measurements 
were performed in duplicate, and a third measurement was added if the difference 
between these measurements exceeded a predefined value (i.e., >2mm for height, 
>0.5kg for weight, >0.5cm for WC, >2mm for all skinfold measurements). All available 
measurements were used to calculate means. Percentage body fat (%BF) was calculated 
on the basis of a hand-to-foot bioelectrical impedance analysis (type BIA 101; Akern, 
Pontassieve, Italy), using the Deurenberg equation 21.
Other measures
We asked how many days per week the adolescents participated in at least 60 minutes 
of moderate or vigorous physical activity, from which “sufficient physical activity” was 
determined as at least 5 days per week 22, in accordance with international recom-
mendations 23. Smoking and alcohol use were assessed with a self-report questionnaire. 
Adolescents who had not smoked in the past 4 weeks were categorized as non-smokers, 
adolescents who had smoked less than one cigarette a day as non-daily smokers, and 
those who had smoked one or more cigarettes per day as daily smokers. Adolescents 
who reported that they did not drink alcohol in the past 4 weeks were categorized as 
abstainers. Adolescents who reported drinking were categorized into two groups: those 
who had drunk alcohol up to 9 times were defined as low-frequent users and those who 
had drunk alcohol 10 times or more as high-frequent users. Depressive problems were 
assessed dimensionally using the mean item score of the DSM-IV Affective Problems 
scale from the Youth Self-Report (YSR: 13 items, α=.78; 24). All items referred to the past 
six months.
statistical analyses
The associations between methylation levels and obesity measures were analyzed in 
SPSS (v21) with generalized linear models. Methylation level was specified as predic-
tor and the different obesity measures were specified as outcome variables in separate 
models for each gene and outcome variable. Each model contained age, smoking and 
alcohol use as covariates, identical to the covariates used by Zhao et al 13. For girls, we 
also added the use of oral contraceptives (OC) as a covariate in the models, as OC use can 
affect DNA methylation and influence obesity associated parameters 25. In a secondary 
analysis, we further included depressive symptoms and physical activity as additional 
covariates in the above mentioned statistical models. These covariates were also used by 
Zhao et al 13 in a sensitivity analyses to examine whether the high prevalence of depres-
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sion and post-traumatic stress disorder in their sample confounded their results, and to 
examine the potential influence of physical activity on their results. They also included 
diet (daily energy intake in Kcal per day) in their sensitivity analyses, but this information 
was not available in the current study.
Given that Zhao’s study 13 provided clear expectations regarding the direction of the 
association between SLC6A4 methylation and obesity measures, we performed one-
sided tests. Although the association between NR3C1 methylation and obesity measures 
has not been described thus far, circumstantial evidence 8, 9 strongly suggested a posi-
tive association between methylation levels in this gene and obesity measures, hence 
these test were performed one-sidedly as well. Effects were regarded as significant if the 
p-value was smaller than 0.05. We chose not to adjust for multiple testing, because the 
obesity measures are not independent.
table 1. Descriptive statistics.
Boys Girls
mean ± sd or % n mean ± sd or % n
Age (years) 16.2 ± 0.6 454 16.2 ± 0.7 487
Oral contraceptive use (% of girls) 31.4 433
Body weight (kg) 68.3 ± 12.3 445 62.0 ± 9.2 472
Body height (cm) 180.3 ± 7.4 445 169.1 ± 6.4 475
Body mass index (BMI; kg/m2) 21.0 ± 3.3 445 21.7 ± 3.0 472
Sum of four skinfolds (S4SF; mm) 40.0 ± 21.8 445 61.8 ± 20.9 472
Body fat percentage (%BF) 25.0 ± 4.6 444 31.3 ± 4.3 465
Waist circumference (WC; cm) 75.7 ± 8.7 445 75.4 ± 8.0 474
Waist to hip ratio (WHR) 0.8 ± 0.1 445 0.8 ± 0.1 473
Smoking 363 389
non-smokers 71.6 260 64.5 251
non-daily smokers 7.2 26 6.7 26
daily smokers 21.2 77 28.8 112
Alcohol use 435 466
abstainers 22.3 97 18.9 88
low-frequent users 61.4 267 71.5 333
high-frequent users 16.3 71 9.7 45
Sufficient physical activity 33.7 436 26.5 475
Depressive problems 0.2 ± 0.2 441 0.4 ± 0.3 478
note: Details on the definitions of smoking categories, alcohol use categories, physical activity and depres-
sive symptoms are given in the method section. 
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rEsuLts
Demographic and clinical characteristics of our sample are presented in Table 1. 
Eighty-four percent of our sample (N=454) was male. Correlations between the differ-
ent obesity measures in boys and girls are presented in Table 2. All obesity measures 
were highly correlated in both boys and girls (p<.001), except for height, which showed 
no correlation with BMI, S4SF and %BF in boys and with S4SF in girls. The associations 
between SLC6A4 and obesity measures in boys and girls are presented in Table 3. SLC6A4 
methylation was positively associated with weight, BMI, S4SF, %BF and WC in boys. 
table 2. Correlations between obesity measures in boys and girls. 
Boys Height (cm) bmi (kg/m2) s4sf(mm) bf (%) WC (cm) WHr
Weight (kg) ρ .49*** .89*** .74*** .69*** .87*** .20***
n 445 445 445 444 445 445
Height (cm) ρ 0.04 0.04 0.00 .23*** -.12*
n 445 445 444 445 445
bmi (kg/m2) ρ .82*** .80*** .87*** .29***
n 445 444 445 445
s4sf (mm) ρ .78*** .81*** .32***
n 444 445 445
bf (%) ρ .76*** .28***
n 444 444
WC (cm) ρ .54***
n 445
Girls Height (cm) bmi (kg/m2) s4sf (mm) bf (%) WC (cm) WHr
Weight (kg) ρ .38*** .86*** .73*** .65*** .83*** .13**
n 472 472 469 465 471 471
Height (cm) ρ -.13** -.03 -.16*** .18*** -.10*
n 472 472 465 474 473
bmi (kg/m2) ρ .81*** .78*** .81*** .19***
n 469 465 471 471
s4sf (mm) ρ .73*** .74*** .23***
n 464 472 471
bf (%) ρ .64*** .11*
n 465 465
WC (cm) ρ .47***
n 473
note: Numbers shown are Spearman correlation coefficients. BMI= body mass index; S4SF= sum of four 
skinfold thicknesses; BF= body fat; WC= waist circumference; WHR= waist-hip-ratio. *p<.05, **p<.01, 
***p<.001. 
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An absolute 1% higher mean methylation was associated with a 2.27mm higher sum 
of four skinfold thicknesses, a 0.54 higher body fat percentage and a 0.68cm higher 
waist circumference in boys. Adjustment for physical activity and depressive problems 
resulted in highly similar regression coefficients, but the associations between SLC6A4 
methylation and BMI and weight were no longer significant (B=0.75, p=0.063 for weight, 
B=0.20, p=0.068 for BMI, from Supplementary Table S1). For girls, we did not find any 
associations between SLC6A4 methylation and obesity measures.
The associations between NR3C1 methylation and obesity measures are presented 
in Table 4. In boys, NR3C1 methylation was only positively associated with height. An 
absolute 1% higher mean methylation was associated with a 1.60cm higher body height 
table 3. Associations between SLC6A4 methylation and obesity measures in boys and girls.
 Obesity measures
 b  95% LCb p* n
Weight
boys  0.81  0.02 0.046 350
Girls - 0.05 - 0.69 0.553 339
BMI
boys  0.22  0.001 0.049 350
Girls - 0.08 - 0.29 0.723 339
S4SF
boys  2.27  0.80 0.006a 350
Girls  0.08 - 1.38 0.465 337
%BF
boys  0.54  0.23 0.002a 349
Girls - 0.04 - 0.35 0.579 334
WC
boys  0.68  0.11 0.025a 350
Girls - 0.28 - 0.85 0.794 339
WHR
boys  0.00 - 0.004 0.469 350
Girls  0.00 - 0.01 0.182 338
Height
boys  0.13 - 0.37 0.334 350
Girls  0.21 - 0.22 0.210 340
note: BMI= body mass index; S4SF= sum of four skinfold thicknesses; %BF= body fat percentage; WC= 
waist circumference; WHR= waist-hip-ratio. LCB= lower confidence bound. Methylation values are mean-
centered. All models adjusted for age, smoking and alcohol use. For girls, models are additionally adjusted 
for OC use. *p-value of the one-sided test. Values in bold script indicate that p<.05. aP-values that remained 
significant after additional adjustment for physical activity and depressive symptoms. 
Chapter 6
118
in boys. Additional adjustment for physical activity and depressive problems resulted in 
highly similar regression coefficients and p-values (Supplementary Table S2). There were 
no associations between NR3C1 methylation and obesity measures in girls.
As a post-hoc analysis, we explored the associations between methylation in indi-
vidual CpG units of SLC6A4 and obesity measures in boys, similarly to Zhao et al 13. The 
results of these analyses are largely in line with the main results and can be found in 
Supplementary Table S3. Methylation levels in CpG units 1, 3, 15, 16 and 22 were associ-
ated with one or more obesity measures.
table 4. Associations between NR3C1 methylation and obesity measures in boys and girls.
 Obesity measures
 b  95% LCb p* n
Weight
boys  0.08 - 1.75 0.472 342
Girls - 0.33 - 1.59 0.670 326
BMI
boys - 0.37 - 0.87 0.895 342
Girls - 0.08 - 0.50 0.623 326
S4SF
boys - 0.63 - 4.06 0.620 342
Girls - 0.76 - 3.62 0.669 324
%BF
boys - 0.08 - 0.78 0.577 341
Girls  0.38 - 0.22 0.149 321
WC
boys - 0.59 - 1.89 0.775 342
Girls - 0.33 - 1.45 0.686 326
WHR
boys - 0.01 - 0.02 0.831 342
Girls - 0.01 - 0.02 0.968 325
Height
boys  1.60  0.50 0.009a 342
Girls - 0.19 - 1.05 0.645 327
note: BMI= body mass index; S4SF= sum of four skinfold thicknesses; %BF= body fat percentage; WC= 
waist circumference; WHR= waist-hip-ratio. LCB= lower confidence bound. Methylation values are mean-
centered. All models adjusted for age, smoking and alcohol use. For girls, models are additionally adjusted 
for OC use. *p-value of the one-sided test. Values in bold script indicate that p<.05. aP-values that remained 
significant after additional adjustment for physical activity and depressive symptoms. 
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disCussiOn
SLC6A4 promoter methylation was significantly associated with obesity measures in 
adolescent boys, in line with the study by Zhao et al 13. These associations were not 
found in adolescent girls. Additionally, NR3C1 methylation was only significantly associ-
ated with height in boys, and there were no associations with any obesity measures in 
girls. In Zhao et al 13, associations between SLC6A4 methylation and obesity measures 
were attenuated after adjustment for the additional covariates physical activity, diet and 
depressive symptoms, but remained statistically significant. In the current study, addi-
tional adjustment for physical activity and depressive symptoms also attenuated the 
results, but resulted in two non-significant associations with weight and BMI. However, 
these associations were already marginally significant prior to the additional adjustment 
and the regression coefficients remained highly comparable to the original results, indi-
cating that additional adjustment for physical activity and depressive symptoms did not 
confound our results.
Despite sample and design differences, our findings are remarkably comparable to 
those reported by Zhao et al 13. They reported an association between SLC6A4 meth-
ylation and weight, BMI and WC, we found associations between SLC6A4 methylation 
and S4SF, %BF and WC. Zhao et al 13 reported that “on average a 1% increase in mean 
methylation was associated with a 0.78cm increase in WC” in their sample, compared 
to an increase of 0.68cm in WC in adolescent boys in our study. This suggests that the 
association between SLC6A4 methylation and obesity measures in males is quite robust, 
and can already be seen in adolescents.
The associations between SLC6A4 methylation and weight and BMI were not very 
strong in our sample. Without accounting for differences in height, weight is not 
necessarily an indicator of overweight or obesity. Also, although BMI is widely used to 
determine overweight or obesity, it does not differentiate between fat or muscle weight. 
The body fat percentage in adolescents with a normal BMI may exceed normal ranges 26, 
and individuals with a normal weight and normal BMI might actually be metabolically 
overweight or obese 27, and run the risk of obesity-related diseases 28. The prevalence of 
obese and overweight individuals in our sample was relatively low (12.9% overweight; 
2.6% obese), and the percentage of body fat and other estimations of body fat per-
centage such as the skinfold measurements may therefore more accurately represent 
overweight or obesity in adolescents and better predict health risks.
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For NR3C1, methylation levels in the promoter region were only associated with height 
in adolescent boys. Glucocorticoids are known to be involved in linear growth, but an 
excess of glucocorticoids is generally considered to be associated with growth impair-
ment 28. Our finding warrants replication and further study. The lack of associations with 
other obesity measures was unexpected. The relationship between glucocorticoids 
and obesity is complex, but evidence of this association has been reported extensively 
(e.g. 6, 29). As we did not obtain gene expression data in the current study, we could 
not examine the effect of methylation on receptor functionality directly. In a previous 
study we found that higher methylation levels in the promotor region of NR3C1 were 
associated with an impaired glucocorticoid response recovery following stress 30, so 
methylation does seem to affect HPA-axis functioning, but the effect may have been 
too weak to influence the likelihood of developing an overweight or obese phenotype.
Contrary to expectations, there were no associations between methylation levels and 
obesity measures in girls. Possibly, the lack of associations in girls can be attributed to 
sex hormones, in particular estrogens. Estrogens are known to be involved in appetite 
regulation and energy expenditure and considered protective against obesity 31. To 
prevent natural cyclic fluctuations in estrogen levels we adjusted for the use of oral 
contraceptives, but this did not change the outcomes. Perhaps the higher basal level of 
estrogens affects the association between DNA methylation and obesity in girls. More 
research is needed to investigate this possible link.
Several limitations have to be acknowledged. Firstly, because of the cross-sectional 
nature of the study and the single assessment of DNA methylation, we cannot make 
statements on causality. Secondly, we cannot account for the cellular heterogeneity of 
the blood cells, and thus cannot rule out that the associations may be in part a reflection 
of differences in cellular composition. Thirdly, there was no direct overlap between the 
region studied by Zhao et al 13 (Chr17: 28562784-28562928) and the region investigated 
in the current study (Chr17: 28562358-28562783). Nonetheless, our results provide extra 
coverage of the SLC6A4 CpG island and strengthens the association between SLC6A4 
methylation and obesity.
In conclusion, this replication study provides further support for involvement of 
epigenetic modifications in obesity in males. Deeper understanding of the involvement 
of SLC6A4 in obesity may help target interventions for obesity and possibly even associ-
ated health risks. Epigenetics seems to be a promising field for investigating obesity, and 
a logical next step would be investigation of causality and gender differences to develop 
strategies to target the obesity epidemic.
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suPPLEmEntAry infOrmAtiOn
table s1. Associations between SLC6A4 methylation and obesity measures in boys and girls, adjusted for 
additional covariates.
 Obesity measures
 b  95% LCb P* n
Weight
boys  0.75 - 0.05 0.063 345
Girls - 0.07 - 0.71 0.568 338
BMI
boys  0.20 - 0.02 0.068 345
Girls - 0.08 - 0.30 0.731 338
S4SF
boys  2.26  0.77 0.006 345
Girls  0.02 - 1.44 0.492 336
%BF
boys  0.53  0.23 0.002 344
Girls - 0.04 - 0.35 0.585 333
WC
boys  0.63  0.06 0.036 345
Girls - 0.32 - 0.89 0.822 338
WHR
boys  0.00 - 0.005 0.487 345
Girls  0.00 - 0.01 0.170 337
Height
boys  0.12 - 0.38 0.347 345
Girls  0.20 - 0.23 0.220 339
note: BMI= body mass index; S4SF= sum of four skinfold thicknesses; %BF= body fat percentage; WC= 
waist circumference; WHR= waist-hip-ratio. LCB= lower confidence bound. Methylation values are mean-
centered. All models adjusted for age, smoking, alcohol use, physical activity and depressive symptoms. 
For girls, we additionally adjusted for OC use. *p-value of the one-sided test. Values in bold script indicate 
that p<.05. 
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table s2. Associations between NR3C1 methylation and obesity measures in boys and girls, adjusted for 
additional covariates.
 Obesity measures
 b  95% LCb P* n
Weight
boys  0.10 - 1.70 0.463 338
Girls - 0.42 - 1.68 0.709 325
BMI
boys - 0.38 - 0.88 0.900 338
Girls - 0.08 - 0.51 0.627 325
S4SF
boys - 0.64 - 4.07 0.621 338
Girls - 0.88 - 3.77 0.693 323
%BF
boys - 0.12 - 0.81 0.613 337
Girls  0.40 - 0.21 0.141 320
WC
boys - 0.62 - 1.91 0.784 338
Girls - 0.47 - 1.60 0.755 325
WHR
boys - 0.01 - 0.02 0.841 338
Girls - 0.01 - 0.02 0.964 324
Height
boys  1.68  0.59 0.006 338
Girls - 0.30 - 1.16 0.716 326
note: BMI= body mass index; S4SF= sum of four skinfold thicknesses; %BF= body fat percentage; WC= 
waist circumference; WHR= waist-hip-ratio. LCB= lower confidence bound. Methylation values are mean-
centered. All models adjusted for age, smoking, alcohol use, physical activity and depressive symptoms. 
For girls, we additionally adjusted for OC use. *p-value of the one-sided test. Values in bold script indicate 
that p<.05. 
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AbstrACt
Substance use often starts in adolescence and poses a major problem for society and 
individual health. The dopamine system plays a role in substance use, and catechol-
O-methyltransferase (COMT) is an important enzyme that degrades dopamine. The 
Val108/158Met polymorphism modulates COMT activity and thus dopamine levels, and 
has been linked to substance use. COMT gene methylation, on the other hand, may 
affect expression and thus indirectly COMT activity. We investigated whether methyla-
tion of the COMT gene was associated with adolescents’ substance use. Furthermore, 
we explored whether the COMT Val108/158Met polymorphism interacts with COMT 
gene methylation in association with substance use. In 463 adolescents (mean age=16, 
50.8% girls), substance use (cigarette smoking, alcohol and cannabis use) was assessed 
with self-report questionnaires. From blood samples, COMT Val108/158Met genotype and 
methylation rates of membrane bound (MB) and soluble (S) COMT promoters were as-
sessed. MB-COMT promoter methylation was associated with non-daily smoking [odds 
ratio (OR)=1.82, P =0.03], but not with daily smoking (OR=1.20, P =0.34), MB-COMT 
promoter methylation was not associated with alcohol use. Adolescents with the Met/
Met genotype and high rates of MB-COMT promoter methylation were less likely to be 
high-frequent cannabis users than adolescents with the Val/Val or Val/Met genotype. 
S-COMT promoter methylation was not associated with substance use. These results in-
dicate that there is an association between substance use and COMT gene methylation. 
Although this association is complex, combining genetic and epigenetic variation of the 
COMT gene may be helpful in further elucidating the influence of the dopamine system 
on substance use in adolescence.
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intrOduCtiOn
Substance use (i.e. alcohol, cigarettes or cannabis) often starts in adolescence. Prolonged 
use can lead to poor health, and detrimental social and economic outcomes 1. The do-
paminergic reward system plays an important role in substance use and addiction 2. 
Frequent substance use is associated with altered dopamine levels in the brain reward 
system 3. Catechol-O-methyltransferase (COMT) degrades dopamine, and variations in 
COMT expression and activity could modify reward system functioning, thereby influ-
encing vulnerability to substance use.
The COMT gene (chr:22, q11.21 4) encodes two different protein isoforms, each with 
its own promoter 5: the membrane-bound isoform (MB-COMT, 271 amino acids), and the 
soluble isoform (S-COMT, 221 amino acids). The functional Val108/158Met single nucleotide 
polymorphism (SNP) in the COMT gene, rs4680, has been associated with altered COMT 
activity 6. The Val/Val genotype results in a three to fourfold increase in COMT activity 
and was more prevalent in substance users 7-11, albeit not consistently 12. These findings 
indicate a higher COMT activity, hence faster dopamine degradation, in substance users, 
which arguably is associated with a drive for constant activation of the reward system.
While COMT genotypes influence COMT activity, epigenetic modifications (e.g. DNA 
methylation) of the COMT gene may affect gene expression. Indeed, increased COMT 
gene methylation was associated with decreased gene expression 13, 14, but very little 
is known about the association between COMT gene methylation and substance use. 
In the only general population study we know of, nicotine dependence was related to 
higher MB-COMT promoter methylation, suggesting lower COMT gene activity and thus 
less dopamine degradation in smokers 15. In schizophrenia patients, alcohol use was 
associated with increased MB-COMT promoter methylation 13. While studies on genetic 
variation suggest COMT hyperactivity in substance users, these first epigenetic results 
indicate lower COMT gene activity in substance users. No studies have yet investigated 
the relationship between cannabis use and COMT gene methylation.
In this study we investigated the association between substance use (i.e., cigarettes, 
alcohol and cannabis) and COMT gene methylation in the MB-COMT promoter (previ-
ously studied by Xu et al 15), as well as the S-COMT promoter (not studied previously). We 
used DNA from a large general population sample of adolescents (14-18 years). Given 
the lack of studies so far, we carefully hypothesized that COMT gene methylation will 
not only be associated with tobacco and alcohol use, but also with cannabis use. Given 
the seemingly contradictory findings on COMT genotype and COMT gene methylation 
(increased activity vs lower expression of COMT in substance users), an interplay be-
tween the two may be present, with indirect oppositional effects on dopamine levels. 
Therefore, we explored whether the association between COMT gene methylation and 
substance use depended on the COMT Val108/158Met polymorphism.
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mAtEriAL And mEtHOds
subjects
This study was part of the TRacking Adolescents’ Individual Lives Survey (TRAILS), a 
prospective population study in which Dutch preadolescents (N=2230) are followed into 
adulthood. Assessment waves, involving interviews, biological measures and validated 
questionnaires, are conducted biennially or triennially, and five assessment waves have 
been completed so far. The present study involves data collected during the third as-
sessment wave, which took place from September 2005 to December 2007 (N=1816, 
mean age 16.3 years, SD=0.71). Written consent was obtained from each subject and 
their parents at every assessment wave. The study was approved by the Dutch Central 
Medical Ethics Committee (CCMO) and all subjects received compensation for their par-
ticipation. A detailed description of sampling and methods can be found in Huisman et 
al 16 and Ormel et al 17. In short, the assessment at T3 included an extensive experimental 
session, in which 715 adolescents participated (focus sample, response rate 96.1%). 
Adolescents with a higher risk of mental health problems had a greater chance of be-
ing selected for the experimental session. Risk was defined based on T1 measures of 
temperament (high frustration and fearfulness, low effortful control), lifetime parental 
psychopathology, and living in a single-parent family. In total 66.0% of the focus sample 
had at least one of the above described risk factors; the remaining 34.0% were selected 
randomly from the ‘low-risk’ TRAILS participants. Although ‘high-risk’ adolescents were 
slightly oversampled, the sample included the total range of mental health problems 
present in a community population of adolescents. T3 also involved a blood draw. Selec-
tion for methylation analyses (N=475) was based on the participation in the extensive 
experimental session, availability of a blood sample with sufficient DNA concentration, 
Dutch ethnicity, and we randomly excluded one of each sibling pair. This selection of 475 
adolescents did not differ significantly (p>.05) from the TRAILS focus sample (N=715) 
with regard to sex, socioeconomic status and age. Following drop-out after methylation 
analyses (for further explanation see section on methylation analyses), we obtained MB-
COMT promoter methylation rates for 458 subjects, and S-COMT promoter methylation 
rates for 463 subjects.
substance use
Substance use was assessed with a self-report questionnaire at T3, which was filled 
out at school or at the subjects’ home. Confidentiality of the study was important and 
adolescents were reassured that their parents or teachers would not have access to 
the information they provided. Smoking was assessed with the question: “How many 
cigarettes did you smoke in the past 4 weeks?”. Adolescents who had not smoked in 
the past 4 weeks were categorized as non-smokers. Adolescents who had smoked less 
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than one cigarette a day in the past 4 weeks were categorized as non-daily smokers and 
those who had smoked one or more cigarettes per day as daily smokers 18. Cannabis 
use was assessed with the question: “How many times have you used weed (marijuana) 
or hash in the past 4 weeks?”. Adolescents who had not used cannabis in the past 4 
weeks were categorized as non-users. Adolescents who had used up to four times were 
categorized as low-frequent users and those who used more than four times as high-
frequent users 19. Alcohol use was assessed with the question: “How many times have 
you had alcohol in the past 4 weeks? By this, we mean the number of occasions, like 
going to a party, going out, or an evening at home”. Adolescents who reported that they 
had not drunk alcohol in the past 4 weeks were categorized as abstainers. Adolescents 
who reported drinking were categorized into two groups: those who had drunk alcohol 
up to 9 times were defined as low-frequent users and those who had drunk alcohol 10 
times or more were defined as high-frequent users 19.
dnA methylation
Analysis. DNA was extracted from whole-blood samples using a manual salting-out 
procedure 20. Primer sets described previously 15, 21 were used to analyze regions of the 
CpG islands (regions containing high frequencies of CpG sites) in the S-COMT (S2, Chr 22: 
19949993-19950393 21) and MB-COMT (Chr 22: 19928950-19929359 15) promoters (Figure 
1).
DNA methylation rates were analyzed using the EpiTYPER method from Sequenom. 
Bisulfite conversion was followed by PCR amplification, reverse transcription and 
base-specific cleavage. Fragments were analyzed on a mass spectrometer (Sequenom 
EpiTYPER, San Diego, CA, USA). Bisulfite conversion of DNA was performed using EZ-96 
3 1 2 5 6 4 
rs 4680 
COMT gene 
MB-COMT S-COMT 
1 2 3 4 5 6 
figure 1. Schematic representation of the COMT gene (location: 22q11.21). Black numbered boxes repre-
sent exons 1-6 and the approximate position of the COMT Val108/158Met polymorphism (rs4680, GuanineàAd-
enine, substituting the amino acid Valine (Val) for Methionine (Met) at position 108/158 in the amino acid 
chain for S-COMT and MB-COMT respectively) in exon 4 is shown. Grey boxes represent the CpG islands in 
the MB-COMT and S-COMT promoters in exon 1 and 3 respectively. The DNA fragments of MB-COMT and S-
COMT promoters used for methylation analyses are shown in relative position to the CpG islands. Adapted 
from Zhao et al 21.
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DNA Methylation Kit (Shallow; Zymo Research, CA, USA), according to manufacturers’ 
protocol. PCR, reverse transcription, cleavage and mass spectrometry were performed 
in triplicate, according to EpiTYPER protocol. The mass signal patterns generated were 
translated to quantitative methylation rates for different CpG-units by the MassARRAY 
EpiTYPER analyzer software from Sequenom. (v1.0, build1.0.6.88 Sequenom, Inc, San 
Diego, USA). Fragments with CpG dinucleotides are referred to as CpG units. One CpG 
unit can contain one or more CpG dinucleotides. CpG units with a mass outside the 
range of the mass spectrometer, or with overlap in mass of another CpG unit, could not 
be analyzed (MB-COMT: 7 CpG units, S-COMT: 6 CpG units).
Data cleaning procedures. All samples were analyzed in triplicate and for each CpG 
unit, methylation rates of the triplicates were averaged 22. Samples with a standard 
deviation of ≥10% between replicates were removed for analysis. CpG units with ≥25% 
missing values were not included in the analyses (two CpG units, CpGU2 and CpGU3, in 
the S-COMT promoter and one CpG unit, CpGU16, in the MB-COMT promoter). We ac-
counted for mass-change in CpG units by SNPs (only when minor allele frequency >5%) 
by removing CpG units containing SNPs from analyses (1 CpG unit (S-COMT promoter, 
CpGU7)), and by removing units with the same mass as non-CpG units containing SNPs 
or other CpG units containing SNPs (none in our sample)). In total, eleven CpG units were 
available for the MB-COMT promoter region and five CpG units were available for the 
S-COMT promoter region.
Genotyping
The COMT Val108/158Met SNP (rs4680) genotyping was performed on the Illumina Bead-
Station 500 platform (Illumina Inc., San Diego, CA) using Golden Gate assay and array 
technology (for details, see 23, 24). Data on the Val108/158Met genotype (Val/Val, Val/Met or 
Met/Met) was available for 1411 of the TRAILS subjects, of whom 452 had complete data 
on both genotype and methylation rates (Table 1). The lower number available for meth-
ylation analyses resulted from a pre-selection of subjects (see above). The genotyping 
call rate for rs4680 was 100%. A X2 -test confirmed that rs4680 was in Hardy-Weinberg 
equilibrium (P=0.92).
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statistical analyses
Descriptives were computed and ANOVA was performed to compare S-COMT/MB-COMT 
promoter methylation rates between different genotypes. We used multinomial logistic 
regression to study the association between COMT genotype and substance use, using 
the Met/Met genotype (with the lowest enzyme activity) as the reference category. To 
avoid loss of power when comparing different substance use categories, we did not limit 
our sample to individuals with methylation data, but we used the genotype data of the 
1411 TRAILS subjects.
As missing methylation values (1-6% MB-COMT promoter, 2-22% S-COMT promoter) 
in higher methylated units affect the average methylation rate, we mean-centered our 
methylation data for each CpG unit (resulting in a mean methylation of 0, with original 
standard deviation (SD)) thereby maintaining the individual variation in CpG-units. We 
then averaged mean-centered methylation over the CpG units within the MB-COMT and 
S-COMT promoter regions. This procedure was used previously in van der Knaap et al 22.
To test whether substance use was associated with methylation rates of the MB-COMT 
or S-COMT promoter regions, we used multinomial logistic regression analyses. The 
group of non-substance users was used as reference group in all analyses. In addition, 
we tested whether the interaction between the COMT Val108/158Met genotype and meth-
table 1: Descriptives
n (%) mean (sd)
Age 463 (100%) 16.1 (0.6)
Girls 235 (50.8%)
Smoking (n=458)
None 332 (72.5%)
not daily  34 (7.4%)
Daily  92 (20.1%)
Cannabis use (n=452)
None 391 (86.5%)
Low-frequent  34 (7.5%)
High-frequent  27 (6.0%)
Alcohol use (n=449)
None  89 (19.8%)
Low-frequent 303 (67.5%)
High-frequent  57 (12.3%)
Val/Met polymorphism (n=452)
Met/Met 141 (31.2%)
Val/Met 222 (49.1%)
Val/Val  89 (19.7%)
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ylation was significantly associated with substance use. If this was the case, analyses 
were stratified by COMT genotype.
As Xu et al demonstrated CpG-site specific associations of the MB-COMT promoter with 
nicotine dependence (for overlap with CpG units in the current study, see Table S1/Fig-
ure S1), we tested whether methylation rates differed between substance use categories 
for individual CpG units using multinomial logistic regression, with non-substance users 
as reference category. For these exploratory analyses, we adjusted for multiple testing 
using the Bonferroni method. The new p-value regarded as significant was 0.0045.
We adjusted all our analyses for age and sex, as age and sex are both related to DNA 
methylation 25 and substance use 26. The sample size varied over analyses depending on 
the number of missing data (see Table 1).
rEsuLts
descriptives
Alcohol use was the most commonly reported type of substance use in our study popu-
lation. Smoking was also frequently reported (Table 1). The ranges of methylation of the 
different CpG units are shown in Table S2. S-COMT promoter methylation was higher in 
adolescents with the Met/Met genotype (F2,449=4.178, P<0.05, Figure 2).
Val/Val adolescents were less likely to be low-frequent cannabis users [odds ratio 
(OR)=0.57, confidence interval (CI)=0.32; 1.01, P=0.06) or high-frequent cannabis users 
(OR=0.45, CI=0.21; 0.96, P=0.04) than non-users, compared to adolescents with the Met/
Met genotype. The Val/Met genotype did not have significantly different odds of canna-
bis use compared to the Val/Val genotype. There was no significant association between 
COMT genotype and smoking or alcohol use.
substance use and COMT gene methylation
As shown in Table 2, MB-COMT promoter methylation was associated with non-daily 
smoking, but not with daily smoking. MB-COMT or S-COMT promoter methylation were 
not associated with cannabis use or alcohol use (Table 2). Due to differences in S-COMT 
promoter methylation according to COMT genotype (described above, Figure 2) we 
added genotype as a covariate in the analyses with S-COMT promoter methylation. This 
did not change the relationships between S-COMT promoter methylation and substance 
use.
In the individual CpG unit analyses (Figure 3), we found that MB-COMT promoter 
methylation in CpG unit 3 (OR=1.17, 95% CI= 1.05;1.30, P=0.004) and CpG unit 9 
(OR=1.64, 95% CI= 1.06; 2.52, P=0.03) were associated with non-daily smoking, although 
only the effect for MB-COMT-promoter CpGU3 remained significant after correction for 
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multiple testing. There were no associations between methylation rates of single CpG 
units and cannabis use. For alcohol use we found that MB-COMT promoter methylation 
was associated with low frequent alcohol use in CpGU5 (OR=0.76, 95% CI= 0.58; 0.995, 
P=0.046) and in CpGU19 (OR=0.79, 95% CI=0.64; 0.98, P=0.03). These associations were 
not significant after correction for multiple testing. No effects were found for S-COMT 
promoter methylation.
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figure 2. Centered methylation rates of the S-COMT and MB-COMT promoter for each genotype (A=Met, 
G=Val, bars: p25-p75). *p<0.05, **p<0.01
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moderation by COmt genotype
When included in our model, the interaction term ‘COMT genotype x MB-COMT promoter 
methylation’ was associated with cannabis use (Table 3). Therefore, we stratified the 
analyses for methylation and cannabis use by COMT Val108/158Met genotype. In adoles-
cents with the Met/Met genotype, methylation rates were associated with lower odds of 
high frequent cannabis use (OR=0.25, 95% CI=0.08; 0.82, P=0.02). The interaction term 
‘COMT genotype x MB-COMT promoter methylation’ was not associated with smoking or 
alcohol use and we also did not find any significant association between the interaction 
term ‘COMT genotype x S-COMT promoter methylation’ and substance use.
A
B
C
MB-COMT S-COMT
0%
2%
4%
6%
8%
10%
12%
M
et
hy
la
tio
n 
No alcohol use Low-frequent alcohol use High-frequent alcohol use
70%
75%
80%
85%
90%
95%
100%
0%
2%
4%
6%
8%
10%
12%
M
et
hy
la
tio
n 
No smoking Non-daily smoking Daily smoking
70%
75%
80%
85%
90%
95%
100%
0%
2%
4%
6%
8%
10%
12%
M
et
hy
la
tio
n 
No cannabis use Low-frequent cannabis use high-frequent cannabis use
70%
75%
80%
85%
90%
95%
100%
* 
figure 3. Methylation rates of individual CpG Units, divided into substance use categories. Separate graphs 
were used for the MB-COMT promoter (left) and S-COMT promoter (right). Mean methylation rates are pre-
sented for smoking categories (A), alcohol use categories (b), and for cannabis use categories (C). Error bars 
represent SEs. *p<0.0045
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disCussiOn
This is the first study in which the association between COMT gene methylation and 
adolescents’ substance use is analyzed. We found higher methylation rates in non-daily 
smokers compared to non-smokers and daily smokers. Also, in adolescents homozygous 
for the Met allele, methylation was associated with lower odds for cannabis use.
Higher rates of MB-COMT promoter methylation were associated with non-daily 
smoking in adolescents. It is difficult to explain why no association with daily smoking 
was found. We could speculate that specific, currently unknown, regulation mechanisms 
table 3: Influence of Val108/158Met genotype on association between MB-COMT promoter methylation and 
substance use. 
Or 95% Ci p Or 95% Ci p
Smoking non daily daily
Val/Met genotype 0.61 0.34; 1.08 0.09 0.92 0.65; 1.29 0.62
MB-COMT promoter methylation 1.10 0.10; 12.49 0.94 1.69 0.32; 8.97 0.54
Val/Met*MB-COMT promoter methylation 1.16 0.49; 2.73 0.74 0.86 0.49; 1.51 0.61
Cannabis Low frequent High frequent
Val/Met genotype 0.45 0.26; 0.79 0.01 0.60 0.33; 1.10 0.10
MB-COMT promoter methylation 1.33 0.12; 15.07 0.82 0.07 0.01; 0.75 0.03
Val/Met*MB-COMT promoter methylation 0.83 0.34; 2.06 0.69 2.42 1.03; 5.66 0.04
Alcohol Low frequent High frequent
Val/Met genotype 0.97 0.69; 1.37 0.87 1.00 0.62; 1.62 1.00
MB-COMT promoter methylation 1.11 0.21; 5.77 0.90 3.08 0.62; 35.51 0.34
Val/Met*MB-COMT promoter methylation 0.95 0.55; 1.64 0.84 0.66 0.30; 1.43 0.29
Abbreviations: OR, odds ratio; CI, confidence interval. Reference categories: No smoking, no cannabis use 
and no alcohol use. Adjusted for sex and age.
table 2. Associations between methylation of the COMT gene and substance use
Or 95% Ci p Or 95% Ci p
Smoking non daily daily
MB-COMT promoter methylation 1.82 1.07; 3.09 0.03 1.20 0.83; 1.73 0.34
S-COMT promoter methylation 1.04 0.83; 1.30 0.76 1.09 0.94; 1.27 0.27
Cannabis Low frequent High frequent
MB-COMT promoter methylation 0.82 0.47; 1.42 0.48 0.70 0.38; 1.31 0.27
S-COMT promoter methylation 0.96 0.77; 1.19 0.68 1.06 0.82; 1.36 0.67
Alcohol Low frequent High frequent
MB-COMT promoter methylation 0.91 0.63; 1.33 0.63 1.00 0.59; 1.67 0.99
S-COMT promoter methylation 0.99 0.85; 1.15 0.85 0.90 0.73; 1.10 0.30
Abbreviations: OR, odds ratio; CI, confidence interval. Reference categories: No smoking, no cannabis use 
and no alcohol use. Adjusted for sex and age.
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are at work linking methylation of the MB-COMT promoter with non-daily smoking, 
which represents a more controlled form of smoking in adolescents. In the study by 15, 
no association between daily smoking and overall MB-COMT promoter methylation was 
found. However, differences in methylation between their daily smokers and controls 
became apparent when testing individual CpG sites: methylation rates were higher in 
daily smokers compared to non-smokers at CpG sites -193 and -39, which correspond 
with CpGU3 and CpGU12 in the current study (Table S1/Figure S1). Interestingly, in the 
unit specific analyses for smoking, we also found a higher methylation of CpGU3, but 
specific for non-daily smoking. We did not find differences in methylation of CpGU12 
between the smoking groups. It is possible that during adolescence the relationship 
between methylation and smoking status is different from that later in life. The rate 
of methylation in the MB-COMT promoter in our study was relatively low compared 
to the methylation rates reported by 15, possibly due to chronic heavy smoking. Or, as 
DNA methylation rates increase with age 25, particularly in CpG islands 27, differences 
in methylation rates may reflect differences in age between the samples (~16-year-old 
adolescents vs. ~45-year-old adults). Our findings and those from Xu et al show that 
COMT gene methylation is associated with smoking status, but also raise many ques-
tions concerning the exact relationship. Since these are the first studies in this area this 
should not be surprising and obviously further research is necessary to gain insight 
into smoking habits and COMT gene methylation. Longitudinal studies with repeated 
measures of both methylation and smoking habits will be necessary to further increase 
our understanding of how both interrelate.
Although other studies have found relationships between methylation of genes in 
the dopamine system and alcohol dependence, e.g., higher rates of methylation in the 
dopamine transporter gene 28 and methylation of monoamine oxidase-A 29, we did 
not find a relationship between mean MB-COMT or S-COMT promoter methylation and 
alcohol use in adolescents. Neither did we find associations between methylation and 
alcohol use in our unit-specific analyses. We are not aware of any other study relating 
methylation of the COMT gene to alcohol use in adolescents.
In this study, the Val/Val variant was associated with lower odds of high frequent can-
nabis use in adolescents. A recent meta-analysis of the association between the COMT 
Val108/158Met polymorphism and substance use identified the Val-allele as risk factor for 
smoking and for cannabis use 12, but the populations studied were highly heteroge-
neous. Adolescence is a phase in which novelty-seeking, impulsivity and peer behavior 
may play a major role in the initiation of substance use 30-32. In line with this theory are 
findings from studies that have linked the Met/Met variant to increased novelty-seeking, 
which could drive cannabis use in adolescents 33-35. Another study associated the Val/Val 
variant with novelty-seeking 36. The relationship might be dependent on genetic varia-
141
Ch
ap
te
r 7
COMT methylation and substance use
tions in other genes in addition to the COMT polymorphism 37 and might be moderated 
by personality, stress or other environmental factors.
We found that adolescents with the Met/Met genotype and higher methylation rates 
had a lower risk for cannabis use. Hence, there seems to be an interaction between the 
COMT Val108/158Met polymorphism and MB-COMT promoter methylation rates in relation 
to cannabis use. This is a novel finding which is in line with the anhedonia hypothesis of 
substance use 38.The combination of the low enzyme activity (Met/Met genotype) and 
reduced expression of the enzyme (higher methylation rates) might result in higher lev-
els of dopamine through diminished dopamine degradation. It is known that low brain 
dopamine levels result in an under-active reward system, accompanied by anhedonia. 
Substance use could be explained as an attempt to alleviate this unfavorable anhedonic 
state 39, 40. Arguably, individuals with a combination of the low enzyme activity Met/
Met genotype have high dopamine levels - and do not have an anhedonic state - which 
might be preventive for substance use.
A strength of this study is the measurement of both genetic and epigenetic varia-
tions of the COMT gene, which provides a more complete picture of the role of COMT in 
substance use. In addition, we analyzed several types of substance use that are highly 
prevalent in adolescence and assessed recent use to minimize recall bias, thereby gain-
ing reliable measures for substance use. Some limitations of our study have to be noted 
as well. The cross-sectional nature of this study prevented us from investigating whether 
methylation is a consequence of substance use, or whether methylation predisposes an 
individual to drug seeking behavior; a question with no definitive answer in the litera-
ture thus far 41. To this end, repeated measurements of methylation status are needed. 
This paper includes a multiplicity of comparisons, which increases the risk of obtaining 
chance findings. This is especially relevant for the analyses of the single CpG unit data. To 
minimize this risk we applied a Bonferroni correction. However, for the analyses including 
methylation data, genotypes and substance use we did not correct for multiple testing. 
Therefore, we were cautious with interpreting our findings and would like to emphasize 
that replication is warranted. It should be noted that we studied adolescents who have 
had a relatively short exposure to substance use. Associations may be stronger in adults 
who have developed a substance addiction earlier in life or have a more intense and 
longer history of use. Adolescents in this study may still be experimenting with drugs, 
and this may be motivated by different brain mechanisms than drug addiction. We were 
interested in methylation of the COMT gene in the brain, but as this is impossible to 
determine in a cohort study of adolescents, we used DNA from blood cells to determine 
methylation rates. This is probably a valid approach as identical methylation patterns for 
the COMT gene in blood and the brain were reported previously 42, which indicates that 
COMT gene methylation in blood may be used as a proxy for COMT gene methylation in 
the brain.
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To conclude, we showed that methylation of the MB-COMT promoter was associated 
with non-daily smoking in adolescents. This study further suggests that epigenetics, 
in combination with the COMT Val108/158Met polymorphism, could be associated with 
cannabis use during adolescence. Maybe through altering COMT activity and gene 
expression, and thereby influencing the dopamine metabolism in the brain. However, 
this finding warrants replication in other populations, including adults and individuals 
who are addicted to substances. The findings of the study may also provide a first step 
in the prevention of substance use disorders. Epigenetic modifications may prove to be 
useful biomarkers to identify susceptibility or vulnerability for substance use, and, in 
time, our findings may even contribute to the development or improvement of effective 
behavioral or pharmacological interventions for substance use disorders. In order to 
obtain more insight into the mechanisms involved in substance use and abuse it may be 
helpful to include both genetic and epigenetic factors.
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suPPLEmEntAry infOrmAtiOn
For the MB-COMT genomic region, we used a primer set that was previously reported 
by Xu et al., 2010. While Xu et al present the exact positions of CpG sites relative to the 
transcription start site, in the current study we present CpG units that contained one or 
multiple CpG sites. The overlap between the CpG sites as presented by Xu et al and the 
CpG units in the current study is shown in Table S1.
table s1. Overlap between CpG units in the current study and CpG sites reported by Xu et al., 2010.
CpG units presented in our study CpG site positions relative
 to the transcription start site as presented by Xu et al.
MB-COMT CpGU2 -211
MB-COMT CpGu3 -195a -193b
MB-COMT CpGU5 -161 -158 -156a -154a
MB-COMT CpGU7 -131a -127a -125 -123a
MB-COMT CpGU8 -112a -110
MB-COMT CpGU9 -104a -99a
MB-COMT CpGU11 -55 -51
MB-COMT CpGU12 -46a -39b -35a
MB-COMT CpGU14 -23
MB-COMT CpGU15 -8a
MB-COMT CpGU19 +19a +22a
Note: most units contain more than one CpG. a No information on methylation in Xu et al., 2010. b Difference 
found between smokers and non smokers in Xu et al., 2010. Units printed in bold represent units that were 
significantly related to substance use (non-daily smoking) in the current analyses.
table s2. CpG Unit descriptive statistics: methylation rates of the individual CpG units. 
n minimum maximum mean std. deviation
MB-COMT CpGU2 458 0%  3% 0.1% 0.4%
MB-COMT CpGU3 445 1% 19% 8.9% 3.4%
MB-COMT CpGU5 457 0%  6% 0.8% 0.8%
MB-COMT CpGU7 456 2% 10% 5.2% 1.5%
MB-COMT CpGU8 436 2% 14% 5.4% 1.4%
MB-COMT CpGU9 458 0%  6% 1.9% 0.8%
MB-COMT CpGU11 458 0%  9% 3.3% 1.7%
MB-COMT CpGU12 456 0%  6% 2.1% 0.9%
MB-COMT CpGU14 456 0%  8% 0.9% 1.0%
MB-COMT CpGU15 458 0%  8% 1.0% 0.9%
MB-COMT CpGU19 455 2%  9% 4.4% 1.1%
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table s2. CpG Unit descriptive statistics: methylation rates of the individual CpG units.  (continued)
n minimum maximum mean std. deviation
S-COMT CpGU8 362 70% 100% 93.1% 4.3%
S-COMT CpGU11 447 87% 100% 97.5% 2.0%
S-COMT CpGU12 366 65%  98% 86.8% 4.8%
S-COMT CpGU13 456 88% 100% 95.7% 2.2%
S-COMT CpGU14 437 89% 100% 97.8% 1.8%
MB-COMT 
5’-
tggg|at|acc|agctctggg|ag|acc|ac|aggtgc|agtc|agc|ac|agc|agg|acctt|ag|ac|a|aggc|accc|agcccc|agtttcccc|acctggg|a|agggggct|ac
ttgtggct|ag|a|agc|AGCC­243CGG1|actcctg|agc|a|ag|act|ag|acc|a|ag|AGGC­211CGGT2|atgtgg|ac|ACCCC­195CG­193CGTGGGC3|accccc|
A­179CGGGG4|ac|accctggcc|AC­161CGC­158CG­156CG­154CGG5|ac|accctc|A­142CG6|agg|ac|ACCC­131CGGC­127CG­125CG­123CGG7|ac|acct|
AC­112CG­110CGGGG8|A­104CGCCC­99CG9|acccc|atcct|ACCTGCTG­79CGCCC­74CG­72CGC­69CG­67CGCCC­62CGC10|ACCC­55CGCC­51CGC
C11|A­46CGGCCTG­39CGTC­35CGCC12|AC­29CGG13|a|AG­23CGCCCTCCT14|a|ATCCC­8CGC15|AG­3CGCC16|AC+4CGCC17|ATTGCCGCC18|A
TCGTCGTGGGGCTTCTGGGGC19|agct|agggctgcc -3’ 
 
S-COMT 
5’-
gtgggtgctgc|agg|agg|agc|ac|ag|agc|ACTGGCGCCCCTCCCCTCCCGCCCTGC1|ag|ATGCCGG2|AGGCCCCGCCTCTGCTGTTGGC3|ag
ctgtgttgctgggcctggtgctgctggtggtgctgctgctgcttctg|aggc|actggggctggggcctgtgcctt|ATCGGCTGG4|a|ACG5|agttc|atcctgc|agccc
|atcc|ac|a|acctgctc|atgggtg|ac|acc|a|agg|agc|AGCGC6|atcctg|a|acc|ACGTGCTGC7|agc|ATGCGG8|AGCCCGGG9|a|ACGC10|ac|ag|A
GCGTGCTGG11|aggcc|attg|ac|acct|ACTGCG12|agc|ag|a|agg|agtgggcc|atg|a|ACGTGGGCG13|ac|a|ag|a|a|AGGTGGGGTCCGGGCC1
4|agc|aggtgctc|agctctggg|ac|aggg|accc|agg|acc|aggc|a -3’ 
 
figure s1. The sequence and position of individual CpG sites and CpG units is shown for both MB-COMT 
(upper panel) and S-COMT (lower panel) DNA fragments. The vertical lines represent the position of splice 
sites on the complementary RNA strand (not shown), and any fragment containing one or more CpG sites 
(bold letters) is considered a CpG unit and are represented by uppercase letters and numbered at the right 
end side. For MB-COMT, the individual CpG sites are labeled by their relative position in relation to the tran-
scription start site (+1, the underlined C in CpG unit 16) according to Xu et al., (2010) 1. Methylation rates for 
grey CpG units could not be obtained or used for analyses (see method section for further details).
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 1. Xu Q, Ma JZ, Payne TJ, Li MD. Determination of Methylated CpG Sites in the Promoter Region of 
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GEnErAL disCussiOn 
In this thesis I investigated whether DNA methylation serves as an underlying biological 
mechanism that could predispose individuals with a history of adversity to poor health 
outcomes. Animal studies reported that an adverse early life environment was associ-
ated with high levels of methylation in the glucocorticoid receptor gene (NR3C1), and 
consequently elevated stress responses and more fearful behavior. At the time I started 
this research, first studies in humans had partly replicated these findings, and extended 
them to other genes of interest, such as the serotonin transporter (SLC6A4). However, 
sample sizes were small and larger studies with a wider range of exposures and out-
comes were necessary.
AdvErsE LifE EvEnts And dnA mEtHyLAtiOn
In Chapter 2 and 3 I investigated the relation between the type and timing of adverse 
life events and NR3C1 and SLC6A4 methylation. Firstly, the effect of type of adversity on 
methylation was studied, and a distinction was made between perinatal stress, stressful 
life events (SLEs), and traumatic youth experiences (TYEs). Secondly, the effect of timing 
of SLEs on methylation was studied by analyzing the independent associations between 
SLEs at different developmental periods (i.e., childhood and adolescence) and NR3C1 
and SLC6A4 methylation.
For both genes there was no association between perinatal stress and DNA methyla-
tion in adolescence. This was somewhat surprising, as the lack of an association between 
NR3C1 or SLC6A4 methylation and perinatal stress reported in our studies contrasts 
with initial reports in animal studies. Several human studies have reported associations 
between perinatal stress and altered NR3C1 or SLC6A4 methylation in cord-blood 1-3, but 
the long-term effects of perinatal stress, however, had not been investigated. The results 
reported in Chapter 2 and 3 of this thesis thus suggest that perinatal stress may not 
have long-term effects on NR3C1 and SLC6A4 methylation. Although DNA methylation 
is considered to be stable, the recent discovery of active removal of methyl groups4, 5 in-
dicates that DNA methylation is reversible and regulation might be more dynamic than 
was originally thought. This theory is in line with another result of our study; only SLEs 
experienced in adolescence were associated with NR3C1 or SLC6A4 methylation, and 
there were no associations between childhood SLEs and methylation in these genes. 
As our methylation data originated from blood collected in adolescence, methylation 
marks from perinatal stress or childhood SLEs may have been gradually lost over time. 
For the TYEs there was no data available on the age of the participants at the time of 
abuse. Because of this, we could not determine whether the association between TYEs 
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and methylation was due to recent traumatic experiences. It is possible that the effects of 
repeated exposure to TYEs on DNA methylation differs from the experience of multiple 
different SLEs on methylation, resulting in more stable methylation following repeated 
TYEs. However, this is highly speculative and more research is necessary combined with 
repeated measures of methylation to determine causality.
Exposure to TYEs was only associated with methylation of NR3C1, whereas associa-
tions between TYEs and methylation have been reported before for both NR3C1 6-8 and 
SLC6A4 9-11. The lack of association between TYEs and SLC6A4 methylation was therefore 
unexpected. Although we had a relatively large sample size, the number of individuals 
who had experienced TYEs was limited. Perhaps we did not have enough power in our 
sample to detect differences in SLC6A4 methylation. On the other hand, small sample 
sizes in other similar studies may also have a reduced likelihood of reflecting a true ef-
fect 12. Also, some of these studies made use of a clinical sample, which could also be 
related to high methylation levels (e.g. high SLC6A4 methylation has been associated 
with more severe psychopathology 11). Another possibility is that methylation by TYEs 
may be gene-specific, as we did find a positive association between TYEs and NR3C1 
methylation with a smaller sample size.
Another interesting finding in Chapter 2 concerns the regional differences of NR3C1 
methylation. Exposure to multiple SLEs between birth and adolescence was positively 
associated with methylation in region 1 of the NR3C1 CpG island (see page 22 for more 
information regarding NR3C1 regions 1-3). Regions 1 and 3 were designed to optimize 
coverage of the CpG island study and had not been investigated before in relation to 
adverse life events. Methylation in region 2, on the other hand, had been investigated 
in relation to early life adversity in animal and human studies (e.g., 6, 13). Region 2 was 
known to contain a transcription factor binding site that, when methylated, was known 
to inhibit the expression of this gene. Yet, most of the associations between stress and 
NR3C1 methylation in our study were found in region 1. Since methylation in other 
regions of the CpG island is known to be highly variable between individuals 14, it is 
unlikely that the environmental influences on methylation are restricted to region 2. 
Indeed, childhood abuse has been related to methylation in other regions of the CpG 
island than regions 1, 2 or 3 in human post-mortem brain tissue 15. A logical next step 
would be to investigate the presence of important transcription binding sites in region 
1, to see how methylation in this region affects expression, and investigate biological 
pathways associated with changes in methylation.
For SLC6A4, I additionally investigated whether different 5HTTLPR genotypes, are 
equally sensitive to be methylated after exposure to SLEs. The polymorphism 5HTTLPR 
was thought to moderate the relation between SLEs and risk for depression 16. The short 
(s)-allele was generally considered to be the susceptibility allele 17, with increased risk of 
depression in a high stress environment, and the long (l)-allele was considered to have 
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a protective function, but attempts at replication have resulted in mixed findings 18, 19. 
One way to improve our understanding of gene-environment interactions could be to 
incorporate methylation patterns into these interactions. In Chapter 3 we have seen 
that 5HTTLPR genotype influenced the relationship between SLEs and SLC6A4 methyla-
tion; only in carriers of two l-alleles methylation levels were higher when more SLEs were 
experienced. A highly methylated l-allele is considered to have a poor transcriptional 
activity, and methylation might nullify the protective function of the l-allele, which 
could contribute to the mixed findings mentioned earlier. This theory is supported by a 
study that showed more unresolved loss or trauma in highly methylated l-allele carriers 
and low methylated s-allele homozygotes, and less unresolved loss or trauma in high 
methylated s-allele homozygotes 20. This suggests that epigenetic regulation may serve 
as an adaptive mechanism to adjust gene expression and compensate for changes in 
gene expression caused by genetic variation 20, 21.
dnA mEtHyLAtiOn And (mEntAL) HEALtH PrObLEms
internalizing problems
The relationship between NR3C1 or SLC6A4 methylation and internalizing problems 
(i.e., anxiety and depression problems) had only scarcely been investigated. Therefore, 
I studied whether NR3C1 and SLC6A4 methylation were associated with concurrent 
and future internalizing problems, i.e., clinical diagnoses of internalizing disorders and 
internalizing symptom scores.
Higher NR3C1 methylation was associated with concurrent and prospective (3 years 
later) internalizing symptom scores, and lifetime internalizing disorders. Our findings 
also indicated that high NR3C1 methylation is associated with an increased vulnerability 
to develop new internalizing problems over time. High SLC6A4 methylation only showed 
a tendency for association with internalizing symptom scores. By investigating the re-
lationship between methylation in these genes and anxiety and depression problems 
separately, I explored whether these associations were driven by one of these pheno-
types. For depression, the relationship between NR3C1 and SLC6A4 methylation has been 
investigated, albeit scarcely, but the relationship between NR3C1 or SLC6A4 methylation 
and anxiety problems has not been studied before. However, this relationship seems 
plausible because associations between SLEs and anxiety disorders have been reported 
in the literature 22, 23. Also, for some anxiety disorders an association with hyperactivity 
of the HPA axis has been reported 24, which suggests that NR3C1 methylation may be 
related to anxiety. For SLC6A4, the effectiveness of selective serotonin reuptake inhibi-
tors (SSRIs) in the treatment of anxiety disorders makes this gene a plausible candidate 
for the involvement in anxiety disorders.
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NR3C1 methylation appeared to have a generic role in internalizing problems, as high 
methylation was associated with both more anxiety and depression problems. The 
role of SLC6A4 methylation was more complex and somewhat less consistent across 
phenotypes; there was no significant main effect of high methylation and internalizing 
problems, but post hoc analyses indicated that there were significant associations 
with lifetime anxiety disorders, and concurrent and prospective depressive symptom 
scores. Before we can draw a firm conclusion from this study, replication is needed, and 
extension of the current findings to more specific phenotypic internalizing problems is 
warranted. Nonetheless, our findings may provide a first step towards understanding 
the physiological processes that underlie the different internalizing problems.
HPA-axis regulation
HPA-axis activity is regulated by glucocorticoids, cortisol in humans, through binding to 
glucocorticoid receptors, and mediating the negative feedback control of CRH and ACTH 
secretion. Studies on the relation between NR3C1 methylation and HPA-axis responses 
to stress are scarce 1, 8, 25. As high NR3C1 methylation is considered to reduce NR3C1 gene 
expression, the consequences of high methylation may specifically target the feedback 
inhibition or recovery of the HPA-axis, as HPA-axis activation is independent of gluco-
corticoid receptor availability. Therefore, I investigated the associations between NR3C1 
methylation and activation and recovery of the cortisol response following social stress.
High NR3C1 methylation was associated with a delayed recovery following social 
stress. Cortisol response activation was not associated with NR3C1 methylation. As 
DNA methylation generally reduces gene expression, a delayed recovery likely fol-
lows a reduced availability of glucocorticoid receptors and has no effect on HPA-axis 
activation. The positive association between NR3C1 methylation and cortisol response 
recovery was only found in region 2 of the NR3C1 CpG island, in which high methylation 
levels were previously associated with childhood maltreatment in suicide victims 6 and 
reduced NR3C1 expression 26. However, in our research on adverse life events and NR3C1 
methylation, and NR3C1 methylation and internalizing problems, we found associations 
in region 1 of NR3C1. These findings suggest that regulation of the HPA-axis via meth-
ylation is independent of methylation associated with stress exposure or internalizing 
problems and may be related to regional differences in methylation. A first step towards 
expanding these findings would be to perform a replication study, to ensure that these 
results are not chance findings. In case of replication, it would be interesting to inves-
tigate whether these associations are indeed CpG-site specific, and whether regional 
differences in methylation have distinct effects on gene expression or gene splicing, 
which could lead to alternate biological pathways and health outcomes.
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Obesity
The genes NR3C1 and SLC6A4 are not only involved in the development of mental health 
problems; they are also involved in the pathogenesis of obesity. Thus far, there has been 
only one report on the association between SLC6A4 methylation and obesity measures 
(i.e. weight, BMI, WC, waist-hip ratio, and height), and research on NR3C1 methyla-
tion and obesity is lacking. The study on SLC6A4 methylation and obesity was limited 
to adult male veterans with a high prevalence of post-traumatic stress disorder and 
depression 27, which made generalization to the general population difficult. Therefore, 
I wanted to study whether these findings can be replicated in a population sample of 
adolescent boys, and extend the study by including adolescent girls, NR3C1 methylation 
and additional measures of obesity, i.e., body fat percentage and skinfold thickness.
In line with the first publication on SLC6A4 methylation and obesity measures by Zhao 
et al 27 , we also found associations between SLC6A4 methylation and obesity measures. 
However, the type of obesity measures associated with high methylation differed some-
what between the first publication and our study. Zhao et al 27 reported associations 
with weight, BMI, and WC, whereas in our study we only found an association with WC 
and with body fat percentage, and the sum of skinfold thicknesses. No associations 
were found between weight or BMI and methylation, but weight, without factoring in 
height, is a poor indicator of overweight or obesity. Similarly, BMI does not differentiate 
between fat or muscle weight and a normal BMI may not always be indicative of good 
health. Some adolescents with a normal BMI have an elevated body fat percentage 28, 
and might actually be metabolically overweight or obese 29, which increases the risk 
of obesity-related diseases 30. The prevalence of obese and overweight individuals in 
our sample based on BMI was relatively low (12.9% overweight; 2.6% obese), and the 
percentage of body fat and other estimates of body fat percentage, such as the skinfold 
measurements, may therefore be more accurately representations of overweight or 
obesity in adolescents and better predict health risks.
For NR3C1, high methylation levels were only associated with height in boys. Whereas 
glucocorticoids are known to be involved in linear growth, an excess of glucocorticoids 
is generally considered to be associated with growth impairment 30 and our finding thus 
warrants further study. The lack of associations with other obesity measures was un-
expected. Although the relationship between glucocorticoids and obesity is complex, 
there are many reports on the existence of this association (e.g. 31, 32). In our previous 
section we have shown that higher methylation in region 2 of NR3C1 was associated 
with a delayed glucocorticoid response recovery following stress, but this effect on HPA-
axis functioning may have been too weak to influence the likelihood of developing an 
overweight or obese phenotype, or may not have affected basal cortisol levels.
Another interesting finding was the lack of associations between NR3C1 or SLC6A4 
methylation and any obesity measures in girls. This may be attributed to the sex hor-
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mone estrogen, which is considered to be relatively protective against obesity 33. Adjust-
ment for oral contraceptives use, which prevents natural cyclic fluctuations in estrogen 
levels, did not change the outcomes; so perhaps higher basal level of estrogens affects 
the association between DNA methylation and obesity in girls.
substance use
Besides psychiatric disorders and obesity, exposure to adverse life events has also been 
linked with substance use 34, 35. Only a few studies have investigated the association 
between COMT gene methylation and substance use. While studies on genetic variation 
suggest COMT enzyme hyperactivity in substance users, these first epigenetic results 
indicate lower COMT gene activity in substance users. No studies have yet investigated 
the relationship between cannabis use and COMT gene methylation. Therefore, we 
investigated the association between the use of different substances (i.e., cigarettes, 
alcohol and cannabis) in adolescents and COMT gene methylation in the MB-COMT 
promoter and the S-COMT promoter. As the findings on COMT genotype and COMT gene 
methylation (increased activity vs lower expression of COMT in substance users) were 
contradictive, there might be interplay between genetic and epigenetic factors with 
indirect oppositional effects on dopamine levels. Therefore, we also explored whether 
the association between COMT gene methylation and substance use was dependent on 
the COMT Val108/158Met polymorphism.
High levels of MB-COMT methylation were only associated with non-daily smoking. 
This finding was unexpected, but might suggest some regulatory mechanism linking 
MB-COMT methylation to a more controlled form of smoking, or, a perhaps more likely 
option, this could be a chance finding. In a previous study by Xu et al 36, no association 
was found between daily smoking and mean MB-COMT methylation, but associations 
were found in individual CpG sites of this promoter, with higher methylation levels in 
daily smokers compared to non-smokers at two CpG sites. These CpG sites were also 
investigated in our study, and we only found a higher methylation in one of these two 
CpG sites, but specifically for non-daily smoking. These inconsistencies between studies 
could be due to differences in age or smoking habits or a combination of both (i.e. long-
term heavy smoking). For alcohol use and cannabis use, we did not find a relationship 
with MB-COMT mean or unit-specific methylation. For S-COMT, no associations were 
found between methylation and substance use. But methylation levels in this promoter 
were very high, which could indicate that this gene is silenced in DNA from blood, and 
therefore unresponsive to external environmental factors.
In our study, adolescents with the Val/Val genotype were less likely to be cannabis 
users than non-users, compared to Met-allele carriers. Thus far, there is no consensus 
on which risk allele is associated with substance use, as mixed findings have been re-
ported, but this relationship might also be dependent on other environmental factors. 
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We therefore investigated the interaction between the COMT Val108/158Met genotype and 
MB-COMT methylation, and found that adolescents with the Met/Met genotype and 
high methylation levels had low odds of high-frequent cannabis use. This combination 
of the low enzyme activity (Met/Met genotype) and reduced expression of the enzyme 
(higher methylation rates) might result in higher dopamine levels through diminished 
dopamine degradation, which may be preventative for substance use. Genetically, the 
Met allele was considered a risk allele for higher odds of cannabis use in our study, yet 
in combination with methylation, these odds of cannabis use were reduced. This may 
again be an indication that epigenetic regulation can compensate for changes in gene 
expression caused by genetic variation.
syntHEsis
In the introduction of this thesis I mentioned that I wanted to investigate whether 
DNA methylation is a plausible mechanism that may explain why adverse life events 
predispose individuals to adverse health outcomes. I introduced a mediation model, 
in which DNA methylation could act as mediator of the association between adversity 
and adverse health outcomes if we could find associations between adverse life events 
and DNA methylation, and between DNA methylation and adverse health outcomes. In 
Chapters 2 and 3 we have seen that SLEs experienced between birth and adolescence 
were positively associated with both NR3C1_1 and SLC6A4 methylation at age 16. In 
Chapter 4 we found an association between NR3C1_1 methylation at age 16 years and 
internalizing problems at age 19 years and a tendency for such an association for SLC6A4 
methylation. As a next step, I will combine the variables used in Chapters 2-4 to test 
the possibility of mediation by DNA methylation. Specifically for the synthesis of these 
results, I will test if the relationship between SLEs (0-15 years) and later internalizing 
symptom scores (19 years) is mediated by (mean-centered) methylation of NR3C1_1 (i.e. 
region 1 only, as the other two regions of NR3C1 were not associated with either SLEs 
or internalizing symptom scores) and SLC6A4, using the PROCESS routine for SPSS (v21) 
developed by A.F. Hayes 37. This proposed mediation model is presented in figure 1.
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The effect estimates of the mediation analyses for NR3C1_1 and SLC6A4 are presented 
in and figures 2 and 3 respectively. For NR3C1_1 there was a mediation effect (B=0.005 
(β=0.02), [95%CI: 0.001; 0.011], p<.05). This mediation effect persisted after adding 
the covariates sex and age (βa=0.12, p<.05, βb=0.16, p<.05, βc=0.29, p<.05, βc’=0.27, 
p<.05, mediation effect: β=0.02, p<.05).
 
SLEs  
(age 0-15) 
DNA 
methylation 
(age 16) 
Internalizing 
problems  
(age 19) βc’ 
SLEs  
(age 0-15) 
Internalizing 
problems  
(age 19) 
βc 
figure 1. The proposed mediation model. βa: effect estimate for the association between SLEs and DNA 
methylation. βb: effect estimate for the association between DNA methylation and internalizing problems. 
βc: effect estimate for the association between SLEs and internalizing problems. βc’: effect estimate for the 
association between SLEs + DNA methylation and internalizing problems.
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figure 2. Results of testing the proposed mediation model for NR3C1_1. No covariates were added in this 
model.
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For SLC6A4, there also was a mediation effect (B=0.002 (β=0.007), [95%CI: 0.0001; 
0.0043], p<.05). However, after adding sex and age as covariates, this mediation effect 
was no longer significant (βa=0.08, p<.05, βb=0.02, p=.55, βc=0.26, p<.05, βc’=0.26, 
p<.05, no mediation effect: β=0.002, p>.05). To find out whether the loss of the media-
tion effect was due to age or sex, these covariates were added to the model separately. 
From these analyses we can conclude that only sex affected the results.
These results confirm the proposed mediating role, albeit partial, of DNA methylation 
in the association between SLEs and internalizing problems. One thing to note about 
these mediation analyses is that the effect sizes are very small and the mediation effect is 
not complete, but partial. This is, however, not entirely unexpected as it is very likely that 
epigenetic modifications in other genes also link SLEs to later internalizing problems.
strEnGtHs And LimitAtiOns
The use of the TRAILS database allowed for a large sample size, detailed accounts of SLEs 
between birth and adolescence, various outcome variables measured within TRAILS, 
and also genetic variation (e.g. Val108/158Met and 5HTTLPR genotypes). But some limita-
tions also have to be acknowledged. As I have listed specific limitations for each study in 
their respective chapter, I will focus solely on the shared limitations in the next section.
Blood for the isolation of DNA and methylation analysis was only collected at the third 
assessment wave. As a consequence changes in methylation could not be analyzed, and 
statements about the causality of the associations could not be made. This limitation is 
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figure 3. Results of testing the proposed mediation model for SLC6A4. No covariates were added in this 
model.
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often encountered in epigenetic studies, possibly because many ongoing population 
studies were not originally designed for epigenetic research 38. Another important 
limitation concerns the use of peripheral tissue (blood) as a proxy of the target tissue 
(the brain), which is often inaccessible in living humans. However, correlations between 
methylation levels in CpG islands in the brain and blood have been found to be high 39. 
Also, associations between childhood adversity and NR3C1 and SLC6A4 methylation 
have repeatedly been replicated in studies using peripheral samples, despite differences 
in adversity measures 40, 41. Another aspect to consider when using peripheral tissue, 
such as blood, is the cellular heterogeneity. Since we were unable to account for the 
cellular heterogeneity of the blood cells, which could be influenced by stress exposure 
(either acute or chronic), we could not rule out that the associations may in part be a 
reflection of differences in cellular composition. However, for NR3C1, it is likely that DNA 
methylation in blood is not associated with cellular heterogeneity 42. Although cellular 
heterogeneity does not affect methylation levels in all genes, implementing cell count 
measures in whole blood (or other samples consisting of a mixture of cell types), or 
purification of cell populations is necessary to prevent confounding by cellular hetero-
geneity, particularly in studies with age related outcome measures (due to age-related 
changes in cell type proportions 43) or immune related genes 44. Also, we were unable to 
analyze gene expression levels of NR3C1 and SLC6A4, although it should be noted that 
for both NR3C1 and SLC6A4, higher methylation levels have been associated with lower 
expression levels before 6, 13, 21, 45. Another limitation is the lack of a replication sample, 
but obtaining a suitable replication sample of adolescents with comparable measures of 
adverse life events and population characteristics is very challenging.
mEtHOdOLOGiCAL COnsidErAtiOns And rECOmmEndAtiOns fOr 
futurE rEsEArCH
In the last few decades the field of epigenetics has greatly expanded and new discov-
eries have been made, but our understanding of epigenetic processes in disease and 
causes of epigenetic change are still far from complete. Many questions still remain and 
technological advances have also introduced more questions over the last few years. 
The first studies on the impact of the social environment on DNA methylation have 
shown that environmental influences early in life may have long-term consequences on 
DNA methylation. This was later replicated in humans, most notably in a study report-
ing higher levels of methylation in victims of suicide who have experienced childhood 
abuse 6. However, the studies performed in this thesis seem to contradict the impor-
tance of the early life environment, and point towards a more reactive form of DNA 
methylation with higher levels of methylation following more recent events, and thus 
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a more dynamic mechanism. Because earlier studies in humans have not incorporated 
repeated measures of methylation, it remains difficult to determine the stability of the 
stress-reactive epigenome. It is also unknown whether differences in methylation were 
already present at birth, or have been introduced later in life. Similarly, it is important 
to consider differences in environmental exposure during different developmental peri-
ods, such as childhood and adolescence. The transition from childhood to adolescence 
is accompanied with many differences in internal (e.g. hormonal) and external (e.g. 
transition from elementary school to high school) changes in environment. Therefore, 
adversities experienced in childhood and adolescence may differ, as was the case in 
two of the studies described in this thesis. These different SLEs were appropriate for 
each developmental phase, but may have accounted for the differences in methylation. 
However, this remains a difficult subject to investigate further, as humans are exposed to 
countless environmental exposures during their lifetime, and it is impossible to focus on 
specific events that may be related to DNA methylation. This also complicates reproduc-
tion of the results in a replication sample. A first step towards understanding the relation 
between SLEs and methylation could be to focus on a smaller time frame (e.g. 1 year), 
incorporate a subjective measure of experienced stress, and include any emotional 
support received after stress exposure (which might dampen the effect), combined 
with a repeated measure of methylation. Still, it may be an insurmountable feat to fully 
understand the effects of the social environment on methylation in humans. Another 
possible explanation for the discrepancy between our study and previous reports is that 
stress-induced epigenetic modifications may become gradually lost or recovered over 
time. The recent discovery of active demethylation mechanisms (e.g. by methyl-CpG-
binding domain (MBD) protein 2b or ten-eleven translocation (TET) proteins) supports 
this theory of a more dynamic epigenome 5. Indeed a recent study reported changes in 
individual CpG methylation following acute stress in adult rats 46. Perhaps with a much 
longer lifespan in humans than rats, and thus a more variable environment, a more reac-
tive and dynamic regulation in humans may be an evolutionary advantage.
Over the years, the techniques for analyzing DNA methylation and other epigenetic 
modifications have greatly improved and have become less expensive. The studies per-
formed in this thesis focuses on specific candidate genes. The method that was used 
(mass spectrometry by Seqenom EpiTYPER) is roughly based on mass differences 
between methylated and non-methylated CpG units, i.e. fragments of nucleotides con-
taining one or more CpG sites. This method allows for the analyses of relatively large 
fragments (200-600bp) that can cover larger regions of CpG islands in promoter regions 
than alternative approaches, such as pyrosequencing. In recent years, the popularity 
of the genome-wide DNA methylation has increased. Although this technique enables 
researchers to analyze a large amount of CpGs (450 000 sites with the Illumina 450K 
bead array), these CpGs are spread over thousands of genes and the coverage of CpG 
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sites per gene is very low. It does, however, give a more complete image of the epigen-
etic changes associated with disease. Genome-wide techniques would be preferable in 
order to identify the possible involvement of genes, but to gain more understanding of 
the contribution of individual genes to health outcomes, extensive methylation analyses 
in candidate gene studies (selected based on theory or previous mentioned genome-
wide analyses) are necessary to discover which single CpG sites or small CpG units may 
play a role in the regulation of gene expression. As technology advances and becomes 
cheaper, new possibilities of whole-genome bisulfite sequencing are a relatively new 
option that combines the advantages of genome-wide and candidate gene studies. 
With this technique, it is possible to profile DNA methylation across the whole genome 
at a single nucleotide resolution. This allows for a more complete understanding of CpG 
methylation, also in regions other than CpG islands within gene promoters, such as gene 
bodies, where high levels of methylation have been associated with increased gene 
expression 47, 48, and may be preferable over the earlier mentioned techniques.
Once DNA methylation levels have been determined, there are different statistical 
approaches for DNA methylation analyses. Thus far, there is no consensus on the contri-
bution or biological relevance of methylation in single CpG sites, multiple CpGs within 
a promoter region, or even on the promoter wide level. Because of this, there is no fixed 
method of using DNA methylation in statistical analyses. In our candidate gene studies, 
we have mostly studied mean (centered) methylation over the individual regions within 
each gene, and sometimes explored methylation in individual CpG units. The risk of 
analyzing CpG methylation over larger regions is that the contribution of a single CpG 
may become diluted and effects might be overlooked. However, exploring associations 
with multiple individual CpG sites may increase the risk of type I errors (chance findings). 
When methylation between CpGs is correlated, the mean methylation level may give a 
better overall picture and reduces the number of tests performed. Detailed investiga-
tion of methylation on the level of individual CpGs can then be done in a subsequent 
step. For example, in this thesis analyses with mean methylation indicated that one 
particular region in NR3C1 (NR3C1_1) may be especially reactive to stress and health 
outcomes as this region was associated with adversity and adverse health outcomes. 
These results on a more regional level may be an indication that there are functionally 
relevant sites in this region and further investigation for transcriptionally active bind-
ing sites is necessary. Small effect sizes are not uncommon in methylation studies, and 
often raise questions on the functional relevance of these small methylation changes in 
specific regions of the genome, but they may also be an indication that that changes in 
methylation are only present in a selection of the sample.
Another new development in DNA methylation research is the discovery of 5-hydroxy-
methylcytosine (5hmC), also termed the sixth DNA base of the genome. Whereas 5hmC 
was initially seen as an intermediate process of demethylation, this sixth base may actu-
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ally have an important function in regulating gene expression and cellular function. TET 
proteins catalyze the conversion of 5-methylcytosine to 5hmC followed by conversion 
to 5-formylcytosine and 5-carboxylcytosine, which can be converted back to cytosine 49. 
Of these intermediate forms of cytosine, 5hmC is most common and may have an in-
dependent association with adverse health outcomes 50. However, most methods used 
for DNA methylation analyses (including the Seqenom EpiTYPER technique used in 
this thesis) rely on bisulfite treatment to convert non-methylated cytosine bases into 
the base uracil (U), which does not distinguish between the different forms of cytosine 
methylation. Making this distinction is necessary, because the presence of intermediate 
forms of cytosine methylation may be an indication of removal or recovery of methyla-
tion marks. Several new techniques now exist that distinguish between 5mC and 5hmC 
in order to further understand the dynamics of demethylation, but further development 
is necessary. Perhaps, if this distinction could have been made in the studies presented 
in this thesis, we could have investigated whether the presence of more intermediate 
forms of cytosine methylation was related to a decrease in internalizing symptoms 
over time. Repeated measures of methylation could also provide new insights into this 
phenomenon of active demethylation.
Although the focus in this thesis is on DNA methylation, it is important to remem-
ber that other epigenetic modifications may co-occur. DNA methylation is the easiest 
epigenetic modification to study, and is therefore most often used in research. Other 
epigenetic modifications include various histone modifications (e.g. acetylation, meth-
ylation, phosphorylation, ubiquitination), non-coding RNA, and micro RNA. Some 
epigenetic modifications are connected, such as histone modifications and DNA meth-
ylation. As mentioned in the introduction of this thesis, gene silencing by DNA methyla-
tion occurs through direct prevention of transcription factor binding, or by recruiting 
methyl-CpG-binding domain proteins (MBDs). These proteins recruit other proteins that 
modify histones (histone deacetylases), which results in a structural change that makes 
the DNA inaccessible for other transcriptional proteins 51. On the other hand, histone 
modifications may also be a prerequisite for DNA methylation 52. Although the focus 
on DNA methylation only may be highly informative, effects may be strengthened by 
incorporating other epigenetic mechanisms, which might also help with understanding 
the small but significant effect sizes seen in methylation studies.
The field of epigenetics keeps developing rapidly, but we are still a long way removed 
from fully understanding its implications in clinical practice. However, some discoveries 
may help with the development of strategies for diagnosis, treatment or intervention. 
Correlations between blood and brain methylation that have been reported may open a 
window for the use of blood as a biomarker for disorders. Pharmacological manipulation 
of DNA methylation has also been investigated. For several psychotropic drugs there 
have been reports of epigenetic changes in either DNA methylation or histone modi-
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fications, but the full extent of the changes induced by medication is still unknown 53. 
Thus far the association between adversity and methylation seems quite robust, but it 
is not yet known whether positive experiences may also affect the epigenome or pos-
sibly undo the effects of a negative environment in humans. In mice, there have been 
reports of a reduction of brain 5hmC when exposed to an enriched environment, and 
improvements in memory and learning behaviors 54. Although some of these prospects 
seem promising, we first need a better understanding of epigenetics in adverse health 
outcomes before we can think of implementations. The research described in this thesis 
provides valuable new insights into the epigenetics of stress and adverse health out-
comes. However, incorporating repeated measures of methylation (on single-nucleotide 
level) and gene expression data is necessary in subsequent research to provide a better 
understanding on causality and the pathways leading to disease.
We must also keep in mind that there are two sides of the epigenome; on one hand 
the vulnerability for adverse environments, the ability of negative experiences to silence 
proper biological functioning, but on the other hand it provides the ability to adapt 
to changing environments despite the rigidity of the genome and to improve one’s 
endowment. Thus, a responsive epigenome might be either a blessing or a curse, but 
understanding the dynamics of epigenetic modifications might one day lead towards 
intervention or possibly treatment strategies to rectify the negative effects instilled by 
an adverse environment. Although epigenetic research still faces many challenges, with 
improving techniques, statistical analyses, repeated measures of methylation and large 
samples we may be able to clarify the role of epigenetics in health and disease.
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Summary
summAry
Adverse life events are strong risk factors for adverse health outcomes, such as psychi-
atric problems, obesity and related cardiovascular disease and diabetes. The pathways 
through which stressful events can promote the development of such divergent disor-
ders in humans were largely unknown, but in recent years, a promising explanation has 
risen from the field of epigenetics (derived from the Greek “epi”, which means “on top of”). 
Epigenetics refers to modifications of DNA or associated histone proteins, which alter 
gene expression and may result in adverse health outcomes. Epigenetic modifications 
can be actively remodeled by environmental signals, and may therefore be considered 
as a candidate mechanism for the environmental ‘programming’ of gene expression. 
In this thesis the epigenetic modification DNA methylation is studied, which involves 
the addition of a methyl group (CH3) to a cytosine base to form 5-methylcytosine in a 
cytosine-phosphate-guanine (CpG) dinucleotide combination. Higher levels of methyla-
tion in CpG sites is generally associated with gene silencing or reduced gene expression.
In this thesis I have investigated whether DNA methylation may serve as an underlying 
biological mechanism that predisposes individuals with a history of adversity to adverse 
health outcomes. DNA methylation could be an eligible mediator of the association 
between adversity and adverse health outcomes when there is an association between 
adverse life events and DNA methylation, and between DNA methylation and adverse 
health outcomes. I therefore studied the associations of DNA methylation (in adoles-
cents) with both possible predictors and possible health outcomes.
In Chapter 2 and 3 I investigated whether stressful life events (SLEs), during child-
hood and adolescence, are associated with higher CpG methylation in the genes encod-
ing the glucocorticoid receptor (NR3C1) and the serotonin transporter (SLC6A4). Firstly, 
the effect of type of adversity on methylation was studied, and a distinction was made 
between perinatal stress, SLEs, and traumatic youth experiences (TYEs). Secondly, the 
effect of timing of SLEs on methylation was studied by analyzing the independent as-
sociations between SLEs at different developmental periods (i.e., childhood [0-11 years] 
and adolescence [12-15 years]) and NR3C1 and SLC6A4 methylation. For NR3C1, high 
levels of methylation were associated with more SLEs, particularly when experienced 
in adolescence, and exposure to TYEs. The results on TYEs are consistent with prior 
studies, but we did not find support for the notion of a sensitive period (perinatal and 
childhood period) for NR3C1 methylation in adolescents. The results of these studies 
seem to contradict the importance of the early life environment, and point towards 
a more reactive form of DNA methylation with higher levels of methylation following 
more recent events, and thus a more dynamic mechanism. For NR3C1, most associations 
between methylation and adverse life events were found in a region that had not been 
studied before. It would be meaningful to further investigate how methylation in this 
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region affects NR3C1 expression, and investigate biological pathways associated with 
changes in methylation. For SLC6A4, high levels of methylation were only associated 
with more SLEs, again with a more pronounced association for SLEs in adolescence than 
in childhood. The lack of association between TYEs and SLC6A4 methylation, seemed 
to contradict earlier findings. This contradiction may be due to differences in sample 
characteristics (i.e., size or the use of a clinical sample). For SLC6A4, we have seen that the 
5HTTLPR genotype influenced the relationship between SLEs and SLC6A4 methylation; 
only in carriers of two l-alleles methylation levels were higher when more SLEs were 
experienced. This suggests that epigenetic regulation may serve as an adaptive mecha-
nism to adjust gene expression and compensate for changes in gene expression caused 
by genetic variation
In Chapter 4 I investigated whether higher methylation levels of NR3C1 and SLC6A4 
were associated with concurrent and future (3 years later) internalizing problems 
(anxiety and depression), operationalized as clinical diagnoses of internalizing disorders 
and internalizing symptom scores. Higher NR3C1 methylation was associated with 
higher concurrent and future internalizing symptom scores, and higher odds of lifetime 
internalizing disorders. NR3C1 methylation also appeared to have a more generic role in 
internalizing problems, as high methylation was associated with both more anxiety and 
depression problems. High SLC6A4 methylation only showed a tendency for association 
with internalizing symptom scores, and the role of SLC6A4 methylation across pheno-
types was more complex and somewhat less consistent; post hoc analyses indicated 
that there were significant positive associations with lifetime anxiety disorders, and 
concurrent and future depressive symptom scores. Replication and extension of the 
current findings to more specific phenotypic internalizing problems is needed, but our 
findings may provide a first step towards understanding the physiological processes 
that underlie the different internalizing problems.
In Chapter 5 I investigated whether NR3C1 methylation was associated with HPA-axis 
regulation, more specifically; activation and recovery of the cortisol response following 
social stress. High NR3C1 methylation was associated with a delayed recovery following 
social stress, but not with cortisol response activation. As DNA methylation generally 
reduces gene expression, a delayed recovery likely follows a reduced availability of glu-
cocorticoid receptors and has no effect on HPA-axis activation. The association between 
NR3C1 methylation and cortisol response recovery was only found in region 2 of the 
NR3C1 CpG island, in which high methylation levels were previously associated with 
childhood maltreatment in suicide victims and reduced NR3C1 expression.
In Chapter 6, I investigated whether methylation of SLC6A4 and NR3C1 was associated 
with measures of obesity. This study was intended as a replication study on the associa-
tion between SLC6A4 methylation and obesity measures (i.e. weight, body mass index, 
waist circumference, waist-hip ratio, and height), which had only been investigated 
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in adult males veterans. Also, research on NR3C1 methylation and obesity is lacking. 
Therefore, I wanted to replicate the findings of the previously mentioned SLC6A4 study 
in adolescent boys and extend the study by including adolescent girls, methylation of 
NR3C1, and additional measures of obesity, i.e., body fat percentage and skinfold thick-
ness. SLC6A4 promoter methylation was significantly associated with obesity measures 
in adolescent boys, in line with the results of the original study, but the associations 
were not found in adolescent girls. For NR3C1, methylation levels in the promoter region 
were only associated with height in adolescent boys. Glucocorticoids are known to be 
involved in linear growth, but an excess of glucocorticoids is generally considered to 
be associated with growth impairment, thus replication of our findings is necessary. 
Possibly, the lack of associations in girls can be attributed to sex hormones, in particular 
estrogens. Estrogens are known to be involved in appetite regulation and energy expen-
diture and considered protective against obesity.
In Chapter 7, I investigated whether COMT methylation (in the MB-COMT and S-COMT 
promoter) was associated with substance use (i.e., cigarettes, alcohol and cannabis) in 
adolescents, and explored whether the association between COMT methylation and 
substance use was dependent on the COMT Val108/158Met polymorphism. High levels 
of MB-COMT methylation were only associated with non-daily smoking. Perhaps this 
is an indication of a regulatory mechanism that links MB-COMT methylation to a more 
controlled form of smoking, or, perhaps more likely, this could be a chance finding. There 
was no relationship between mean MB-COMT or S-COMT promoter methylation and 
alcohol or cannabis use in adolescents. Adolescents with the Met/Met genotype and 
high methylation levels were at reduced risk of cannabis use, while genetically the Met 
allele was considered a risk allele for higher odds of cannabis use in this study. This may 
again be an indication that epigenetic regulation can compensate for changes in gene 
expression caused by genetic variation.
In Chapter 8, I further discuss the main findings of the studies presented in this thesis, 
and the developments in epigenetic research. In addition, I combined the information 
from Chapters 2-4, to test whether DNA methylation acts as a mediator in the association 
between SLEs and internalizing symptom scores. These results of the mediation analyses 
indicate that there is indeed a partial mediation effect of DNA methylation in the asso-
ciation between SLEs and internalizing symptom scores. The research described in this 
thesis provides valuable new insights into the epigenetics of stress and adverse health 
outcomes, but incorporating repeated measures of methylation (on single-nucleotide 
level) and gene expression data is necessary in subsequent research to provide a better 
understanding on causality and the pathways leading to disease.
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sAmEnvAttinG
Het meemaken van negatieve levenservaringen is een sterke risicofactor voor het 
ontwikkelen van nadelige gezondheidsuitkomsten, zoals psychische problemen, obe-
sitas en gerelateerde cardiovasculaire aandoeningen en diabetes. Het achterliggende 
mechanisme waardoor stressvolle gebeurtenissen de ontwikkeling van deze gevari-
eerde gezondheidsuitkomsten kunnen bevorderen was lange tijd onbekend, maar in 
de afgelopen jaren is er een mogelijk veelbelovende verklaring ontstaan vanuit het 
onderzoeksveld van de epigenetica (afkomstig van het Griekse prefix ‘epi’, dat staat voor 
‘bij’ of ‘op’). De term epigenetica doelt op onderzoek naar modificaties van het DNA, 
of de geassocieerde histonen, die de gen expressie kunnen beïnvloeden en hierdoor 
mogelijk tot nadelige gezondheidsuitkomsten kunnen leiden. Deze epigenetische 
modificaties kunnen actief herstructureerd worden door signalen uit de omgeving, en 
worden daardoor gezien als kandidaat mechanisme dat zou kunnen verklaren hoe de 
omgeving de gen expressie programmeert. In dit proefschrift is onderzoek gedaan naar 
de epigenetische modificatie ‘DNA methylering’. Bij DNA methylering wordt er een me-
thyl groep (CH3) aan een cytosine base van het DNA toegevoegd wanneer deze zich in 
een cytosine-fosfaat-guanine (CpG) combinatie bevind. Hierdoor veranderd cytosine in 
5-methylcytosine. Een hogere mate van methylering in CpGs wordt over het algemeen 
geassocieerd met het uitschakelen van genen (ook wel gene silencing genoemd) of het 
verminderen van de gen expressie.
In dit proefschrift heb ik onderzocht of DNA methylering kan dienen als een on-
derliggend mechanisme dat de relatie tussen negatieve levenservaringen en latere 
nadelige gezondheidsuitkomsten kan verklaren. DNA methylering zou deze relatie kun-
nen verklaren wanneer er een associatie is tussen negatieve levenservaringen en DNA 
methylering, en wanneer er een associatie is tussen DNA methylering en nadelige 
gezondheidsuitkomsten. Daarom heb ik onderzoek gedaan naar mogelijke voorspellers 
van DNA methylering (in adolescenten) en naar mogelijke gezondheidsuitkomsten van 
DNA methylering.
In Hoofdstuk 2 en 3 heb ik onderzocht of stressvolle levensgebeurtenissen (SLEs), 
meegemaakt tijdens de kindertijd en de adolescentie, geassocieerd zijn met hogere 
waarden van DNA methylering in de genen die coderen voor de glucocorticoïd receptor 
(NR3C1) en de serotonine transporter (SLC6A4). Als eerste is onderzoek gedaan naar het 
type stress en DNA methylering, waarbij onderscheid gemaakt werd tussen perinatale 
stress, SLEs en traumatische gebeurtenissen (TYEs). Ten tweede is onderzoek gedaan 
naar de blootstelling van SLEs gedurende verschillende periodes van de ontwikkeling, 
tijdens de kindertijd (0-11 jaar) en tijdens de adolescentie (12-15 jaar), en methylering 
in de genen NR3C1 en SLC6A4. Voor NR3C1 werd er gevonden dat het meemaken van 
meer SLEs geassocieerd was met hogere methylering waarden, voornamelijk wanneer 
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deze SLEs meegemaakt waren in de adolescentie. Ook was het meemaken van TYEs 
geassocieerd met hogere NR3C1 methylering waarden. De bevindingen van de TYEs 
analyses komen overeen met eerdere studies, maar bieden geen steun aan de notie dat 
er een gevoelige periode is (in de perinatale periode en de kindertijd) voor methylering 
van het NR3C1 gen in adolescenten. De resultaten van onze studie lijken het belang van 
de vroege blootstelling aan omgevingsfactoren tegen te spreken en lijken te wijzen op 
een meer reactieve vorm van DNA methylering. We vinden namelijk hogere waarden 
van methylering na recente gebeurtenissen, wat kan duiden op een meer dynamisch 
mechanisme. De meeste associaties tussen stressvolle gebeurtenissen en methylering 
zijn gevonden in een specifiek regio van NR3C1 dat nog niet eerder onderzocht is. Het 
zou waardevol zijn om verder onderzoek te doen naar de effecten van methylering in 
dit gebied op de gen expressie en andere biologische processen. Hoge methylering 
waarden in het SLC6A4 gen waren alleen geassocieerd met het meemaken van meer 
SLEs, voornamelijk tijdens de adolescentie. De afwezigheid van een associatie tussen 
TYEs en SLC6A4 methylering lijkt tegenstrijdig te zijn aan eerdere bevindingen. Deze 
tegenstrijdigheid wordt mogelijk veroorzaakt door verschillen in eigenschappen van 
steekproef (bijvoorbeeld de grootte van de steekproef, of het gebruik van een klinische 
steekproef ). Voor SLC6A4 bleek ook dat het 5HTTLPR genotype de relatie tussen SLEs en 
SLC6A4 methylering beïnvloedde. Alleen in dragers van twee l-allelen waren methyle-
ring waarden hoger wanneer er meer SLEs meegemaakt zijn. Dit houdt mogelijk in dat 
epigenetische regulatie een adaptief mechanisme is dat veranderingen in gen expressie 
door genetische variatie kan compenseren.
In Hoofdstuk 4 heb ik onderzocht of hogere methylering waarden van NR3C1 en 
SLC6A4 geassocieerd waren met huidige en toekomstige (3 jaar later) internaliserende 
problemen (angst en depressie), geoperationaliseerd als klinische diagnoses van in-
ternaliserende stoornissen en internaliserende symptoomscores. Hogere waarden van 
NR3C1 methylering waren geassocieerd met hogere huidige en toekomstige interna-
liserende symptoomscores en een hogere kans verhouding op het ontstaan van een 
internaliserende stoornis. Methylering van NR3C1 bleek tevens een meer algemene 
rol te spelen bij het ontstaan van internaliserende problemen, aangezien hogere me-
thylering waardes geassocieerd waren met zowel angst- als depressieve problemen. 
Bij hogere methylering waarden in SLC6A4 bleek er alleen een trend te zijn naar meer 
internaliserende symptoomscores. Ook was de rol van SLC6A4 methylering bij angst en 
depressie wat minder duidelijk en inconsistent: uit post hoc analyses bleek dat er een 
significantie positieve associatie was tussen methylering in dit gen en het ontwikkelen 
van een angststoornis, en tussen methylering en huidige en toekomstige depressieve 
symptoomscores. Het is nodig om deze bevindingen te repliceren en uit te breiden naar 
meer specifieke fenotypes, maar desondanks leveren deze analyses een eerste bijdrage 
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om de processen te begrijpen die ten grondslag liggen aan het ontstaan van verschil-
lende internaliserende problemen.
In Hoofdstuk 5 heb ik onderzocht of NR3C1 methylering geassocieerd is met HPA-as 
regulatie, dat wil zeggen, de activatie en het herstel van de cortisol response na sociale 
stress. Hogere waarden van NR3C1 methylering waren geassocieerd met een vertraagd 
herstel van de cortisol respons na sociale stress, maar niet met de activatie van de cortisol 
response. Aangezien DNA methylering over het algemeen de gen expressie verminderd, 
volgt een vertraagd herstel waarschijnlijk uit een verminderde beschikbaarheid van 
glucocorticoïd receptoren. De associatie tussen NR3C1 methylering en het herstel van 
de cortisol response is alleen gevonden in regio 2 van het NR3C1 CpG eiland, waarin 
eerder hogere methylering waardes zijn gerelateerd aan kindermisbruik in slachtoffers 
van zelfdoding en aan verminderde NR3C1 expressie.
In Hoofdstuk 6 heb ik onderzocht of methylering in de genen SLC6A4 en NR3C1 geas-
socieerd is met maten van obesitas. Deze studie is bedoeld als replicatie studie naar de 
associatie tussen SLC6A4 methylering en maten van obesitas (namelijk gewicht, body 
mass index [BMI], taille omtrek, taille-heup ratio, en lengte), dat alleen onderzocht was 
in volwassen oorlogsveteranen (enkel mannen). Er is nog niet eerder onderzoek gedaan 
naar de relatie tussen NR3C1 methylering en obesitas. Om deze redenen wilde ik de 
eerder genoemde associatie tussen SLC6A4 methylering en obesitas maten repliceren 
in adolescente jongens en de studie uitbreiden door adolescente meisjes te includeren, 
en zowel methylering van NR3C1 als additionele obesitas maten (dat wil zeggen, vetper-
centage en huidplooimetingen) aan de studie toe te voegen. SLC6A4 methylering bleek 
significant gerelateerd te zijn aan maten van obesitas in jongens, wat overeenkomt met 
de resultaten van de originele studie. Deze associaties waren afwezig in meisjes. Voor 
het NR3C1 gen waren hogere methylering waarden alleen gerelateerd aan lengte in 
jongens. Van glucocorticoïden is bekend dat ze betrokken zijn bij lineaire groei, maar 
een overdaad aan glucocorticoïden is over het algemeen geassocieerd met een vermin-
derde groei en dus is het nodig deze bevindingen te repliceren. De afwezigheid van een 
associatie tussen methylering en obesitas maten in meisjes zou mogelijk verklaard kun-
nen worden door het hormoon oestrogeen. Oestrogenen zijn betrokken bij de regulatie 
van het hongergevoel en energieverbruik en worden over het algemeen beschouwd als 
beschermend tegen obesitas.
In Hoofdstuk 7 heb ik onderzocht of methylering in het COMT gen (in zowel de MB-
COMT als de S-COMT promotor) geassocieerd was met middelengebruik (hieronder 
vallen sigaretten, alcohol en cannabis) in adolescenten. Ook heb ik gekeken of de as-
sociatie tussen COMT methylering en middelengebruik afhankelijk was van het COMT 
Val108/158Met polymorfisme. Hogere waarden van MB-COMT methylering waren alleen 
geassocieerd met niet-dagelijks roken. Dit zou mogelijk kunnen wijzen op een regulatie 
mechanisme dat MB-COMT methylering relateert aan een gecontroleerde vorm van ro-
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ken, of, een logischere optie, er is hier sprake van een kansbevinding. Er was geen relatie 
tussen MB-COMT of S-COMT methylering en alcohol of cannabis gebruik. Adolescenten 
met het Met/Met genotype en hogere methylering waarden hadden een verminderd 
risico om cannabis te gebruiken, terwijl genetisch gezien het Met allel gerelateerd was 
aan een hoger risico op cannabis gebruik in deze studie. Dit zou mogelijk opnieuw een 
indicatie zijn dat epigenetische mechanisme kunnen compenseren voor veranderingen 
in gen expressie door generische variatie.
In Hoofdstuk 8 beschrijf ik de belangrijkste bevindingen van de onderzoeken die in 
dit proefschrift gepresenteerd zijn en de nieuwe ontwikkelingen in het epigenetische 
onderzoek. Ook heb ik de informatie uit Hoofstukken 2-4 gecombineerd om te testen 
of DNA methylering de associatie tussen SLEs en internaliserende symptoomscores me-
dieert. Uit de resultaten van deze mediatie analyses blijkt dat er inderdaad een partieel 
mediatie effect is van DNA methylering in de associatie tussen SLEs en internaliserende 
symptoomscores. Het onderzoek dat beschreven is in dit proefschrift biedt waardevolle 
nieuwe inzichten in de epigenetica van stress en nadelige gezondheidsuitkomsten, 
maar voor vervolg onderzoek is het nodig om herhaalde metingen van methylering (op 
het niveau van individuele CpGs) toe te passen en onderzoek te doen naar genexpressie 
om een beter beeld te krijgen van de oorzaken en gevolgen van methylering en de 
biologische processen die kunnen leiden tot gezondheidsproblemen.
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